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In this research, the apoptotic effects of adenosine and the mechanisms by which 
adenosine exerts these effects were studied. Adenosine-induced apoptosis was 
characterized by both early and late stage apoptosis criteria and observed to be 
cell type-dependent. Using different adenosine receptor agonists and antagonists, 
it was found that GPCRs can mediate apoptosis at low adenosine concentrations 
while nucleoside transporters are involved in the apoptotic effects at high 
adenosine concentrations. Receptors and transporters of adenosine appeared to 
mediate the contrasting biphasic, non-biphasic apoptotic and non-apoptotic effects 
of adenosine observed in different cell types. Key players/events of the apoptosis 
were identified, including the hyperpolarization and depolarization of 
mitochondria, translocation of Bax and cytochrome c, elevation of cytosolic Ca2+ 
level, cellular acidification and activation of caspases. An intrinsic apoptosis 
pattern was suggested with mitochondria being at the centre of the apoptosis 
pathway. Based on the experimental data, an intracellular mechanism for 
adenosine-induced apoptosis was proposed. In this model, two apoptotic signaling 
pathways respond to adenosine at low and high extracellular adenosine 
concentrations. This model also provides an explanation for the multifaceted 
character of adenosine-induced apoptosis across a wide range of adenosine 
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In this research, the apoptotic effect of adenosine and the mechanisms whereby 
adenosine exerts its apoptotic effect were studied. Adenosine-induced apoptosis 
was characterized by both early and late stage apoptosis criteria. Adenosine-
induced apoptosis was observed to be cell type-dependent in BHK, HeLa, 
SKW6.4, H9, SY5Y and MN9D cell lines. Evidence was found to support the 
possibility that G protein-coupled receptors can mediate apoptosis and that 
nucleoside transporters can also mediate adenosine’s functions. An extracellular 
model is hypothesized to explain the biphasic, non-biphasic apoptotic and non-
apoptotic effects of adenosine observed in different cell types. In the extracellular 
signaling model, a receptor-mediated pathway is responsible for the apoptosis 
induced by low concentrations of adenosine (20-50 μM); a transporter-mediated 
pathway is responsible for the apoptosis induced by high adenosine concentrations 
(500-1000 μM). Key events of the intracellular apoptosis were identified, 
including the hyperpolarization and depolarization of mitochondria, translocation 
of Bax and cytochrome c, elevation of cytosolic Ca2+, cellular acidification and 
activation of caspases. An intrinsic apoptosis pattern was suggested with 
mitochondria being at the centre of the apoptosis pathway. The mechanism of 
cytochrome c release from mitochondria was investigated. Cristae remodeling as 
an early event prior to the cyt c release is proposed in cases where matrix swelling 
did not occur. Based on the experimental data, an intracellular mechanism was 
proposed. In the intracellular model, two intracellular signaling pathways respond 
to extracellular apoptotic signal of adenosine transduced by two pathways through 
which adenosine initiates apoptosis at low and high adenosine concentrations. 
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1 Chapter 1 Introduction 
 
1.1 Adenosine and Its Receptors 
1.1.1 Adenosine Structure and Functions 
1.1.1.1 Adenosine: A Pursuit of 80 Years 
Adenosine (Fig. 1.1), a ubiquitous purine nucleoside present in all body cells, has 
important and diverse effects in many biological processes including smooth 
muscle contraction, neurotransmission, exocrine and endocrine secretion, the 
immune response, inflammation, platelet aggregation, pain, modulation of cardiac 
function and most recently, cell growth and cell death (Abbracchio et al. 1996, 
Ralevic & Burnstock 1998). Pioneer work on adenosine as one of the first 
signaling molecules was carried out more than 70 years ago. The concept of 
adenosine as an extracellular signaling molecule was introduced by Drury and 
Szent-Györgyi in 1929 in a comprehensive report showing that adenosine and 
adenosine 5’-monophosphate (AMP), extracted from heart muscle, brain, kidney 
and spleen have pronounced biological effects, including heart block, arterial 
dilatation, lowering of blood pressure and inhibition of intestinal contraction 
(Drury & Szent-Györgyi 1929), which was also the first documentation on the 
physiological actions of adenosine. Gillespie (Gillespie 1934) drew attention to 
the structure-activity relationships of adenine compounds, showing that 
deamination greatly reduces pharmacological activity and that removal of the 
phosphates from the molecule influences not only potency but also the type of 
response. Removal of phosphates was shown to increase the ability of adenine 
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compounds to cause vasodilatation and hypotension, and ATP caused an increase 
in rabbit and cat blood pressure that was rarely or never observed with AMP or 
adenosine (Gillespie 1934). Furthermore, in the same research, ATP was shown to 
be more potent than AMP and adenosine in causing contraction of guinea-pig 
ileum and uterus (Gillespie 1934). This was the first indication of different actions 
of adenosine and ATP and, by implication, the first indication of the existence of 
different purine receptors. 
 
Modern research on adenosine revived in the early 1970s. In the seminal review in 
1972, Burnstock conceptualized what turned out to be the foundation of the 
present knowledge on purinergic signaling (Burnstock 1972). Many biologists and 
chemists have since contributed to the body of knowledge over the past 30 years, 
with the advances in the molecular biology and functional 
pharmacology/physiology of P1 (adenosine) and P2 (ATP, ADP, UTP, UDP) 
receptors over the past decade as the result (Abbracchio & Williams 2001a). 
 
Since the 1970s, the field of purinergic signaling research has gradually evolved 
to a mainstream biomedical research activity that promises to deliver novel 
medications within the next decade or two in many diseases where purines play a 



















1.1.1.2 Physiological Roles of Adenosine 
The findings that adenosine can stimulate cAMP formation in brain cells (Sattin & 
Rall 1970) was the start of a new era of adenosine research, which led to the 
discovery of adenosine receptors and their subclassification. Modern research on 
adenosine’s physiological roles reached its peak in the last two decades of the last 
century. In the cardiovascular system, adenosine was shown to increase blood 
flow and decrease excitatory nerve firing. Adenosine reduces rate and force of 
contraction and preconditions the heart against injury by prolonged ischemia. 
Important roles of adenosine in the central nervous system (CNS) are widely 
accepted too. A general consensus has been reached on the crucial role of 
adenosine as a modulator of neurotransmission and a neuroprotective agent 
against ischemic- and seizure-induced neuronal injury (Latini & Pedata 2001). 
Adenosine has also been proposed to be a potent regulator of cerebral blood flow 
(Phillis et al.1989; Dunwiddie & Fredholm 1997). Besides its more general 
involvement in cellular metabolism, the specific actions of adenosine in the CNS 
as a neuroeffector are believed to be mediated through specific receptors, which 
have been cloned and classified as A1, A2A, A2B and A3 receptors (Fredholm et al. 
1994). 
 
The widespread distribution of adenosine receptors in the mammalian body 
suggests the participation of the nucleoside in numerous processes underlying 
normal functions. First, adenosine is an important modulator in cardiovascular 
physiology. Adenosine is a potent vasodilator in all vascular beds (Berne 1980, 
Collis 1989, Newby 1984). Blood cell functions are affected by physiological 
concentrations of adenosine. Indeed, platelet aggregation is inhibited by adenosine 
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(Dawicki et al. 1986). Likewise, lymphocyte and lymphoblast proliferation is 
inhibited by adenosine (Hirschhorn et al. 1970, Van der Weyden & Kelley 1976), 
whereas red cell production is stimulated (Schooley & Mahlmann 1975). In 
adipose tissue, adenosine appears as a regulatory factor in metabolism. It acts as a 
local insulin-like effector, enhancing glucose uptake into fat cells and inhibiting 
lipolysis (Vannucci et al. 1989). In the kidney, adenosine is able to decrease the 
rate of glomerular filtration, sodium excretion and rennin release (Tagawa & 
Vander 1970). Adenosine has also been shown to induce bronchoconstriction 
(Pauwels & van der Straeten 1986). Finally, adenosine is also involved in neural 
transmission (Fredholm & Hedqvist 1980). Adenosine and its metabolically stable 
analogues are able to inhibit both spontaneous firing of neurons and evoked 
electrical potentials in virtually all brain regions. It also inhibits the release of 
many neurotransmitters (Kuroda 1978). Reports have shown that adenosine and 
its analogues produce sedation (DeLong et al. 1985), analgesia (Ahlijanian & 
Takemori 1985), hypothermia (Jonzon et al. 1986), and prevent seizure activity 
(Dunwiddie & Worth 1982). In addition, adenosine is also a modulator of 
inflammatory responses (Cronstein 1994). For example, it binds to 
polymorphonuclear neutrophils (PMN), resulting in inhibition of superoxide anion 
and hydrogen peroxide (H2O2) release (Cronstein et al. 1985), and also inhibits 
PMN adherence to endothelium (Cronstein et al. 1986). 
 
Not only is adenosine an important regulatory compound, the adenosine structure 
is also a constituent of other bioactive molecules such as ATP (energy source of 
cells), RNA (important for protein synthesis), several coenzymes (such as NAD, 
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FAD, CoA), cAMP (second messenger), and S-adenosyl methionine (important 
compound for biochemical methylation reaction). 
 
The products of endothelial cell metabolism of adenosine may also influence the 
process of vascular injury. ADP causes platelet aggregation (Agarwal et al. 1975). 
Depending on vascular tone and endothelial integrity, ATP acts as a vasodilator or 
vasoconstrictor (Kennedy & Burnstock 1985). Both hypoxanthine and xanthine 
are substrates for xanthine oxidase, the action of which causes production of 
injurious oxidants (McCord 1985). The deamination product of adenosine, 
inosine, has also been shown to enhance cell growth (Ganassin et al. 1994). 
 
1.1.2 Adenosine/P1 Receptors 
1.1.2.1 Classification and Nomenclature of Adenosine/P1 Receptors 
Extracellular adenosine acts as a local modulator with a generally cytoprotective 
function in the body (Fredholm et al. 2001). Its effects on tissue protection and 
repair fall into four categories: increasing the ratio of oxygen supply to demand, 
protecting against ischaemic damage by cell conditioning; triggering anti-
inflammatory responses, and the promotion of angiogenesis (Linden 2005). 
 
Purines and pyrimidines, including adenosine, mediate their effects mostly by 
interactions with distinct cell-surface receptors. There are two main families of 
purine receptors: adenosine or P1 receptors responding to adenosine, and P2 
receptors recognizing primarily ATP, ADP, UTP and UDP (Table 1). Early 
pharmacological evidence for the existence of adenosine receptors has been 
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provided by specific antagonism by methylxanthines of adenosine-mediated 
accumulation of adenosine 3’, 5’-cyclic monophosphate (cAMP) in rat brain slices 
(Sattin & Rall 1970). “Purinergic” receptors were first formally recognized by 
Burnstock in 1978, when he proposed that these can be divided into two classes 
termed “P1-purinoceptors”, at which adenosine is the principal natural ligand and 
“P2-purinoceptors”, recognizing ATP and ADP (Burnstock et al. 1978). This 
division was based on several criteria, namely the relative potencies of ATP, 
ADP, AMP and adenosine, selective antagonism of the effects of adenosine by 
methylxanthines, activation of adenylate cyclase by adenosine and stimulation of 
prostaglandin synthesis by ATP and ADP. This major division remains a 
fundamental part of purine receptor classification, although adenosine/P1 and P2 
receptors are now characterized primarily according to their distinct molecular 
structures, supported by evidence of distinct effector systems, pharmacological 
profiles and tissue distributions. In addition, receptors for pyrimidines are now 
included within the P2 receptor family (Table 1) (Fredholm et al. 1994, Fredholm 
et al. 1996a). It has been recommended that “P1 receptor” and “P2 receptor” 
replace the “P1/P2 purinoceptor” terminology (Fredholm et al. 1996a). The terms 
“adenosine receptor” and “P1 receptor” are synonymous and used interchangeably 






Table 1. Families of receptors for purine and pyrimidine nucleosides and 
nucleotides 
 
 P1 receptors P2 receptors 
Natural ligand(s) adenosine ATP, ADP,UTP, Adenine dinucleotides 









A1, A2A, A2B and 
A3 
P2X1-7, P2Xn 








There are four known subtypes of adenosine receptors (ARs) — referred to as A1, 
A2A, A2B and A3, on the basis of their distinct molecular structures, tissue 
distributions and pharmacological profiles. All four subtypes are members of the 
superfamily of G-protein-coupled receptors (GPCRs), and are most closely related 
to the receptors for biogenic amines. Structurally, all adenosine receptors couple 
to G proteins (Ralevic & Burnstock 1998). In common with other G protein-
coupled receptors, P1 receptors have seven putative transmembrane (TM) 
domains of hydrophobic amino acids, each believed to constitute an α-helix of 
approximately 21 to 28 amino acids. The N-terminal of the protein lies on the 
extracellular side and the C-terminal on the cytoplasmic side of the membrane. A 
pocket for the ligand binding site is formed by the three-dimensional arrangement 
of the α-helical TM domains. The agonists are believed to bind within the upper 
half of this pore (Ralevic & Burnstock 1998). The transmembrane domains are 
connected by three extracellular and three cytoplasmic hydrophilic loops of 
unequal size. Typically the extracellular loop between TM4 and TM5 and the 
cytoplasmic loop between TM5 and TM5 are extended. These features are 
illustrated in a schematic of the A1 receptor in Figure 1.2 (Ralevic & Burnstock 
1998). Analogs with greater stability and selectivity than adenosine are produced 
by modifying the N6 and C2 positions of the adenine ring and the 5’-position of 
the ribose moiety of adenosine (Fig. 1.3); chemical structures of xanthine, 
xanthine derivatives and non-xanthine compounds as antagonists of P1 receptors 
are illustrated in Figure 1.4. Adenosine receptor agonists and antagonists have 
been extensively used in the characterization of adenosine receptors and the study 
of the physiological roles of adenosine. A milestone in the development of 






Fig. 1.2 Schematic of the A1 adenosine receptor. In common with other G protein-
coupled receptors, the A1 receptor has seven putative transmembrane domains (I-VII) of 
hydrophobic amino acids, each believed to constitute an α-helix which is connected by 
three extracellular and three intracellular hydrophilic loops. The number of amino acids 
comprising the extra- and intracellular loops and the extracellular N-terminal and 
intracellular C-terminal regions of the bovine A1 receptor are indicated in parentheses 
(Olah et al. 1992). The transmembrane regions comprise 23-25 amino acids in the bovine 
A1 receptor (Olah et al. 1992). The arrangement of the transmembrane regions forms a 
pocket for the ligand binding site. The location of histidine residues (H) in the 
transmembrane regions VI (position 254) and VII (position 278) in the bovine A1 
receptor, which are believed to be important in ligand binding (Olah et al. 1992), are 
indicated. Extracellular and transmembrane regions of the protein believed to be 
important in agonist and antagonist binding are indicated (Olah et al. 1994a, b), S-S 
denotes the presence of hypothetical disulfide bridges (Jacobson et al. 1993). 










Fig. 1.4 Chemical structures of some antagonists at adenosine/P1 receptors. 
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and classification of adenosine receptors by International Union of Pharmacology 
in which the history, development and the current knowledge of the molecular 
biological, biochemical, physiological and pharmacological aspects of adenosine 
receptors were best reviewed (Fredholm et al. 2001). The nomenclature and 
classification of adenosine receptors, together with P2 receptors are briefly 
summarized in Table 1. 
 
P2 receptors were shown to be either ligand-gated cation channels (Benham & 
Tsien 1987) or involved in G protein activation (Dubyak 1991), which formed the 
basis of their subdivision into two main groups termed P2X receptors (ligand-
gated cation channels) and P2Y receptors (G protein-coupled receptors) 
(Abbracchio & Burnstock 1994, Fredholm et al. 1994). Subtypes are defined 
according to the molecular structures of cloned mammalian P2 receptors, 
discriminated by different numerical subscripts (P2Xn or P2Yn) (Burnstock & 
King 1996, Fredholm et al. 1996a). This forms the basis of a system of 
nomenclature that will replace the earlier subtype nomenclature (including P2X, 
P2Y, P2U, P2T and P2Z receptors) as correlations between cloned and 
endogenous receptors are established. P3, P4 and P2Yap4A (or P2D) receptors 
have been proposed, but evidence for their existence was based solely on the 
distinct pharmacological profiles exhibited in some biological tissues. As this is 
no longer tenable for the identification and subclassification of receptors, it 
remains to be determined, preferably by molecular studies, how these correlate 
with cloned P2 receptors, and therefore exactly how they will fit within a unifying 
system of purine and pyrimidines receptor nomenclature.  
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1.1.2.2 Signal Transduction of Adenosine/P1 Receptors 
1.1.2.2.1 Signal Transduction of A1 Receptors 
The adenosine/P1 receptor family comprises A1, A2A, A2B and A3 adenosine 
receptors, identified by confirming data from molecular, biochemical and 
pharmacological studies (Table 2). Receptors from each of these four distinct 
subtypes have been cloned from a variety of species and characterized following 
functional expression in mammalian cells or Xenopus oocytes (Ralevic & 
Burnstock 1998). A1 and A2 receptors were described by Van Calker et al. and 
Londos et al. independently (van Calker et al. 1979, Londos et al. 1980), using 
different nomenclature (Ri corresponding to the A1 subtype and Ra to the A2 
subtype, “R” to designate the “ribose” moiety of the nucleoside, “i” and “a” to 
indicate inhibition and activation of adenylate cyclase respectively). A1A and A1B 
receptors have been proposed (Tucker & Linden 1993), but this subdivision of the 
A1 receptors remains equivocal. A1 receptors mediate multiple physiological 
functions of adenosine. Cardiac A1 receptors activation result in negative 
chronotropic, inotropic and dromotropic effects (Olsson & Pearson 1990), and 
play a role in the protective effect of adenosine in preconditioning (Lasley et al. 
1990). A1 receptors in kidney are implicated in vasoconstriction and inhibition of 
rennin release (Osswald et al. 1978). In the central nervous system (CNS), A1 
receptors mediate the prejunctional inhibition of neurotransmission (Masino et al. 
2002). A1 receptors are also involved in bronchoconstrictive (Mann & Holgate 
1985), antilipolytic (Ebert & Schwabe 1973) and antinociceptive responses 




In common with other G protein-coupled receptors, signal transduction by all 
adenosine receptor subtypes proceeds through activation of specific G protein 
subsets (Table 2). The A1 adenosine receptors are coupled to pertussis toxin-
sensitive G proteins of the Gi/G0 family (Munshi & Linden 1989, Munshi et al. 
1991, Freissmuth et al. 1991, Jockers et al. 1994). Species differences in this 
coupling may direct signaling differently depending on the species (Freissmuth et 
al. 1991). Human and rat A1 receptors preferentially interact with Gi isoforms 
rather than with G0 (Jockers et al. 1994, Lorenzen et al. 1998). 
 
The relevance of the contribution of G protein βγ-subunits to signal transduction 
via adenosine receptors has been less well studied than the α subunit. Evidence for 
the importance of βγ-subunits comes from studies which demonstrate that the 
composition of βγ-subunits modulates agonist binding and the interaction of the 
A1 receptor with G protein α subunit (Figler et al. 1996, Figler et al. 1997). The 
phenyl group on the G protein γ subunit influences high-affinity agonist binding to 
A1 receptors and agonist-induced guanine nucleotide exchange on the α subunit 






Table 2. Classification of adenosine/P1 receptors. 
 A1 A2A A2B A3 
Molecular mass 36.5 kDa 44.7 kDa 36.3 kDa 36.2 kDa 
Amino acids 326 412 332 318 
Sequence 
information P30542 P29274 P29274 P33765 
Gene 1q32.1 22q11.2 17p11.2 1p13.3 































N 0861,  
FK 453,  
WRC 0571 












AC, adenylate cyclase; PLC, phospholipase C; K+, potassium channels; Ca2+, calcium 
channels. ↑ and ↓ denote stimulation or inhibition, respectively. Sequence information is 
given as the SwissProt accession number for human adenosine receptors. 
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1.1.2.2.2 Signal Transduction of A2A and A2B Receptors 
A2 receptors are further subdivided into A2A and A2B, originally based on the fact 
that adenosine-mediated stimulation of adenylate cyclase in rat brain was effected 
via distinct high affinity binding sites (localized in striatal membranes) and low 
affinity binding sites (present throughout the brain) (Daly et al. 1983). This 
subdivision was supported by Bruns et al. (Bruns et al. 1986) in a similar study 
carried out in a human fibroblast cell line. Definitive evidence for the existence of 
these two subtypes comes from the cloning and sequencing of distinct A2A and 
A2B receptors which show distinct pharmacological profiles in transfected cells 
similar to those of the endogenous receptors. A2A receptors inhibit spontaneous 
locomotor activity and induce a hypomotility resembling that induced by typical 
neuroleptics (Bridges et al. 1987). A2A receptor gene knock-out mice exhibited 
aggressive behavior and could not be stimulated by caffeine, suggesting that A2A 
receptors exert a tonic central depressant action (Ledent et al. 1997). Adenosine 
A2A receptors also mediate the adenosine-induced inhibition of neutrophil 
activation (Fredholm et al. 1996b), the inhibition of human T-cell activation 
(Koshiba et al. 1999) and the mitogenic action of adenosine on human endothelial 
cells (Sexl et al. 1997). The most important functional role of A2B receptors may 
be the involvement in adenosine-induced vasodilation in some vascular beds 
(Webb et al. 1992). In addition, A2B receptors modulate secretion of 
neurotransmitters in the brain and in the periphery and may mediate effects of 
lamin-related secretory protein netrin-1 on axon outgrowth (Corset et al. 2000). 
 
The most thoroughly investigated signal transduction mechanism of A2B adenosine 
receptors is the stimulation of adenylate cyclase via Gs protein, to their activation 
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of protein kinase A (PKA). The selective action of the protein Gs by A2A receptors 
is dependent on the aminoternimal region of the third intracellular loop, especially 
Lys-209 and Glu-212, with some additional modulation by Gly-118 and Thr-119 
(Olah 1997). Other signaling pathways independent of increased cAMP have been 
described, but are less well understood: A2A adenosine receptors on striatal nerve 
terminals inhibit the release of GABA through a mechanism which involves N-
type Ca2+ channels and protein kinase C (PKC), but is independent of PKA or 
PKC (Kirk & Richardson 1995). In the A2A receptor-induced increase of 
acetylcholine release from striatal nerve terminals, two distinct signaling pathways 
are activated: a cholera-toxin sensitive mechanism involving Gs, cAMP increase, 
PKA and P-type Ca2+ channels and secondly, a cholera-toxin-insensitive pathway 
in which PKC and N-type channels contribute to the signal (Gubitz et al. 1996). 
 
A2B adenosine receptors are coupled to adenylate cyclase in a stimulatory manner 
(Brackett & Daly 1994, Feoktistov & Biaggioni 1995, Auchampach et al. 1997) 
and to activation of phospholipase C (PLC) via a pertussis- and cholera-toxin-
insensitive G protein, probably Gq (Feoktistov & Biaggioni 1995, Auchampach et 
al. 1997, Yakel et al. 1993). In a probably cAMP- and PLC-independent manner, 
A2B adenosine receptors reduce nicotinic agonist-stimulated catecholamine release 
from bovine adrenal chromaffin cells, possibly activation of a protein 
phosphastase in the cytosol (Mateo et al. 1995). Mitogenic signaling through 
activation of p21ras secondary to Gs or Gq activation is stimulated by A2B 





1.1.2.2.3 Signal Transduction of A3 Receptors 
In contrast to A1, A2A and A2B receptors, A3 receptor was identified by homology 
cloning (Zhou et al. 1992). Subsequent studies in sheep, human and rat suggested 
a wide mRNA expression in many tissues including testis, lung, liver, aorta, 
kidney, placenta, heart, brain, spleen, uterus, bladder, jejunum, eye and discrete 
loci of CNS (Linden 1993, Salvatore et al. 1993, Dixon et al. 1996, Atkinson et 
al. 1997). Important functional responses mediated by A3 receptors are the 
stimulation of histamine release from a rat mast cell line (Ramkumar et al. 1993), 
depression of locomotor activity in mice (Walker et al. 1997a) and 
cardioprotective and neuroprotective actions of adenosine (Von Lubitz et al. 1994, 
Liang & Jacobson 1998). 
 
A3 adenosine receptors interact with Gi (αi2 and αi3) and Gq-like G proteins 
(Palmer et al. 1995), inhibiting adenylate cyclase (Zhou et al. 1992) via a pertussis 
toxin sensitive G protein and stimulating PLC, leading to inositol phosphate 
generation and increased levels of intracellular Ca2+ (Ramkumar et al. 1993, 
Abbracchio et al. 1995a). 
 
Noticeably, there is a considerable lack of amino acid sequence homology 
between cloned A1, A2A, A2B and A3 receptors. The homology between rat A1 and 
A2B receptors is only 44% (Stehle et al. 1992), the human A3 receptor only shows 
approximately 47%, 38% and 36% homology with human A1, A2A and A2B 
receptors respectively. (Table 3). The homology between A2A and A2B receptors is 
also slight, being approximately 46% when these subtypes are cloned from rat and 




Table 3. Amino acid sequence homologies (%) between human adenosine 
receptor subtypes. 
 A1 A2A A2B A3 
A1 100    
A2A 47 100   
A2B 44 56 100  
A3 47 38 36 100 
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1.1.3 Nucleoside Transporters 
In spite of the vast involvement of adenosine receptors in adenosine’s 
physiological roles, some actions of adenosine cannot be attributed to P1 
adenosine receptors. Receptor agonist and antagonist studies showed that many 
effects of adenosine are not mimicked by its agonists nor blocked by its 
antagonists (Ethier & Dobson 1997, Braumann et al. 1986, Haun et al. 1996, Zurn 
& Do 1988, Rosenthal & Lowenstein 1991, Van Daele et al. 1992). These 
observations suggest the existence of adenosine transportation in some of its 
physiological actions. Although adenosine transportation was traditionally 
believed to play an important role in adenosine metabolism, further studies 
showed that it is an important determinant of the pharmacokinetics, plasma and 
tissue concentration, disposition and in vivo biological activity of adenosine in 
mammals (Thorn & Jarvis 1996). 
 
Adenosine transportation is conducted by non-specific membrane nucleoside 
transporters. Unlike adenosine receptors, nucleoside transporters have a wide 
spectrum of physiological substrates. Membrane nucleoside transporters are 
categorized into two groups on the basis of transport mechanisms: the 
equilibrative or facilitated-diffusion and the concentrative or active nucleoside 
transporters driven by the transmembrane sodium gradient (Griffith & Jarvis 
1996). 
 
The equilibrative nucleoside transporters are “facilitators” and are driven solely by 
the concentration of nucleoside permeates. These transporters are independent of 
the sodium levels across the plasma membrane and further subdivided on the basis 
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of sensitivity to nanomolar concentrations of the transport inhibitor 
nitrobenzylthioinosine (NBMPR/NBTI) into es (equilibrative & sensitive) type 
and ei (equilibrative & insensitive) (Griffith & Jarvis 1996). The es transporter has 
a broad substrate specificity (apparent Km for adenosine ~ 25 μM in many cells at 
25 oC) is a glycoprotein with an average Mr. of 57,000. The ei transporter also has 
broad substrate specificity with lower affinity for adenosine than the es carrier. 
 
Concentrative or active nucleoside transporters are Na+-dependent and transport 
nucleosides downhill the sodium gradient. They are classified into 5 subtypes 
according to the permeate selectivity and sensitivity to NBTI: cif, cit, cib, cs and 
csg (Cass et al. 1998). Table 4 summarizes the family of nucleoside transporters. 
                                                 
NBTI, S-(4-nitrobenzyl)-6-thioinosine, acquired its early name NBMPR because it was formerly 
named as nitrobenzylmercaptopurine ribonucleoside. NBMPR was the name used exclusively in 
most early pharmacological studies on nucleoside transporter studies. To avoid confusion, NBTI is 

























Driven by transmembrane sodium 
gradient 
NBTI sensitivity + - - - - - + 




1.1.4 The Physiological Distribution of Adenosine 
 
1.1.4.1 Physiological Release of Adenosine 
With the unequivocal demonstration that purine and pyrimidine nucleosides and 
nucleotides function as key extracellular messengers in all mammalian tissue 
systems (Ralevic & Burnstock 1998), a major challenge has been to understand 
the factors that govern purine availability in the extracellular space and the 
dynamics of the process. 
 
Recent advances in the molecular biology of nucleoside transporters identified 
two protein families responsible for the transmembrane transport of nucleosides. 
These two families have been designated as the equilibrative and concentrative 
nucleoside transporters families (Cabrita et al. 2002, Cass et al. 1998). Among 
them, the concentrative nucleoside transporters are primarily expressed in 
epithelial cells, while the equilibrative transporters are found in most mammalian 
cell types (Cabrita et al. 2002, Cass et al. 1998, Thorn & Jarvis 1996). 
Equilibrative transporters have different isoforms and the members of this family 
correspond to nucleoside transporters identified biochemically in earlier papers in 
brain synaptosomes (Thorn & Jarvis 1996) and dissociated cells (Geiger et al. 
1988). These carriers might be sensitive or insensitive to nanomolar 
concentrations of the transport inhibitor nitrobenzylthioinosine (NBTI), the latter 
corresponding to [3H] NBTI binding sites (Geiger & Nagy 1984), and they form 
the target site of different nucleoside uptake inhibitors used in clinical practice, 
such as dipyridamole and dilazep (Thorn & Jarvis 1996). Equilibrative 
transporters can function bidirectionally, i.e., they are able to transport adenosine 
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in both inward and outward directions depending on the chemical gradient. 
Although different isoforms of this family exhibit different substrate specificities, 
and other nucleosides, like inosine and uridine could be also transported by this 
carrier, the preferred substrate is adenosine (Geiger et al. 1988, Thorn & Jarvis 
1996). 
 
When adenosine is taken up into cells via nucleoside carrier transport it is readily 
incorporated into ATP stores via phosphorylation by adenosine kinase (EC 
2.7.1.20) and adenylate kinase (EC 2.7.4.3) (Fisher & Newsholme 1984) such that 
intracellular adenosine concentrations are at the submicromolar level under 
physiological energetic conditions (Fredholm et al. 1984). The same pathway, 
however, may also work in the opposite direction and give rise to the formation of 
adenosine by the cytosolic 5’-nucleotidase enzyme when ADP and AMP levels 
are increased due to decreased ATP production or increased ATP utilization. 
Adenosine might as well be produced from S-adenosylhomocysteine by S-
adenosylhomocysteine hydrolase enzyme as part of an essential transmethylation 
pathway (Lloyd et al. 1988). The third important mechanism to balance the 
intracellular adenosine level is the adenosine deaminase enzyme, which 
metabolizes adenosine to inosine by deamination and prevents any increase in 
intracellular adenosine above the normal level (McCaman & McAfee 1986). 
 
Ex vivo values of adenosine range from 0.067 to 1.05 μM (Capogrossi et al. 
1982). Adenosine is subjected to extremely rapid elimination in biological 
material with a plasma half-life in human blood of approximately 10 s (Klabunde 
1983, Moser et al. 1989). Adenosine is released by a variety of normal, 
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stimulated, and /or injured cells and tissues. Unlike various endocrine hormones, 
adenosine represents a general regulatory substance, since no particular cell type 
or tissue appears uniquely responsible for its formation. Adenosine plays a role as 
an autocrine-paracrine regulator. 
 
In non-excitable cells, the major stimulus which elevates intercellular adenosine 
levels is energy deprivation simulated by O2 and glucose deprivation in in vitro 
experiments (Lloyd et al. 1993, Juranyi et al. 1999) and blood vessel occlusion in 
in vivo models (Phillis et al. 1994, Hagberg et al. 1987). Under these conditions, 
cytoplasmic adenosine levels, which typically do not surpass micromolar levels, 
now increase up to 30 μM (Latini et al. 1999). The increased extracellular 
accumulation of adenosine during energy deprivation is well documented, and 
previous studies emphasized the intracellular formation of adenosine (Hagberg et 
al. 1987, Lloyd et al. 1993). However, intracellular ATP stores are replenished 
within a relatively short period of time after the ischemic insult (Doolette 1997), 
and the possibility that ATP release might occur during reperfusion also exists. 
ATP is released from heart cells in response to hypoxia (Forrester & Williams 
1977, Vial et al. 1987), which can be enzymatically converted to adenosine 
quickly under physiological and pathological conditions, and ischemia-induced 
release of purine nucleotides in the isolated perfused guinea pig Langendorff heart 
has been also reported (Borst & Schrader 1991). Combined hypoxia-
hypoglycemia for 5 min resulted in a massive efflux of [3H] purines from rat 
hippocampal slices with a net efflux of ATP (2.5-fold) and adenosine (5-fold) and 
other purines including inosine and hypoxanthine, but not AMP or ADP (Juranyi 
et al. 1999). During ischemia, purines may be released in a receptor-mediated 
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manner in response to the action of other mediators released either during or after 
ischemia. These include excitatory amino acids or nitric oxide (NO) (Juranyi et al. 
1999).  
 
1.1.4.2 Pathological Release of Adenosine 
Extracellular purines, especially adenosine and ATP, may also act as pathological 
signaling substances contributing to disease pathophysiology. In cases of 
ischemia, extracellular purine levels are increased when the supply/demand ratio 
of energy inside the cell is unbalanced (Bruns 1990) as occurs following ischemia 
when the main substrates necessary for mitochondrial oxidative phosphorylation 
and energy production, e.g., oxygen and glucose, are cut off because of the 
shortage of these substrates, cells cannot synthesize high-energy phosphates, and a 
massive reduction of tissue ATP content occurs (Milusheva et al. 1996). The 
relative ADP and AMP levels are therefore increased and the energy charge used 
to define the energetic condition of the cell (defined as [ATP] + 0.5[ADP]/[ATP] 
+ [ADP] + [AMP] (Atkinson 1968)) falls (Milusheva et al. 1996). Increased AMP 
levels in turn activate 5’-nucleotidase and give rise to increased formation of 
adenosine, which might leave the cell via the nucleoside transport system (Meghji 
et al. 1988). Cytoplasmic adenosine levels therefore are coupled to small changes 
of ATP levels and energy charge and this mechanism provided the basis of the 
concept on the role of adenosine as a ‘retaliatory’ (Newby 1984) or ‘homeostatic’ 
regulator (Schrader 1990, Cunha 2001).  
 
In addition to hypoxia/hypoglycemia/energy deprivation, inflammatory stimuli 
cause significant adenosine and ATP release as well. ATP is released by mast 
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cells in response to antigenic stimulus (Osipchuk & Cahalan 1992), from 
lymophocytes (Filippini et al. 1990), and from macrophages and microglial cells, 
in response to bacterial lipopolysaccharide (LPS)  stimulus (Sperlagh et al. 1998, 
Ferrari et al. 1997). 
 
ATP release may also occur as the result of hypotonia. Cultured liver or ocular 
ciliary epithelial cells release ATP in response to hypotonic solution, a response 
blocked by chloride channel blockers (Mitchell et al. 1998, Wang et al. 1996), 
indicating that an increase in cell volume leads to ATP efflux through the opening 
of a conductive pathway, which in turn stimulates P2 receptors and initiates 
chloride secretion. ATP may therefore function as an autocrine factor that couples 
increases in cell volume to opening of Cl- channels. Since hypotonic swelling 
occurs in pathophysiological states, this mechanism may also account for the 
release of purines in these conditions. 
 
1.1.4.3 Nucleoside/Nucleotide Release by Cell Death 
Since ATP is present in the cytoplasm of every living cell, disruption of the cell 
membrane results in ATP leakage to the extracellular space. ATP released 
following cytolysis is several orders of magnitude higher in concentration than 
that occurring as the result of either stimulus-evoked or receptor-mediated purine 
release. Additionally, it is irregular, variable, and independent of the functional 
activity of the tissue. Therefore, it is unlikely that a significant cytolysis occurs 
under physiological conditions. Cytolytic release of ADP may gain significance 
under any kind of pathological conditions which result in substantial cell damage. 
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This might occur in neurodegenerative diseases, ischemia-related diseases, 
inflammation, disruption of tumors etc. 
 
The ubiquitous cellular distribution of adenosine and ATP provides a unique 
plasticity for purinergic signaling. Functional adenosine and ATP release occurs 
from various types of neurons such as catecholaminergic, cholinergic, 
glutamatergic neurons, and from glial cells, epithelial and endothelial, skeletal, 
cardiac, smooth muscle, and immune cells. Purine release potentially occurs via 
quantal vesicular exocytosis, carrier mediated release, or by membrane leakage 
and has different characteristics under normal physiological conditions and in 
pathological states such as hypoxia, hypoglycemia, inflammation as well as 
apoptosis and necrosis, providing an ‘inducible’ response under disease conditions 
that can have both detrimental and beneficial effects. 
1.2 Apoptosis 
1.2.1 Apoptosis: Past and Present 
The modern study of apoptosis, also known as programmed cell death (Lockshin 
& Williams 1965a, b, c, d) started with the early recognition in the 1970’s by 
Kerr, Wyllie and their co-workers that a variety of animal cells die with similar 
morphological features which appeared to be the result of an active suicidal 
process (Kerr et al. 1972). The Greek-originated name of apoptosis was also 
coined in the same article suggesting as it does the discrete image of leaves 
dropping off here and there from a tree (apo, meaning from; ptosis, meaning fall). 
Pathologists and developmental biologists have cataloged the occurrences of 




What propelled apoptosis into the forefront of basic research has been the 
identification of genes that control cell death and the appreciation of the role of 
apoptosis in development and disease. The study of apoptosis only saw a 
remarkable boom since the identification of genes involved in oncogenesis such as 
Bcl-2, and genetic research on cell death mutants by Professor Horvitz and his 
coworkers in the nematode Caenorhabditis elegans (C. elegans) in the 1980’s.  
 
The C. elegans hermaphrodite undergoes a distinct and invariant pattern of 
programmed cell death where the same 131 cells out of 1090 cells die during the 
development of this 959 cell nematode. Sydney Brenner envisioned that this 
nematode would be an ideal model organism to define specific genes responsible 
for the developmental cell fates (Brenner 1974). John Sulston mapped cell 
lineages in C. elegans, noting they were invariant and that specific cells always 
die (Sulston 1976). Horvitz had the insight to mutagenize C. elegans, in order to 
identify genes regulating all 131 somatic cell deaths (Ellis & Horvitz 1986). For 
their pioneering contributions to developmental genetics and programmed cell 
death, the triumvirate of Brenner, Horvitz, and Sulston received the 2002 Nobel 
Prize. Three genes, ced (cell death abnormality)-3, -4, and -9 were identified to be 
involved for all deaths (Hengartner & Horvitz 1994), ced-9 proved to be the worm 
homolog of the mammalian Bcl-2 (B cell lymphoma) oncogene, which had been 




1.2.2 Physiological and Pathological Significance of Apoptosis 
Apoptosis is used by multicellular organisms for development and morphogenesis, 
to control cell number, and as a defensive strategy to remove infected, mutated, or 
damaged cells. 
 
Apoptosis is an essential means for removal of unwanted cells in normal 
development and adult tissue homeostasis, and is an important defense against 
viral infection and the emergence of cancer. In a human about a hundred thousand 
cells are produced every second by mitosis, and a similar number die by a 
physiological suicide process, i.e. apoptosis. Most of the cells produced during 
mammalian embryonic development undergo physiological apoptosis before the 
end of the parental period. During our life span, over 99.9% of our cells undergo 
the same fate. (Vaux & Korsmeyer 1999).  
 
Dysregulation of apoptosis leads to a variety of human pathologies ranging from 
myocardial infarction, stroke, neurodegenerative disorders such as Alzheimer's 
and Parkinson's that are due to inappropriate cell loss to illnesses that are 
associated with excessive cell accumulation (cancer) and failure to eradicate 




1.2.3 Bcl-2 Family of Proteins 
The proto-oncogene bcl-2 was first identified as part of the most common 
translocation in human B cell follicular lymphoma when three laboratories 
independently cloned the t(14;18) chromosomal translocation breakpoint 
(Tsujimoto et al. 1984, Tsujimoto et al. 1985a, Tsujimoto et al. 1985b, Bakhshi et 
al. 1985, Cleary et al. 1986). Unlike other oncogenes characterized at that time, 
Bcl-2 had the unusual property of extending cell survival rather than stimulating 
cell proliferation (Vaux et al. 1988, Hockenbery et al. 1990). Bcl-2 has since been 
shown to enhance cell survival by inhibiting apoptosis induced under a wide 
variety of circumstances, suggesting that it is a ubiquitous inhibitor of cell death 
triggered by multiple routes.  
 
More than 10 other proteins have been identified to share three conserved regions, 
Bcl-2 homology region 1, 2 and 3 (BH1, BH2 and BH3), in mammals, birds, 
frogs, nematodes and viruses up to date (with exceptions of BH3 only members). 
These proteins can be functionally divided into two groups. Those from the first 
group (‘anti-apoptosis’), like its founding member Bcl-2, inhibit apoptosis. They 
include Bcl-xL, Bcl-w, A1, Mcl-1, nematode Ved-9, adenovirus E1B19kD, EBV 
(Epstein Barr Virus) BHRF1, ASFV (African Swine Fever Virus) LMW5-HL, 
Human Herpes Virus 8 KSBcl-2 and Herpes Virus Saimiri ORF16. Proteins from 
the second group (‘pro-apoptosis’) enhance cell death under conditions of stress. 





Caspases are the central components of the apoptotic response (Thornberry & 
Lazebnik 1998, Shi 2002). Caspases are so-named as they are cysteine proteases 
that cleave after an aspartate residue in their substrate (Alnemri et al. 1996). 
Although the first caspase, interleukin-1β-converting enzyme (ICE, a.k.a. caspase-
1), was identified in humans, the critical involvement of caspases in apoptosis was 
discovered in the nematode worm Caenorhabditis elegans, in which the 
indispensable gene ced-3 (cell-death abnormality-3) was found to encode a 
cysteine protease that closely resembles the mammalian ICE (Yuan et al. 1993, 
Xue et al. 1996). Since then, at least 14 distinct mammalian caspases have been 
identified, of which 11 are found in humans (Shi 2002). 
 
Over the past decade, many key events in caspase regulation have been 
documented at the molecular and cellular level, with the earlier focus on the 
genetic and cell biological characterization and later on biochemical and structural 
investigations, giving rise to a clarity in the understanding of caspase function. 
 
Although the first mammalian caspase (caspase-1) was identified as an important 
regulator of the inflammatory response, at least 7 of the 14 known mammalian 
caspases have important roles in apoptosis. The apoptotic caspases are generally 
divided into two classes: the initiator caspases, which include caspase-2, -8, -9 and 
-10 in mammals, and the effector caspases. An initiator caspase is characterized 
by an extended N-terminal region, which comprises one or more adaptor domains 
that are important for its function, whereas an effector caspase usually contains 




All caspases are produced in cells as catalytically inactive precursors which need 
to undergo proteolytic activation during apoptosis. The activation of an effector 
caspase, such as caspase-3, is carried out by an initiator caspase, such as capsase-
9, through cleavage at specific internal Asp residues that separate the large (p20) 
and small (p10) subunits. The p20 and p10 subunits then closely associate with 
each other to form a caspase heterotetramer. By contrast, the initiator caspases are 
auto-activated. The activation of initiator caspases is precisely regulated as it 
inevitably triggers a downstream effector caspase activation cascade. Once 
activated, the effector caspases are responsible for the proteolytic cleavage of a 
broad spectrum of cellular targets, which ultimately leads to cell death. 
 
1.2.5 Intrinsic and Extrinsic Apoptotic Signaling Pathways 
In mammalian cells, apoptosis is mediated though either the intrinsic or the 
extrinsic pathway, depending on the death stimuli. These two distinct signaling 
pathways were first identified by Scaffidi et al. in 1998 in two cell types (Scaffidi 
et al. 1998). In type I cells, SKW6.4 and H9, induction of apoptosis is 
accompanied by activation of large amounts of caspase-8 by the death-inducing 
signaling complex (DISC), the effector caspase 3 is activated by caspase 8 
(extrinsic pathway); whereas in type II cells, CEM and Jurkat, DISC formation is 
strongly reduced and caspase 3 activation occurs following the loss of 
mitochondrial membrane potential (ΔΨm) and cytochrome c release from 




The intrinsic pathway is mediated by mitochondria, and, in response to a wide 
range of death stimuli that are generated from within the cell, such as oncogene 
activation and DNA damage, several proteins are released from the 
intermembrane space of mitochondria into the cytoplasm. Some of the well-
characterized proteins include cytochrome c, SMAC (second mitochondria-
derived activator of caspases)/DIABLO (direct inhibitor of apoptosis (IAP)-
binding protein with low pI), AIF (apoptosis-inducing factor), EndoG 
(endonuclease G) and OMI/HTRA2 (high-temperature-requirement protein A2). 
The most intriguing one of these pro-apoptotic proteins is cytochrome c, which 
binds to and activates the protein Apaf-1 in the cytoplasm, inducing a 
conformational change that allows Apaf-1 to bind to dATP and to form the 
apoptosome, mediating the activation of caspase-9 (Li et al. 1997). 
 
The extrinsic pathway is initiated by the binding of an extracellular death ligand, 
such as FasL, to its cell-surface death receptor, such as Fas. The death ligands are 
constitutively homotrimeric, so binding to their receptors leads to the formation of 
a homotrimeric ligand-receptor complex that recruits further cytosolic factors, 
such as FADD (Fas-associated death domain) and caspase-8, forming an 
oligomeric death-inducing signaling complex (DISC). Formation of the DISC 
leads to the activation of the initiator caspase-8, which in turn cleaves and 
activates the effector caspase-3. 
 
Crosstalk exists between the extrinsic and the intrinsic pathways through the 





1.3 Adenosine-Induced Apoptosis (AIA) 
 
In spite of the wide spectrum of physiological effects by adenosine, its role as a 
regulator of cell growth and/or cell death has drawn attention only recently, 
partially due to the lack of knowledge in apoptosis in the early days. Adenosine 
modulates the proliferation, survival and apoptosis of many different cell types, 
ranging from epithelial, endothelial and smooth muscle cells, to cells of the 
immune and neural lineages. On the one hand, adenosine exerts profound long-
term trophic actions on target cells in many organs. It acts in concert with 
conventional growth factors, cytokines and other growth-regulatory molecules to 
regulate cell proliferation, apoptosis and differentiation (Ceruti et al. 2000, 
Rudolphi et al. 1992). Evidence has been accumulating during the years to support 
a role for adenosine in development, ischemia and reperfusion injury, 
inflammation, aging-associated neurodegenerative diseases, wound healing, bone 
resorption and cancer. Studies also demonstrated that these trophic actions involve 
the activation of specific extracellular receptors or intracellular mechanisms that 
may represent targets for selective ligands to develop novel drugs. On the other 
hand, there is growing evidence showing that adenosine has cytotoxic properties. 
Available data about the cytotoxic effects of adenosine have extended from 
studies involving cells of the immune system (Szondy 1994, Walker et al. 1997b, 
Barbieri et al. 1998) to cells of the nervous system (Abbracchio et al. 1995b, 
Wakade et al. 1995) and endothelial cells (Shneyvays et al. 1998, Peyot et al. 
2000). The effects of extracellular purines on cell growth and cell death and 




Although the pharmacological effects of adenosine result from its interaction with 
cell surface purinoceptors or transporters, our knowledge about the role of these 
receptors in the cytotrophic and cytotoxic effects of adenosine remains 
incomplete. This is mainly due to the fact that only in a few studies selective 
purinoceptor agonists and antagonists have been used. The toxicity of adenosine 
towards mouse thymocytes can be mimicked by 2-chloroadenosine, and to a 
certain lesser extent by NECA, CHA and R-PIA (Kizaki et al. 1990), whereas 
with human thymocytes, the toxicity displays a structure-activity relationship of 
CGS-21680 > NECA > CPA > 2Cl-Ado (Szondy 1994). HL-60 cells on the other 
hand were killed by the analogues, 2Cl-Ado, IB-MECA and Cl-IB-MECA (Kohno 
et al. 1996). Taken together these studies suggest the involvement of P1 
purinoceptors in the toxicity of adenosine, although the intracellular pathways of 
the mechanisms remain unclear. 
 
In addition to the involvement of purinoceptors, there is evidence suggesting that 
transporters may play a role under certain conditions (Barbieri et al. 1998, Tanaka 
et al. 1993, Rounds et al. 1998, Wakade et al. 1995, Szondy 1995). Using 
different cell systems, contrasting data were obtained by independent researchers. 
Blom et al. (1999) and Walker et al. (1997b) showed that adenosine had cell 
proliferative effects mediated by purinoceptors on rat hepatocytes and human 
neutrophils. In spite of the established evidence of the cytotoxic effects of 
adenosine, its cytoprotective role is still considered as the major physiological 




Table 5. Effects of extracellular purines on cell growth. 
Cell type Agonist [Conc] Effect Pathway Reference 













A3  (Kohno et al. 1996) 









(Barbieri et al. 1998) 
mammalian astroglial cells 2Cl-Ado 10mM - P1 (Ceruti et al. 1997) 








P1 (Szondy 1994) 
human thymocytes 2Cl-dAdo 5nM-1M - transporter(s) (Szondy 1995) 



















A3  (Yao et al. 1997) 
immature thymocytes ATP 0-100M  P2X1, P2X7 (Chvatchko et al. 1996) 
human epidermoid carcinoma (A431) cells Ado 0-1mM  A1, A2  (Tey et al. 1992, Tey et al. 1994) 
BHK cells Ado 0-200M  transporter (Mittal et al. 2000) 
HL-60 Ado 1mM - transporter(s) (Tanaka et al. 1993) 
chick embryonic sympathetic neurons Ado 1-100M - transporter(s) (Wakade et al. 1995) 
human arterial smooth muscle cells Ado 1-100M - A2b (Peyot et al. 2000) 






transporter(s) (Rounds et al. 1998) 
rat thymocytes ATP 2mM -  (Kass et al. 1996) 
murine CTLL-R8 cells ATP 0.025-1.5mM -  (Zheng et al. 1991) 
BHK cells Ado 0-1 mM  A1, A3, es/ei (Sun et al. 2005) 
 
Effect: 
+ = cytotrophic   
- = cytotoxic   
 = biphasic 
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frequently ignored, the apoptotic effect of adenosine is underestimated and our 
knowledge about the real mechanisms by which adenosine acts on cells remains 
incomplete. However, the dual cytotrophic and cytotoxic role of adenosine 
suggests a complexity of adenosine signaling as a physiological cellular regulator. 
Several hypotheses have attempted to reconcile these conflicting and paradoxical 
actions. 
 
Firstly, in certain instances, cell death mediated by adenosine may indeed 
represent a protective rather than a detrimental action. This may apply to 
adenosine-induced apoptosis of thymocytes which may play a key role in the 
elimination of auto-reactive clones during immune system development and to 
adenosine-induced neuronal and astroglial cell death, which may participate in the 
elimination of irreversibly-damaged cells in post-ischemic and post-traumatic 
brain (Neary et al. 1996). Such an event may be crucial to reallocating energy and 
resources to damaged brain areas that still retain a chance for recovery.  
 
Secondly, the detrimental effects mediated by adenosine under specific 
pathological conditions may simply represent a dysregulation of the physiological 
control normally exerted by adenosine on specific functions.  
 
Thirdly, the trophic activity of nucleosides on astrocytes and neurons may be 
beneficial in promoting neuronal regeneration while an excess of reactive 
astrocytes may inhibit regeneration and remyelination. Astrocytes also possess 




In addition to the dual cytotrophic and cytotoxic role of adenosine in different cell 
types, it has also become evident that adenosine has biphasic effects on cell 
viability within one cell type at different concentrations. Adenosine can be both 
protective and detrimental and mediate both life-saving and life-threatening 
effects, depending on the experimental setting. In many instances, both trophic 
and toxic actions have been reported in the same target cells, suggesting that 
modulation of cell viability and differentiation by adenosine is a highly-regulated 
phenomenon, which may involve different receptor subtypes and/or intracellular 
pathways depending on specific pathophysiological conditions. Our lab firstly 
observed the biphasic effect of adenosine on cell growth in A431 cell line (Tey et 
al. 1992, Tey et al. 1994); similar effects were also observed in BHK cells (Sun et 
al. 2005). Although apoptosis was not well defined and understood then, these 
pioneer works made important observations and implications, when results re-
examined, on the possible roles of adenosine in apoptosis. The cell lines studied 
previously therefore serve as models for elucidating the mechanisms of adenosine-
induced apoptosis (AIA) and adenosine-induced proliferation. 
 
1.4 Aim of Study 
 
The aim of this study is to investigate the extracellular and intracellular signaling 
mechanism of adenosine-induced apoptosis to better understand the 
pathophysiological roles of adenosine as well as the signaling mechanisms that 
may lead cell death.  
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Analytical grade reagents were used for the preparation of general reagents and 
culture media. Cell culture work was carried out using the molecular biology 
and/or cell culture tested chemicals. Some special reagents and materials were 
obtained from: 
 
Sigma-Aldrich Fine Chemicals 
 
Adenosine 
Minimum Essential Medium, alpha modification (α-MEM) 





N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] (HEPES) 
5’-N-Ethylcarboxamidoadenosine (NECA) 




















Bovine serum albumin (BSA) 
 











Hybond-P PVDF membrane 
ECL plus chemiluminescent reagent 




Caspase-3 assay kit 

























DC Protrin assay kit 
 
Erytho-9-(2-hydroxy-3-nonyl)adenine (EHNA) was a gift from Wellcome 
Research Laboratories. 
 
Unless otherwise stated, all other basic laboratory chemicals were purchased from 
Sigma Chemical Co. (St. Louis, MO, USA). 
 
2.1.2 Instruments 
Confocal Microscope: Carl Zeiss LSM 510 
Flow Cytometer: FACS Vantage SE (Becton Dickinson), ALTRA (Beckman 
Coulter). 
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2.2  Methods  
2.2.1 Cell Culture 
2.2.1.1 Normal Cell Culture 
BHK cells were cultured in α-MEM; HeLa cells in DMEM; SY5Y, MN9D, 
SKW6.4 and H9 cells were cultured in RPMI-1640. All culture media were 
supplemented with 10 % FBS unless adenosine is added in media. 
 
α-MEM was prepared by dissolving the α-MEM powder (10.1 g) in 900 ml Milli-
Q water, with 1.74 g NaHCO3 (20 mM), 1.2 g HEPES (5 mM) and 100 U/ml 
penicillin. pH was adjusted to 7.4 with 1N HCl and 1N NaOH. Additional Milli-Q 
water was added to bring the solution to final volume of 1 liter.  
 
DMEM was either purchased from NUMI (National University Medical 
Institutes) store or prepared by dissolving the DMEM powder (10 g) in 900 ml 
Milli-Q water, with 1.74 NaHCO3 (20 mM), 1.2 HEPES (5 mM) and gentamicin 
with a final concentration of 50 μg/ml. pH was adjusted to 7.4 with 1N HCl and 
NaOH. Additional Milli-Q water was added to bring the solution to final volume 
of 1 liter. 
 
RPMI-1640 was either purchased from NUMI or prepared by dissolving the 
RPMI-1640 powder (10 g) in 900 ml Milli-Q water, pH was lowered to 4.0 with 
1N HCl to completely dissolve the powder. pH was then adjusted to 7.2 with 1N 
NaOH. 2 g NaHCO3 was dissolved in the medium and pH was adjusted to 7.4 
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with 1N HCl and NaOH. Additional Milli-Q water was added to bring the solution 
to final volume of 1 liter. 
 
All media were sterilized immediately after preparation by filtration through a 
Millipore 0.22 micron membrane filtering system and stored at 4 oC in dark. 
 
Adenosine treatment was always carried with the presence of 5 μM EHNA in 
either serum free media or supplemented with 1% heat-inactivated FBS (FBSi). 
FBSi was prepared by heating the FBS for 2 hours at 56 oC. 
 
2.2.1.2 Cytopreservation 
Suspension cells SKW6.4 or H9 were centrifuged at 400  g for 5 min to collect 
the pellet. Adherent cells were trypsinised and suspended in medium before 
proceeded to centrifugation. Pellet was resuspended in medium with 70% FBS at 
0.5-1×106 cells/ml. Glycerol was added drop wise to 10%. 
 
Cell suspensions were aliquoted into cryovials. Cryovials were then slowly frozen 
in -20oC freezer for 2 hours in an igloo then transferred to -80 oC deep freezer 
overnight. Cryovials were stored in liquid nitrogen for long term storage. 
 
2.2.1.3 Thawing of Cryopreserved Cells 
Cryopreserved cells were thawed quickly in 37 oC water bath immediately after 
being removed from storage. Thawed cell solution was diluted with medium drop 
wise to 10 ml in a 50 ml sterilized Falcon tube and centrifuged at 400  g for 5 
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min. Pellet was resuspended in complete growth medium and plated in culture 
flasks. Medium was replaced with fresh complete growth medium 12 hours later. 
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2.2.1.4 Cell culture for AIA studies 
Cell culture for cell cycle, pH and Ca++ (flow cytometry) studies, please see 2.2.5; 
cell culture for mitochondrial membrane potential (confocal microscopy) studies, 
please see 2.2.6; cell culture for early stage and late stage apoptosis determination 
with PI and annexin-V, please see 2.2.7. 
 
2.2.2 DNA Extraction from Cells 
DNA fragmentation of cells was determined using an adaptation of a described 
technique (Liu et al., 1996). Briefly, after gently shaking the culture flasks, 
weakly adherent and non-adherent cells were collected by centrifuging the cell 
culture medium (400  g, 5 min). Adherent cells were trypsinised, harvested and 
processed separately. Cells were incubated at 37 oC for 3 hours in lysis buffer (see 
appendix A) under agitation. This incubation was followed by dropwise addition 
of 5 M NaCl to a final concentration of 1 M and incubation at 4 oC for 1 hour. 
After centrifugation at 15,000  g for 30 min at 4 oC, supernatants were recovered. 
DNA was extracted with an equal volume of 25:24:1 phenol/chloroform/isoamyl 
alcohol (vol:vol:vol) and precipitated in the presence of an equal volume of 
isopropanol at -20 oC overnight. After centrifugation at 15,000  g for 10 min at 
4oC, the pellets were washed in 75% ethanol, resuspended in water and digested 
with 1 mg/ml DNase-free RNase for 30 min at 37 oC. DNA samples were to be 
subjected to Agarose gel electrophoresis for analysis. 
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2.2.3 Agarose Gel Electrophoresis of DNA 
Agarose gel electrophoresis was used for the identification of DNA fragmentation 
in apoptosis. Agarose gel contained 2% (w/v) electrophoresis grade agarose 
melted in 50 ml 1× TBE buffer (see appendix A) containing ethidium bromide at a 
final concentration of 0.5 μg/ml. The samples of DNA were mixed with 6× gel 
loading buffer and the mixture slowly loaded into the slots of the gel submerged in 
1× TBE. Electrophoresis was carried out at 5V/cm field strength and migration of 
DNA was monitored through illumination with UV light. 
 
2.2.4 Photography of DNA Electrophoresis Gels 
Kodak digital science ™ DC120 Zoom digital camera was used to photograph 
gels irradiated by UV light. Photographs were analyzed with Kodak 1D Image 
Analysis Software. 
 
2.2.5 Flow Cytometry 
2.2.5.1 Cell Cycle Studies 
Cells were seeded in 6-well plates at the density of 1×104 cells/cm2 and grown in 
3 ml medium supplemented with 10% FBS for 12 hours at 37 oC with 5% CO2. 
Medium was replaced by fresh medium supplemented with 1% FBSi in the 
presence of 5 μM EHNA. Cells were incubated for another 12 hours. Treatment 
was done by adding the experimental drugs i.e. adenosine, adenosine receptor 
agonists, antagonists or transporter inhibitors at designed concentrations. Cells 
were incubated for another 24 hours at 37 oC with 5% CO2.  
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At the end of incubation period, 6-well plates were gently shaken. Weakly 
attached and non-attached cells were collected by centrifuging the culture 
medium. Adherent cells were trypsinised and harvested. Detached and adherent 
cells were then combined and washed with 5 ml ice-cold PBS (pH 7.2) twice by 
centrifugation (400  g, 5 min). The supernatant was poured off as much as 
possible without disturbing the final cell pellet. Cell pellet was then vigorously 
vortexed in the remaining fluid for 10 sec and fixed by dropwise addition of ice 
cold 70% ethanol with agitation. Cell samples were left in ethanol overnight at 4 
oC for maximum resolution of cellular DNA. Fixed cell samples are stable in 
ethanol for several years at 4 oC.  
 
Prior to flow cytometry, cell samples were vortexed and passed through 0.44 mm 
filter to disperse and remove aggregates. Cells were centrifuged at 1,500  g, 4 oC 
for 5 min. Ethanol was poured off without disturbing the cell pellet. Cell pellet 
was then resuspended in remaining ethanol by vortex. 1ml PI/Triton X-100 
staining solution (see appendix A for recipe) was added with the presence of 
DNase-free RNase A for 15 min at 37 oC with occasional agitation. Apoptotic 
cells were quantified using flow cytometry (Becton Dickinson FACSVantage SE) 
and analyzed with WinMDI software. 10,000 events per sample were counted for 
each sample. 
 
2.2.5.2 Intracellular pH Level Studies 
Cells were cultured in 6-well plate at the density of 1×104 cells/cm2 in the same 
condition as described in 2.2.5.1 but without treatment by adenosine. 
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After 12 hours of incubation in medium supplemented with 1% FBSi in the 
presence of 5 μM EHNA, cells were centrifuged once and resuspended in serum-
free fresh medium with 5 μM EHNA at the concentration of  ~1×106 cells/ml and 
stained with SNARF-1 AM for 15-30 min at 37 oC. SNARF stained samples were 
then treated with adenosine for designed time periods and analyzed on Becton 
Dickinson FACSVantage SE. 10,000 events per sample were counted for each 
sample. 
 
2.2.5.3 Intracellular Ca2+ Level Studies 
Cells were cultured in 6-well plate at the density of 1×104 cells/cm2 in the same 
condition as described in the previous section. 
 
At the end of incubation period, cells were trypsinised and harvested. Cells were 
then centrifuged once and resuspended in serum-free fresh medium with 5 μM 
EHNA at the concentration of ~1×106 cells/ml and stained with Fura-2 AM for 
15-30 min at 37 oC. Fura-2 stained samples were treated with adenosine for 
designed time periods and analyzed on Beckman Coulter ALTRA. 10,000 events 
were counted for each sample. 
 
Fura-2 AM stock solution was made by dissolving 1 mg Fura-2 AM in 1 ml 
anhydrous DMSO (1 mM). Working solution was used at 200× dilution. 
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2.2.6 Mitochondria Membrane Potential Studies 
Cells were seeded on 8-well Lab-Tek™ Chambered Coverglass (Nunc) at the 
density of 1×104 cells/cm2 and grown in 0.4 ml medium supplemented with 10% 
FBS for 12 hours at 37 oC with 5% CO2. Coverglass was then gently shaken, 
medium was replaced by fresh medium supplemented 1% FBSi and cells were 
incubated for another 12 hours before subject to fluorescent staining.  
 
For mitochondria membrane potential study, ApoAlert ™ Mitochondrial 
Membrane Sensor (Clontech) kit was used according to the manufacturer 
instruction. Briefly, immediately prior to use, 1 μl MitoSensor was dissolved in 1 
ml serum-free medium by vortex (final concentration 5 μg/ml); cells were gently 
rinsed with serum-free medium for 3 times, covered with 0.2 ml MitoSensor 
dissolved in serum-free medium and incubated at 37 oC in the presence of 5% CO2 
for 20 min before subject to Carl Zeiss LSM 510 confocal microscope. 
 
At the end of incubation period, 8-well Lab-Tek™ Chambered Coverglass (Nunc) 
was mounted on a CO2 chamber with temperature control ensuring an ideal cell 
culture condition for living cells time course study. Adenosine was then added; 
mitochondrial membrane potential (MMP) was examined on PI and FITC 
channels at designed time points. 
 
2.2.7 Early Stage and Late Stage Apoptosis Determination 
Cells were seeded on 8-well Lab-Tek™ Chambered Coverglass (Nunc) at the 
density of 1×104 cells/cm2 and grown in 0.4 ml medium supplemented with 10% 
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FBS for 24 hours at 37 oC with 5% CO2. Coverglass was then gently shaken, 
medium was replaced by fresh medium supplemented 1% FBSi and cells were 
incubated for another 12 hours before subject to fluorescent staining.  
 
For apoptosis determination study, cells were double stained with propidium 
iodide (PI) and annexin V-FITC for 30 minutes at 37 oC in incubator. Coverglass 
was then mounted on the CO2 chamber and examined with Carl Zeiss LSM 510 
confocal microscope. 
 
2.2.8 Isolation of Mitochondria from Mouse Liver 
 
5 g liver from Swiss Albino was cut into small pieces and put in pre-chilled 
sucrose buffer I (see Appendix A for recipe) to wash off excess blood. Liver 
pieces were then transferred to a 40-ml Dounce homogenizer and topped up with 
sucrose buffer I to 15 ml. Homogenization was performed on ice with 6 strokes of 
loose pestle and 1 stroke of tight pestle. Homogenate was then diluted with 
sucrose buffer I to 40 ml, transferred to centrifuge tubes and centrifuged at 2,200 
rpm for 10 min at 4 oC.  
 
The fat layer was carefully removed before the supernatant was transferred to new 
centrifuge tubes and centrifuged at 10,000 rpm for 10 min at 4 oC. The resulted fat 
layer was removed and the supernatant was gently discarded. Pellet was 
resuspended in 20 ml pre-chilled sucrose buffer II (see Appendix A for recipe) 
and centrifuged at 10,000 rpm for 10 min at 4 oC. 
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2.2.9 Total Cell Lysate Preparation 
Denaturing conditions For denaturing conditions, cells were rinsed with 1× ice-
cold PBS for three times and then lysed with pre-chilled boiling lysis buffer (1ml 
lysis buffer : 50 cm2 culture cells, see appendix A for recipe) for 10 min on ice. 
Cells were scraped off from culture flask, transferred to a 1.5 ml microfuge tube 
and boiled for 5 min. 
 
Cell lysate was then passed through a 26 gauge needle 3 times and centrifuged for 
15 min at 16,000  g, 4oC. The resulting supernatant is the denatured total cell 
lysate. 
 
Native conditions For native cell lysate, cells were rinsed with ice-cold 1× PBS 
for three times before lysed with pre-chilled immunoprecipitation buffer (see 
appendix A) on a shaker for 30 min at 4oC.  
 
Cells were then scraped off from culture flask and passed through a 26 gauge 
needle 3 times to disperse any large aggregates and centrifuged for 15 min at 
16,000  g, 4oC. The resulting supernatant is the native total cell lysate. 
 
2.2.10 Immunoprecipitation 
It is important to pre-clear the lysate immediately before immunoprecipitation. 
Cell lysate was centrifuged at 16,000  g, 4 oC for 15 min, supernatant was 
recovered and boiled for 5 min. 
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To 1 ml supernatant, 5 μg rabbit anti-mouse IgG was added, vortexed, and then 
100 μl Protein A: Agarose (Invitrogen) was then added and incubated at 4 oC for 
30 min with agitation. 
 
Cell lysate was then centrifuged at 9,000  g, 4 oC for 2 min to pellet the agarose 
beads. The supernatant was the pre-cleared total cell lysate. 
 
1 ml cell lysate after pre-clearance was incubated with 15 μl protein A-agarose 
and 1 μg antibody for 24 hours at 4 oC in a 1.5 ml microfuge tube. The mixer was 
then centrifuged at 2,500 rpm for 15 min at 4 oC. Supernatant was carefully 
discarded, pellet (agarose beads) was washed with immunoprecipitation buffer for 
3 times and resuspended in 50 μl SDS-PAGE loading buffer. Sample was 
analyzed by SDS-PAGE followed by western blotting. 
 
2.2.11 SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis) 
 
Almost all analytical electrophoresis of proteins was carried out in polyacrylamide 
gels under denaturing conditions that ensure dissociation of the proteins into their 
individual polypeptide subunits and that minimize aggregation. The effective 
range of separation of SDS-PAGE is from 12kDa to 212 kDa. See Appendix A for 
the preparation of stacking gels and resolving gels for Tris-Glycine SDS-PAGE. 
 
While the stacking gel was polymerizing, the samples were prepared by heating 
them to 100 oC for 5 min in 5× SDS loading buffer (see appendix A) to denature 
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the proteins. The gel was mounted in the Bio-Red Mini-PROTEAN II gel set. 1× 
Tris-Glysine electrophoresis buffer (see appendix A) was added to the top and 
bottom reservoirs. Up to 30 μl of each sample was loaded into the bottom of each 
well. A voltage of 8 V/cm was applied to the gel. After the dye front moved into 
the resolving gel, the voltage was increased to 15 V/cm. 
 
2.2.12 Protein Estimation 
All protein concentrations were determined using the Bio-Rad DC Protein Assay 
(Hercules, CA, USA) as suggested by the user manual but at a reduced scale. 20 
μl of sample or standard was mixed with 100 μl reagent A. 800 μl reagent B was 
added into the system and incubated at room temperature for a minimum of 15 
min for the color development. The absorbance was measured at 750 nm. A 
standard curve was drawn using bovine serum albumin (BSA) at appropriate 
concentration range. 
 
2.2.13 Western Blotting 
Western blotting was performed for the detection of proteins after SDS-PAGE. 
Hybond-P PVDF membrane and the chemiluminescence detection system ECL 
Plus were purchased from Amersham Biosciences. 
 
Electrotransblotting (wet method) was performed as follows: 
 
1. Separate the protein samples using SDS-PAGE. 
2. Remove the stacking gel. 
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3. Equilibrate the gel in the protein transfer buffer (see appendix A for 
recipe) for at least 10 minutes 
4. Pre-wet the PVDF membrane in 100% methanol for 10 sec. Wash in water 
for 5 min and equilibrate in transfer buffer for at least 10 minutes. 
5. Assemble the electroblotting apparatus and start electroblotting with pre-
chilled transfer buffer at 250 mA for 4 hrs. 
6. Use the protein marker on gel as the indicator for the complete 
transblotting of the desired proteins. 
7. Remove the blot from the transfer apparatus, mark the orientation and the 
protein side of the membrane and dry it completely. The membrane can be 
used immediately after drying or stored in refrigerator for months.  
 
Immunodetection was performed as follows: 
 
1. Block the non-specific binding sites on the membrane by using 5% milk in 
TBS-T (see appendix A for recipe) for 1 hour on a shaker. 
2. Briefly rinse the membrane in TBS-T then wash with large volume of 
TBS-T for 3×10 min. 
3. Incubate the membrane with primary antibody dissolved in 5% milk in 
TBS-T with appropriate dilution in 4 oC over night with agitation. 
4. Briefly rinse the membrane in TBS-T then wash with large volume of 
TBS-T for 3×10 min. 
5. Incubate the membrane with secondary antibody dissolved in TBS-T with 
appropriate dilution in 4 oC over night or 1 hour at room temperature. 
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6. Incubate the membrane with ECL plus A+B mix (50:1) for 5 min then 
expose to Kodak film. 
 
2.2.14 Statistics and Graphing 
 
Experimental data were processed and graphed with GraphPad Prism®. The 
means and standard errors (SE) were calculated from data obtained from five 
independent experiments. T test was performed for P values. ns: > 0.05; *: 0.01-
0.05; **: 0.001-0.01 and ***: < 0.001. For data from flow cytometry, 10,000 
events were counted per sample. 
 
Chemical structures were graphed with ChemDraw Ultra®, 3-D structure of 
adenosine was generated with Chem3D Ultra®, signaling models were graphed 
with BioDraw Ultra®, all are trial versions from CambridgeSoft. 
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3 Chapter 3 Mechanisms of Adenosine-Induced 
Apoptosis 
 
In this chapter, the extracellular mechanisms through which adenosine induces 
apoptosis and the intracellular mechanisms whereby apoptosis is initiated and 
executed in AIA were studied in various cell lines and cell-free systems. 
Involvement of adenosine receptors and adenosine transporters was examined by 
using specific receptor agonists, antagonists and transporter inhibitors to elucidate 
the mechanism(s) of AIA. Apoptosis was quantified using fluorescent staining and 
flow cytometry. Key cytosolic players in apoptosis were studied for their 
involvement in AIA to map out the intracellular machinery of AIA. Involvement 
of mitochondria was determined by monitoring the membrane potential. 
Translocations of Bax from cytosol to mitochondria and cytochrome c from 
mitochondria to cytosol were detected. Caspase-3, -8, -9 activities were examined 
to determine their involvement in AIA. Involvement of cytosol Ca++ and cytosol 
acidification in AIA was determined by detection of intracellular Ca++ and pH 
changes. 
 
3.1 Adenosine-Induced Apoptosis (AIA) 
BHK cells were seeded at density of 1104cells/cm2 on 8-well Lab-Tek™ 
Chambered Coverglass and cultured in complete growth medium for 12 hours 
before medium was replaced with α-MEM supplemented with 1% heat-inactivated 
fetal bovine serum (FBSi) in the presence of 5 μM EHNA for 12 hours as 
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described in 2.2.7. Cells were then exposed to adenosine for 2 to 24 hours for 
early and late stage apoptosis study. Typical indications of apoptosis (exposure of 
phosphatidylserine, DNA laddering and chromatin condensation) were examined 
and results are given in Figures 3.1. 
 
2 hours after the treatment with 1 mM adenosine, BHK cells were double-stained 
with annexin V-FITC and propidium iodide (PI). Phosphatidylserine was detected 
by annexin V-FITC on the extracellular side of cell membrane (Fig. 3.1A), but no 
condensed or fragmented chromatin was detected by propidium iodide, indicating 
an early stage of apoptosis prior to chromatin condensation. 
 
Phosphatidylserine normally locates on the intracellular side of cell membrane in 
healthy cells where it cannot be detected by plasma membrane impermeable 
fluorescent dye annexin V-FITC. At the early stage of apoptosis, 
phosphatidylserine flips over to the extracellular side of cell membranes. Thus 
exposed to the environment, it can be detected by specific binding with annexin V 
and visualized by conjugated FITC (Martin et al. 1995). The exposure of 
phosphatidylserine is regarded as a signature of early stage apoptosis (Rimon et 
al. 1997, Homburg et al. 1995). The possibility of cell death by necrosis is 
excluded by morphology and the absense of condensed or fragmented chromatin 
which could be stained by propidium iodide (Fig. 3.1A).  
 
The late stage of apoptosis induced by adenosine was confirmed by the presence 
of intranucleosomal DNA fragmentation of adenosine-treated BHK cells into 
multimers of 180 bp nucleosomal units (Fig. 3.1B). After 24 hours of incubation 
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with adenosine of various concentrations, BHK cells were harvested and lysed. 
DNA was extracted according to 2.2.2 and subjected to 2% sucrose gel for nuclear 
acid electrophoresis as described in 2.2.3. In adherent adenosine-treated BHK 
cells and control cells (non-treated), no DNA fragmentation was detected (lane 6 
and 7 respectively). A 24-hour exposure of BHK cells to 10, 20, 500 or 1000 μM 
adenosine resulted in DNA fragmentation typical of apoptosis (lane 2, 3, 4 and 5 
respectively). Campthetin-induced apoptotic cells were used as positive control 
(lane 1).Together with the morphological changes (blebbing typical to apoptosis) 
observed in BHK cells after a 24-hour exposure to 1 mM adenosine (Fig. 3.1C), 
nucleus fragmentation with condensed chromatin detected by PI (Fig. 3.1C) 
suggests a late stage of apoptosis.  
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Fig. 3.1 Induction of BHK cell apoptosis by adenosine. (A) Photomicrograph showing the exposure of phosphatidylserine in adenosine-treated BHK cells. 
BHK cells were incubated with 1 mM adenosine for 2 hours, double stained with annexin V-FITC and PI, examined by laser scanning microscope LSM 510 
(Call Zeiss). Arrows indicate membrane phosphatidylserine visualized by FITC (magnification 400×). (B) Electrophoretic analysis of internucleosomal DNA 
fragmentation in BHK cells. DNA was isolated from non-treated, campthetin-treated BHK cells or cells treated with adenosine for 24 hours. M, 100-bp DNA 
ladder; lane 1, 10 μM campthetin-treated as positive control; lane 2-5, detached BHK cells treated with 500, 1000, 10 and 20 μM adenosine respectively; lane 
6, adherent BHK cells treaded with 1000 μM adenosine; lane 7, non-treated BHK cells. (C) Photomicrograph showing the nuclear morphology of adenosine-
treated BHK cells. BHK cells were treated with 1 mM adenosine for 24 hours, double-stained with annexin V-FITC and PI. Both morphology and condensed 
or fragmented chromatin suggest a late stage of apoptosis. 
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3.2 Apoptotic Effects of Adenosine 
3.2.1 Apoptosis in BHK Cells  
AIA in BHK cells, quantified by detection of DNA fragmentation using flow 
cytometry, was shown to be dose dependent on the extracellular adenosine 
concentration (Fig. 3.2). It should be noted that in the control cells without 
adenosine added, a low level of apoptosis (~5%) occurred. Treatment with low 
concentrations of adenosine (10-20 μM) decreased cell viability significantly to 
60-70%. Cell viability recovered with increasing concentrations of adenosine (50-
200 μM) while higher concentrations (500-1000 μM) resulted in severe cell death 
(Fig. 3.2). These observations show a biphasic apoptotic effect of adenosine in 
BHK cells. 
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Fig. 3.2 Apoptotic effects of adenosine in BHK cells. BHK cells cultured at the density 
of 1×104 cells/cm2 in -MEM supplemented with 1% FBSi in the presence of 5 μM 
EHNA were treated with various concentrations of adenosine for 24 hours. Cells were 
then harvested, fixed with ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late 
stage) were counted by flow cytometer (10,000 events per sample). Cell viability was 
calculated as the percentage of non-apoptotic cells. Data were obtained from 5 
independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.2.2 Apoptosis in HeLa, SKW6.4 and H9 Cells 
In contrast to the AIA in BHK cells, the adenosine-induced apoptosis in HeLa 
cells is dose-dependent yet non-biphasic (Fig. 3.3). Treatment with low and 
medium concentrations of adenosine (up to 200 μM) did not cause significant cell 
death in HeLa cells compared to control cells. However, adenosine at high 
concentrations (500-1000 μM) appeared to be apoptotic to HeLa cells. Similar 
observations were obtained from SKW6.4 and H9 cell lines (Fig. 3.4). These 
observations suggest a second apoptotic behavior of adenosine as dose-dependent 
in certain cell lines. 
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Fig. 3.3 Apoptotic effects of adenosine on HeLa cells. HeLa cells cultured at the density 
of 1×104 cells/cm2 in DMEM supplemented with 1% FBSi in the presence of 5 μM 
EHNA were treated with various concentrations of adenosine for 24 hours. Cells were 
then harvested, fixed with ethanol and stained with 0.1 mg/ml PI. Data were obtained 
from 5 independent experiments. Apoptotic cells (late stage) were counted by flow 
cytometer (10,000 events per sample). Cell viability was calculated as the percentage of 
non-apoptotic cells. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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Fig. 3.4 Apoptotic effects of adenosine on SKW6.4 and H9 cells. Type I SKW6.4 and 
H9 cells were treated with various concentrations of adenosine for 24 hours. Cells were 
then harvested, fixed with ethanol and stained with 0.1 mg/ml PI. Data were obtained 
from 5 independent experiments. Apoptotic cells (late stage) were counted by flow 
cytometer (10,000 events per sample). Cell viability was calculated as the percentage of 
non-apoptotic cells. SKW6.4 and H9 cells showed HeLa cell like dose-dependent 
apoptotic response to adenosine. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
Mechanism Study of AIA 
69 
3.2.3 Non-apoptotic Effects in SY5Y and MN9D Cells 
While adenosine-induced apoptosis was observed in BHK, HeLa, SKW6.4 and 
H9 cell lines, either biphasic or non-biphasic, neuronal cell lines SY5Y and 
MN9D were found to be unresponsive to adenosine up to 1 mM (Fig. 3.5). 
Adenosine analogues CPA, CGS-21680 and IB-MECA (specific agonists to A1, 
A2 and A3 receptors respectively) were also shown to be non-apoptotic to these 
two neuronal cell lines (Fig. 3.6-3.8). The non-apoptotic response of the neuronal 
cell lines to adenosine can be explained by the fact that neurons are more often 
exposed to high doses of adenosine physiologically where adenosine acts as one 
of the major neurontransmitters. 
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Fig. 3.5 Apoptotic effects of adenosine on SY5Y and MN9D cells. In contrast to the 
biphasic AIA observed in BHK cells and non-biphasic AIA in HeLa, SKW6.4 and H9 
cells, adenosine did not work as an apoptosis inducer to SY5Y or MN5D neuronal cells 
up to 1000M. This non-apoptotic effect of adenosine suggests that adenosine signaling 
mechanisms are cell type dependent, either non-existent or non-activated in these two cell 
lines. SY5Y and MN9D cells cultured at the density of 1×104 cells/cm2 in DMEM 
supplemented with 1% FBSi in the presence of 5 μM EHNA were treated with various 
concentrations of adenosine for 24 hours. Cells were then harvested, fixed with ethanol 
and stained with 0.1 mg/ml PI. Data were obtained from 5 independent experiments. 
Apoptotic cells (late stage) were counted by flow cytometer (10,000 events per sample). 
Cell viability was calculated as the percentage of non-apoptotic cells. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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Fig. 3.6 Apoptotic effects of CCPA on SY5Y and MN9D cells. To further confirm the 
non-apoptotic effect of adenosine and adenosine analogues on SY5Y and MN9D cells, 
A1 receptor signaling pathway was activated with the A1 receptor specific agonist CCPA 
in SY5Y and MN9D cells. Similar to adenosine, CCPA did not induce apoptosis in SY5Y 
and MN9D cells. SY5Y and MN9D cells cultured at the density of 1×104 cells/cm2 in 
DMEM supplemented with 1% FBSi in the presence of 5 μM EHNA were treated with 0, 
0.2, 0.4 or 1.0 nM CCPA for 24 hours. Cells were then harvested, fixed with ethanol and 
stained with 0.1 mg/ml PI. Data were obtained from 5 independent experiments. 
Apoptotic cells (late stage) were counted by flow cytometer (10,000 events per sample). 
Cell viability was calculated as the percentage of non-apoptotic cells. 
 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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Fig. 3.7 Apoptotic effects of CGS-21680 on SY5Y and MN9D cells. To further 
confirm the non-apoptotic effect of adenosine and adenosine analogues on SY5Y and 
MN9D cells, A2 receptor signaling pathway was activated with the A2 receptor 
specific agonist CGS-21680 in SY5Y and MN9D cells. Consistent to adenosine, 
CGS-21680 did not induce apoptosis in SY5Y and MN9D cells. SY5Y and MN9D 
cells cultured at the density of 1×104 cells/cm2 in DMEM supplemented with 1% 
FBSi in the presence of 5 μM EHNA were treated with 0, 10, 20 or 50 nM CGS-
21680 for 24 hours. Cells were then harvested, fixed with ethanol and stained with 
0.1 mg/ml PI. Apoptotic cells (late stage) were counted by flow cytometer (10,000 
events per sample). Cell viability was calculated as the percentage of non-apoptotic 
cells. Data were obtained from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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Fig. 3.8 Apoptotic effects of IB-MECA on SY5Y and MN9D cells. To further 
confirm the non-apoptotic effect of adenosine and adenosine analogues on SY5Y and 
MN9D cells, A3 receptor signaling pathway was activated with the A3 receptor 
specific agonist IB-MECA in SY5Y and MN9D cells. Consistent to adenosine, IB-
MECA did not induce apoptosis in SY5Y and MN9D cells. SY5Y and MN9D cells 
cultured at the density of 1×104 cells/cm2 in DMEM supplemented with 1% FBSi in 
the presence of 5 μM EHNA were treated with 0, 1, 2 or 5 nM IB-MECA for 24 
hours. Cells were then harvested, fixed with ethanol and stained with 0.1 mg/ml PI. 
Apoptotic cells (late stage) were counted by flow cytometer (10,000 events per 
sample). Cell viability was calculated as the percentage of non-apoptotic cells. Data 
were obtained from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.3 Involvement of P1 Receptors in AIA in BHK Cells 
To identify the possible pathway(s) through which adenosine induces apoptosis , 
the BHK cell line in which adenosine exhibited biphasic apoptotic effect was used 
as the primary model for the study. The extracellular mechanism through which 
adenosine initiates apoptosis was first studied. Adenosine receptors and 
nucleoside transporters were examined for their possible involvement. 
 
To investigate the participation of adenosine receptors, specific antagonists of 
each receptor subtype were used to see the drug blockage of AIA as the primary 
indicator. Subtype specific agonists were also used in the study to acquire 
confirming observations. 
 
3.3.1 A1 Receptors 
A1 receptor specific antagonist DPCPX was used to examine the involvement of 
A1 receptor in adenosine-induced apoptosis in BHK cells. As seen in Fig. 3.9, 
apoptosis induced by both low (20, 50 μM) and high (500, 1000 μM) 
concentrations of adenosine was partially blocked by DPCPX, suggesting the 
involvement of A1 receptor in AIA in BHK cells. A1 receptor specific agonist 
CCPA was then used to investigate the activation of A1R in AIA in BHK cells. As 
shown in Fig. 3.10, CCPA mimicked the apoptotic effect of adenosine. 
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Fig. 3.9 Effect of A1 receptor inhibition by DPCPX on AIA in BHK cells. BHK 
cells cultured at the density of 1×104 cells/cm2 in -MEM supplemented with 1% 
FBSi in the presence of 5 μM EHNA were treated with 0, 20, 50, 500 or 1000 M 
adenosine for 24 hours, in the absence or presence of 1, 7.5 or 30 M DPCPX. Cells 
were then harvested, fixed with ethanol and stained with 0.1 mg/ml PI. Apoptotic 
cells (late stage) were counted by flow cytometer (10,000 events per sample). Cell 
viability was calculated as the percentage of non-apoptotic cells. Data were obtained 
from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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Fig. 3.10 Effect of A1 receptor activation by CCPA on apoptosis in BHK cells. 
BHK cells cultured at the density of 1×104 cells/cm2 in -MEM supplemented with 
1% FBSi in the presence of 5 μM EHNA were treated with 0, 0.2, 0.4 or 1.0 nM 
CCPA for 24 hours. Cells were then harvested, fixed with ethanol and stained with 
0.1 mg/ml PI. Apoptotic cells (late stage) were counted by flow cytometer (10,000 
events per sample). Cell viability was calculated as the percentage of non-apoptotic 
cells. Data were obtained from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.3.2 A2A and A2B Receptors 
The involvement of A2A and A2B receptors in adenosine-induced apoptosis in 
BHK cells was examined with A2 receptor antagonist DMPX. As shown in Fig. 
3.11, DMPX did not block the apoptosis induced by adenosine at either low or 
high concentration, implying the absence of A2A and A2B receptor involvement in 
adenosine-induced apoptosis in BHK cells (Fig. 3.11). Further agonist studies 
with CGS-21680 confirmed the absence of A2A or A2B receptor mediated signaling 
pathways (Fig. 3.12). 
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Fig. 3.11 Effect of A2 receptor inhibition by DMPX on AIA in BHK cells. BHK cells 
cultured at the density of 1×104 cells/cm2 in -MEM supplemented with 1% FBSi in the 
presence of 5 μM EHNA were treated with 0, 20, 50, 500 or 1000 M adenosine for 24 
hours, in the absence or presence of 1, 10 or 50 M DMPX. Cells were then harvested, 
fixed with ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were 
counted by flow cytometer (10,000 events per sample). Cell viability was calculated as 
the percentage of non-apoptotic cells. Data were obtained from 5 independent 
experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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Fig. 3.12 Effect of A2 receptor activation by CGS-21680 on apoptosis in BHK cells. 
BHK cells cultured at the density of 1×104 cells/cm2 in -MEM supplemented with 1% 
FBSi in the presence of 5 μM EHNA were treated with 0, 10, 20 or 50 nM CGS-21680 for 
24 hours. Cells were then harvested, fixed with ethanol and stained with 0.1 mg/ml PI. 
Apoptotic cells (late stage) were counted by flow cytometer (10,000 events per sample). 
Cell viability was calculated as the percentage of non-apoptotic cells. Data were obtained 
from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.3.3 A3 Receptors 
A3 receptor specific antagonist MRS-1220 was used to examine the involvement 
of A3 receptor in adenosine-induced apoptosis in BHK cells. As shown in Fig. 
3.13, apoptosis induced by both low (20 μM) and high (500, 1000 μM) 
concentrations of adenosine was partially blocked by MRS-1220, suggesting a 
possible A3R mediated signaling pathway in BHK cell AIA (Fig. 3.13). 5 nM A3 
receptor agonist IB-MECA could also mimic the apoptotic effect of adenosine in 
BHK cells (Fig. 3.14), giving consistent observation. 
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Fig. 3.13 Effect of A3 receptor activation by MRS-1220 on AIA in BHK cells. BHK 
cells cultured at the density of 1×104 cells/cm2 in α-MEM supplemented with 1% FBSi in 
the presence of 5 μM EHNA were treated with 0, 20, 50, 500 or 1000 μM adenosine for 
24 hours, in the absence or presence of 1, 5 or 20 nM MRS-1220. Cells were then 
harvested, fixed with ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) 
were counted by flow cytometer (10,000 events per sample). Cell viability was calculated 
as the percentage of non-apoptotic cells. Data were obtained from 5 independent 
experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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Fig. 3.14 Effect of A3 receptor activation by IB-MECA on apoptosis in BHK cells. 
BHK cells cultured at the density of 1×104 cells/cm2 in -MEM supplemented with 1% 
FBSi in the presence of 5 μM EHNA were treated with 0, 1, 2 or 5 nM IB-MECA for 24 
hours. Cells were then harvested, fixed with ethanol and stained with 0.1 mg/ml PI. 
Apoptotic cells (late stage) were counted by flow cytometer (10,000 events per sample). 
Cell viability was calculated as the percentage of non-apoptotic cells. Data were obtained 
from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.3.4 Expression of P1 receptors in BHK Cells 
Although A1, A2A, A2B and A3 receptors are reported to be universally expressed, 
the existence of all four subtypes on BHK cell plasma membrane was examined in 
this study by fluorescent immunoblotting as shown in Fig. 3.15 A-D. BHK cells 
were seeded on 8-well Lab-Tek™ Chambered Coverglass at the density of 1×104 
cells/cm2 and grown in 0.4 ml medium supplemented with 10% FBS for 12 hours 
at 37 oC with 5% CO2. Cells were washed with fresh medium and incubated with 
A1, A2A, A2B or A3 receptor antibody (Santa Cruz) at 1,000× dilution dissolved in 
medium with 1% serum for 1 hour. Cells were then washed and incubated with 
FITC conjugated secondary antibody and visualized under LSM 510. Therefore 
the expression and involvement of the adenosine receptors in the experiments 
were confirmed. 
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Fig. 3.15 Expression of purinoceptors in BHK cells. Green fluorescence indicates the presence of the P1 receptor detected by its subtype specific antibody. 
(A) A1 receptor, (B) A2A receptor, (C) A2B receptor, (D) A3 receptor. (magnification 400×) 
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3.4 Involvement of Nucleoside Transporters in AIA in BHK Cells 
In the previous studies, A1 and A3 receptors were found to participate in the 
adenosine-induced apoptosis. However, the possible pathways en route nucleoside 
transporters cannot be thus excluded. Therefore, the role of nucleoside 
transporters in the adenosine-induced apoptosis in BHK cells were studied next, 
by combining the use of es specific inhibitor NBTI and non-specific inhibitor 
dipyridamole. 
 
3.4.1 es Transporters 
es specific nucleoside transporter inhibitor NBTI was used to examine if 
adenosine transportation via es transporter played a role in AIA in BHK cells. As 
shown in Fig. 3.16, NBTI was able to block apoptosis induced by high 
concentrations of adenosine (500 and 1000 μM) but not low concentrations (20, 
50 μM), suggesting a second pathway in AIA in BHK cells, i.e. through adenosine 
transportation. 
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Fig. 3.16 Effect of es transporter inhibition by NBTI on AIA in BHK cells. NBTI was 
able to block the apoptotic effect by high concentrations of adenosine (500 and 1000 μM) 
but not by low concentrations (20-50 μM), suggesting the absence of adenosine 
transportation below 50 μM adenosine and the presence of it above 500 μM in AIA in 
BHK cells. BHK cells cultured at the density of 1×104 cells/cm2 in α-MEM supplemented 
with 1% FBSi in the presence of 5 μM EHNA were treated with 0, 20, 50, 500 and 1000 
μM adenosine for 24 hours, in the absence or presence of 1 or 20 μM NBTI. Cells were 
then harvested, fixed with ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late 
stage) were counted by flow cytometer (10,000 events per sample). Cell viability was 
calculated as the percentage of non-apoptotic cells. Data were obtained from 5 
independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.4.2 ei Transporters 
Due to the lack of ei specific inhibitors, non-specific transporter inhibitor 
dipyridamole was used to inhibit both ei and es transporters. As shown in Fig. 
3.17, dipyridamole did not block AIA by low concentrations of adenosine, but it 
blocked apoptosis induced by high concentrations of adenosine (500 and 1000 
μM) like NBTI. This suggests that the adenosine transportation via ei nucleoside 
transporter is not involved in the apoptosis induced by low concentrations of 
adenosine but cannot be excluded from the apoptosis induced by high 
concentrations of adenosine in BHK cells.  
Mechanism Study of AIA 
88 
























Fig. 3.17 Effect of dipyridamole (DIP) on AIA in BHK cells. Similar to NBTI, 
dipyridamole was able to block the apoptosis induced by high concentrations of 
adenosine (500-1000 μM) but not by low concentrations (20-50 μM), suggesting the 
absence of adenosine transportation via ei transporter below 50 μM and the possible 
presence of it above 500 μM adenosine in AIA in BHK cells. BHK cells cultured at the 
density of 1×104 cells/cm2 in α-MEM supplemented with 1% FBSi in the presence of 5 
μM EHNA were treated with 0, 20, 50, 500 and 1000 μM adenosine for 24 hours, in the 
absence or presence of 1, 5 or 20 μM dipyridamole. Cells were then harvested, fixed with 
ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by flow 
cytometer (10,000 events per sample). Cell viability was calculated as the percentage of 
non-apoptotic cells. Data were obtained from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.4.3 Effect of Propentofylline 
As a non-specific adenosine receptor antagonist as well as a nucleoside transporter 
inhibitor, propentofylline (PPF) was used to induce a combination of receptor and 
transporter inhibition, thus providing a more thorough blocking effect on 
adenosine-induced apoptosis in BHK cells. As seen in Fig. 3.18, propentofylline is 
shown to be a more potent blocker than any individual receptor antagonist or 
transporter inhibitor. 
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Fig. 3.18 Effect of combined receptor and transporter inhibition by propentofylline 
(PPF) on AIA in BHK cells. Propentofylline showed to be a more potent AIA blocker in 
BHK cells due to its non-specific inhibiting effect on receptors and transporters. BHK 
cells cultured at the density of 1×104 cells/cm2 in α-MEM supplemented with 1% FBSi in 
the presence of 5 μM EHNA were treated with 0, 20, 50, 500 and 1000 μM adenosine for 
24 hours, in the absence or presence of 50 or 500 μM PPF. Cells were then harvested, 
fixed with ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were 
counted by flow cytometer (10,000 events per sample). Cell viability was calculated as 
the percentage of non-apoptotic cells. Data were obtained from 5 independent 
experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.5 Involvement of P1 receptors in AIA in HeLa, SKW6.4 and 
H9 Cells 
 
Results from previous studies conducted in BHK cells suggest that A1 and A3 
receptors mainly account for the AIA at low adenosine concentrations (20-50 μM) 
and es and ei transporters for the AIA at high adenosine concentrations (500-1000 
μM). To better understand if the role of adenosine receptors and transporters in 
adenosine-induced apoptosis is adenosine concentration-dependent or cell type-
dependent, the receptor and transporter studies were extended to HeLa cells in 
which AIA is dose-dependent but not biphasic (Fig. 3.3). Parallel studies were 
also conducted in SKW6.4 and H9 cell lines due to their similar apoptotic 
response to adenosine (Fig. 3.4). Results from these cell lines shown in this 
section and the following sections provide important information to a better 
understanding of the extracellular initiation mechanisms used by adenosine in 
AIA. 
 
3.5.1 Involvement of Receptors in AIA in HeLa cells 
3.5.1.1 A1 Receptors in AIA in HeLa Cells 
Similar antagonist and agonist methods were used to examine the involvement of 
A1 receptor in adenosine-induced apoptosis in HeLa cells. As shown in Fig. 3.19, 
Apoptosis induced by high concentrations of adenosine (500, 1000 μM) was not 
blocked by A1 receptor specific antagonist XAC, suggesting the absence of A1 
receptor in AIA in HeLa cells. A1 receptor specific agonist CCPA could not 
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induce apoptosis in HeLa cells, confirming the conclusion drawn from the 
antagonist experiment (Fig. 3.20). 
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Fig. 3.19 Effect of A1 receptor inhibition by XAC on AIA in HeLa cells. To further 
study the extracellular AIA mechanism at high adenosine levels, the involvement of A1 
receptor signaling pathway was examined in HeLa cells with the A1 receptor specific 
antagonist XAC. As A1 receptor specific antagonist XAC did not block the apoptotic 
effect caused by high concentrations of adenosine, it suggests that the high-level-
adenosine-induced apoptosis in HeLa cells is not mediated by A1 receptor. HeLa cells 
cultured at the density of 1×104 cells/cm2 in DMEM supplemented with 1% FBSi in the 
presence of 5 μM EHNA were treated with various concentrations of adenosine for 24 
hours in the absence or presence of 1 μM XAC. Cells were then harvested, fixed with 
ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by flow 
cytometer (10,000 events per sample). Cell viability was calculated as the percentage of 
non-apoptotic cells. Data were obtained from 5 independent experiments. 
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Fig. 3.20 Effect of A1 receptor activation by CCPA on apoptosis in HeLa cells. To 
further study the contribution of A1 receptor activation to AIA at high adenosine levels, 
the A1 receptor signaling pathway was selectively activated with the A1 receptor specific 
agonist CCPA in HeLa cells. As CCPA did not exhibit significant apoptotic effect as 
observed in BHK cells, it further supports the absence of A1 receptor-mediated pathway 
in AIA at high adenosine concentrations. HeLa cells cultured at the density of 1×104 
cells/cm2 in DMEM supplemented with 1% FBSi in the presence of 5 μM EHNA were 
treated with 0, 0.2, 0.4 or 1.0 nM CCPA for 24 hours. Cells were then harvested, fixed 
with ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by 
flow cytometer (10,000 events per sample). Cell viability was calculated as the 
percentage of non-apoptotic cells. Data were obtained from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.5.1.2 A2A and A2B Receptors in AIA in HeLa Cells 
The involvement of A2A and A2B receptors in apoptosis induced by high adenosine 
concentrations was studied in HeLa cells with the antagonist DMPX and agonist 
CGS-21680. As shown in Fig. 3.21. A2 receptor antagonist DMPX did not block 
the apoptosis induced by high concentrations adenosine (500-1000 μM), 
excluding the involvement of A2 receptors in AIA at high adenosine levels. On the 
other hand, A2 receptor agonist CGS-21680 was not able to mimic the apoptotic 
effect of adenosine in HeLa cells (Fig. 3.22), supporting the conclusion from 
antagonist study. 
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Fig. 3.21 Effect of A2 receptor inhibition by DMPX on AIA in HeLa cells. To further 
study the extracellular AIA mechanism at high adenosine levels, the involvement of A2 
receptor signaling pathways was examined with the A2 receptor specific antagonist 
DMPX in HeLa cells. As DMPX did not block the apoptotic effect caused by high 
concentrations of adenosine (500-1000 μM) in HeLa cells, it suggests that the apoptosis 
induced by high levels of adenosine is not mediated by A2 receptors. HeLa cells cultured 
at the density of 1×104 cells/cm2 in DMEM supplemented with 1% FBSi in the presence 
of 5 μM EHNA were treated with various concentrations of adenosine for 24 hours, in the 
absence or presence of 1 μM DMPX. Cells were then harvested, fixed with ethanol and 
stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by flow cytometer 
(10,000 events per sample). Cell viability was calculated as the percentage of non-
apoptotic cells. Data were obtained from 5 independent experiments. 
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Fig. 3.22 Effect of A2 receptor activation by CGS-21680 on apoptosis in HeLa cells. 
A2 receptor activation by specific agonist CGS-21680 did not exhibit significant apoptotic 
effect similar to adenosine in HeLa cells. This further supports the absence of an A2 
receptor-mediated pathway in high-level-adenosine-induced apoptosis in HeLa cells. 
HeLa cells cultured at the density of 1×104 cells/cm2 in DMEM supplemented with 1% 
FBSi in the presence of 5 μM EHNA were treated with 0, 10, 20 or 50 nM CGS-21680 for 
24 hours. Cells were then harvested, fixed with ethanol and stained with 0.1 mg/ml PI. 
Apoptotic cells (late stage) were counted by flow cytometer (10,000 events per sample). 
Cell viability was calculated as the percentage of non-apoptotic cells. Data were obtained 
from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.5.1.3 A3 Receptors in AIA in HeLa Cells 
 
The involvement of A3 receptor in apoptosis induced by high concentrations of 
adenosine was studied in HeLa cells with antagonist MRS-1220 and agonist IB-
MECA. As shown in Fig. 3.23, MRS-1220 could not block the apoptotic effect of 
high concentrations of adenosine (500-1000 μM), suggesting the absence of A3 
receptor involvement in AIA at high adenosine levels in HeLa cells. Consistent 
with the antagonist study, A3 receptor specific agonist IB-MECA did not exhibit a 
significant apoptotic effect on HeLa cells (Fig. 3.24). 
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Fig. 3.23 Effect of A3 receptor inhibition by MRS-1220 on AIA in HeLa cells. To 
further study the extracellular AIA mechanism at high adenosine levels, the involvement 
of A3 receptor signaling pathway was examined with the A3 receptor specific antagonist 
MRS-1220 in HeLa cells. As MRS-1220 did not block the apoptotic effect caused by high 
concentrations of adenosine in HeLa cells, it suggests that the apoptosis induced by high 
concentrations of adenosine is not mediated by A3 receptor in HeLa cells. HeLa cells 
cultured at the density of 1×104 cells/cm2 in DMEM supplemented with 1% FBSi in the 
presence of 5 μM EHNA were treated with various concentrations of adenosine for 24 
hours, in the absence or presence of 2.5 nM MRS-1220. Cells were then harvested, fixed 
with ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by 
flow cytometer (10,000 events per sample). Cell viability was calculated as the 
percentage of non-apoptotic cells. Data were obtained from 5 independent experiments. 
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Fig. 3.24 Effect of A3 receptor activation by IB-MECA on apoptosis in HeLa cells. 
HeLa A3 receptor was activated with the A3 receptor specific agonist IB-MECA to study 
the contribution of A3 receptor to the apoptosis induced by high levels of adenosine. As 
IB-MECA did not exhibit significant apoptotic effect similar to adenosine in HeLa cells, 
it further suggests that the adenosine-induced apoptosis in HeLa cells is not en route A3 
receptor. HeLa cells cultured at the density of 1×104 cells/cm2 in DMEM supplemented 
with 1% FBSi in the presence of 5 μM EHNA were treated with 0, 1, 2 or 5 nM IB-
MECA for 24 hours. Cells were then harvested, fixed with ethanol and stained with 0.1 
mg/ml PI. Apoptotic cells (late stage) were counted by flow cytometer (10,000 events per 
sample). Cell viability was calculated as the percentage of non-apoptotic cells. Data were 
obtained from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.5.2 Involvement of Receptors in AIA in SKW6.4 cells 
3.5.2.1 A1 Receptors in AIA in SKW6.4 Cells 
 
The involvement of A1 receptor in adenosine-induced apoptosis in SKW6.5 cells 
was studied with specific antagonist DPCPX and agonist CCPA. As shown in Fig. 
3.25, apoptosis induced by high concentrations of adenosine (500-1000 μM) was 
not blocked by DPCPX, suggesting the absence of A1 receptor in AIA in SKW6.4 
cells. Confirmingly, A1 receptor activation by specific agonist CCPX also caused 
insignificant apoptosis in SKW6.4 cells (Fig. 3.26). 
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Fig. 3.25 Effect of A1 receptor inhibition by DPCPX on AIA in SKW6.4 cells. To 
further study the extracellular AIA mechanism at high adenosine levels, the involvement 
of A1 receptor signaling pathway was examined with the A1 receptor specific antagonist 
DPCPX in SKW6.4 cells. As DPCPX did not block the apoptotic effect caused by high 
concentrations of adenosine, it suggests the absence of A1 receptor signaling pathway in 
the apoptosis induced by high concentrations of adenosine in SKW6.4 cells. SKW6.4 
cells cultured at the density of 1×105 cells/ml in RPMI-1640 supplemented with 1% FBSi 
in the presence of 5 μM EHNA were treated with various concentrations of adenosine for 
24 hours in the absence or presence of 7.5 μM DPCPX. Cells were then harvested, fixed 
with ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by 
flow cytometer (10,000 events per sample). Cell viability was calculated as the 
percentage of non-apoptotic cells. Data were obtained from 5 independent experiments. 
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Fig. 3.26 Effect of A1 receptor activation by CCPA on apoptosis in SKW6.4 cells. To 
further study the extracellular AIA mechanism at high adenosine levels, the A1 receptor 
was activated with the A1 receptor specific agonist CCPA in SKW6.4 cells. As CCPA did 
not exhibit significant apoptotic effect similar to adenosine, it further supports the absence 
of A1 receptor signaling pathway in high-level-adenosine-induced apoptosis. SKW6.4 
cells cultured at the density of 1×105 cells/ml in RPMI-1640 supplemented with 1% FBSi 
in the presence of 5 μM EHNA were treated with 0, 0.2, 0.4 or 1.0 nM CCPA for 24 
hours. Cells were then harvested, fixed with ethanol and stained with 0.1 mg/ml PI. 
Apoptotic cells (late stage) were counted by flow cytometer (10,000 events per sample). 
Cell viability was calculated as the percentage of non-apoptotic cells. Data were obtained 
from 5 independent experiments. 
 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.5.2.2 A2A and A2B Receptors in AIA in SKW6.4 Cells 
 
The involvement of A2A and A2B receptors in adenosine-induced apoptosis in 
SKW6.4 cells was studied with antagonist DMPX and agonist CGS-21680. As 
shown in Fig. 3.27, DMPX did not block the apoptosis induced by high 
concentration adenosine, implying the absence of A2 receptor signaling in 
adenosine-induced apoptosis in SKW6.4 cells. On the other hand, confirming 
result was obtained by the A2 receptor activation study with agonist CGS-21680 
(Fig. 3.28) 
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Fig. 3.27 Effect of A2 receptor inhibition by DMPX on apoptosis in SKW6.4 cells. To 
further study the extracellular AIA mechanism at high adenosine levels, the involvement 
of A2 receptor signaling pathways was antagonized with the A2 receptor specific 
antagonist DMPX in SKW6.4 cells. As DMPX did not effectively block the apoptosis 
caused by high concentrations of adenosine, it suggests that the adenosine-induced 
apoptosis in SKW6.4 cells is not mediated by A2 receptors. SKW6.4 cells cultured at the 
density of 1×105 cells/ml in RPMI-1640 supplemented with 1% FBSi in the presence of 5 
μM EHNA were treated with various concentrations of adenosine for 24 hours, in the 
absence or presence of 10 μM DMPX. Cells were then harvested, fixed with ethanol and 
stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by flow cytometer 
(10,000 events per sample). Cell viability was calculated as the percentage of non-
apoptotic cells. Data were obtained from 5 independent experiments.  
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Fig. 3.28 Effect of A2 receptor activation by CGS-21680 on AIA in SKW6.4 cells. To 
further study the extracellular AIA mechanism at high adenosine levels, the A2 receptor 
signaling was activated with the A2 receptor specific agonist CGS-21680 in SKW6.4 
cells. As CGS-21680 did not exhibit significant apoptotic effect similar to adenosine, it 
further supports the idea that the adenosine-induced apoptosis in SKW6.4 cells is not A2 
receptor-mediated. SKW6.4 cells cultured at the density of 1×105 cells/ml in RPMI-1640 
supplemented with 1% FBSi in the presence of 5 μM EHNA were treated with 0, 10, 20 
or 50 nM CGS-21680 for 24 hours. Cells were then harvested, fixed with ethanol and 
stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by flow cytometer 
(10,000 events per sample). Cell viability was calculated as the percentage of non-
apoptotic cells. Data were obtained from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.5.2.3 A3 Receptors in AIA in SKW6.4 Cells 
The involvement of A3 receptor in adenosine-induced apoptosis in SKW6.4 cells 
was studied with A3 receptor specific antagonist MRS-1220 and agonist IB-
MECA. As MRS-1220 effectively blocked the apoptosis induced by high 
concentrations of adenosine (500-1000 μM), it suggests the contribution of A3 
receptor in AIA in SKW6.4 cells (Fig. 3.29). A3 receptor specific agonist IB-
MECA also exhibited apoptotic effect as adenosine did in SKW6.4 cells (Fig. 
3.30). 
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Fig. 3.29 Effect of A3 receptor inhibition by MRS-1220 on AIA in SKW6.4 cells. To 
further study the extracellular AIA mechanism at high adenosine levels, the involvement 
of A3 receptor signaling pathway was examined with the A3 receptor specific antagonist 
MRS-1220 in SKW6.4 cells. As MRS-1220 showed effective blockage of the apoptosis 
caused by high concentrations of adenosine, it implies that the presence of A3 receptor 
signaling in this scenario. SKW6.4 cells cultured at the density of 1×105 cells/ml in 
RPMI-1640 supplemented with 1% FBSi in the presence of 5 μM EHNA were treated 
with various concentrations of adenosine for 24 hours, in the absence or presence of 5 nM 
MRS-1220. Cells were then harvested, fixed with ethanol and stained with 0.1 mg/ml PI. 
Apoptotic cells (late stage) were counted by flow cytometer (10,000 events per sample). 
Cell viability was calculated as the percentage of non-apoptotic cells. Data were obtained 
from 5 independent experiments. 
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Fig. 3.30 Effect of A3 receptor activation by IB-MECA on apoptosis in SKW6.4 cells. 
To further study the extracellular AIA mechanism at high adenosine levels, the A3 
receptor was activated with the A3 receptor specific agonist IB-MECA in SKW6.4 cells. 
As IB-MECA caused significant apoptosis similar to adenosine, it further implies the 
participation of A3 receptor in the AIA caused by high concentrations of adenosine in 
SKW6.4 cells. SKW6.4 cells cultured at the density of 1×105 cells/ml in RPMI-1640 
supplemented with 1% FBSi in the presence of 5 μM EHNA were treated with 0, 1, 2 or 5 
nM IB-MECA for 24 hours. Cells were then harvested, fixed with ethanol and stained 
with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by flow cytometer (10,000 
events per sample). Cell viability was calculated as the percentage of non-apoptotic cells. 
Data were obtained from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.5.3 Involvement of Receptors in AIA in H9 Cells 
3.5.3.1 A1 receptors in AIA in H9 Cells 
The involvement of A1 receptor in adenosine-induced apoptosis was also similarly 
examined in H9 cells. Results from both antagonist study with DPCPX (Fig. 3.31) 
and agonist study with CCPX (Fig. 3.32) suggest the absence of the contribution 
of such pathway in the apoptosis induced by high concentrations of adenosine 
(500, 1000 μM) in H9 cells. 
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Fig. 3.31 Effect of A1 receptor inhibition by DPCPX on AIA in H9 cells. To further 
study the extracellular AIA mechanism at high adenosine levels, the involvement of A1 
receptor signaling pathway was examined by antagonism with the specific antagonist 
DPCPX. As DPCPX did not block the apoptosis caused by high concentrations of 
adenosine in H9 cells, it suggests the absence of A1 receptor contribution in such 
scenario. H9 cells cultured at the density of 1×105 cells/ml in RPMI-1640 supplemented 
with 1% FBSi in the presence of 5 μM EHNA were treated with various concentrations of 
adenosine for 24 hours in the absence or presence of 7.5 μM DPCPX. Cells were then 
harvested, fixed with ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) 
were counted by flow cytometer (10,000 events per sample). Cell viability was calculated 
as the percentage of non-apoptotic cells. Data were obtained from 5 independent 
experiments. 
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Fig. 3.32 Effect of A1 receptor activation by CCPA on apoptosis in H9 cells. A1 
receptor was activated with the A1 receptor specific agonist CCPA in H9 cells to further 
study the extracellular AIA mechanism at high adenosine levels. As CCPA did not exhibit 
significant apoptotic effect, it supports the observation from the antagonist study that the 
A1 receptor was not engaged in the AIA. H9 cells cultured at the density of 1×105 cells/ml 
in RPMI-1640 supplemented with 1% FBSi in the presence of 5 μM EHNA were treated 
with 0, 0.2, 0.4 or 1.0 nM CCPA for 24 hours. Cells were then harvested, fixed with 
ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by flow 
cytometer (10,000 events per sample). Cell viability was calculated as the percentage of 
non-apoptotic cells. Data were obtained from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.5.3.2 A2A and A2B receptors in AIA in H9 Cells 
The involvement of A2A and A2B receptors in adenosine-induced apoptosis in H9 
cells was studied with antagonist DMPX and agonist CGS-21680. DMPX did not 
block the apoptosis induced by high concentration adenosine (Fig. 3.33), implying 
the absence of A2A and A2B receptors in adenosine-induced apoptosis in H9 cells. 
Similarly, A2 receptor agonist CGS-21680 was not able to mimic the apoptotic 
effect of adenosine in H9 cells (Fig. 3.34). 
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Fig. 3.33 Effect of A2 receptor inhibition by DMPX on AIA in H9 cells. To further 
study the extracellular AIA mechanism at high adenosine levels, the A2 receptor signaling 
pathway was antagonized with the A2 receptor specific antagonist DMPX in H9 cells. As 
DMPX did not block the apoptotic effect caused by high concentrations of adenosine, it 
suggests that the adenosine-induced apoptosis was not mediated by A2 receptor. H9 cells 
cultured at the density of 1×105 cells/ml in RPMI-1640 supplemented with 1% FBSi in 
the presence of 5 μM EHNA were treated with various concentrations of adenosine for 24 
hours, in the absence or presence of 10 μM DMPX. Cells were then harvested, fixed with 
ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by flow 
cytometer (10,000 events per sample). Cell viability was calculated as the percentage of 
non-apoptotic cells. Data were obtained from 5 independent experiments. 
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Fig. 3.34 Effect of A2 receptor activation by CGS-21680 on apoptosis in H9 cells. To 
further study the extracellular AIA mechanism at high adenosine levels, A2 receptor was 
activated with the A2 receptor specific agonist CGS-21680 in H9 cells. As CGS-21680 
did not cause significant apoptosis in H9 cells, it further supports the absence of A2 
receptor contribution in the AIA in H9 cells. H9 cells cultured at the density of 1×105 
cells/ml in RPMI-1640 supplemented with 1% FBSi in the presence of 5 μM EHNA were 
treated with 0, 10, 20 or 50 nM CGS-21680 for 24 hours. Cells were then harvested, fixed 
with ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by 
flow cytometer (10,000 events per sample). Cell viability was calculated as the 
percentage of non-apoptotic cells. Data were obtained from 5 independent experiments. 
 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.5.3.3 A3 receptors in AIA in H9 Cells 
The involvement of A3 receptor in adenosine-induced apoptosis in H9 cells was 
studied with A3 receptor specific antagonist MRS-1220 and agonist IB-MECA. As 
shown in Fig. 3.35, MRS-1220 partially blocked apoptosis caused by high 
concentrations of adenosine (500-1000 μM), suggesting the engagement of A3 
receptor signaling in AIA in HeLa cells. Confirmingly, A3 receptor specific 
agonist IB-MECA exhibited significant apoptotic effect in H9 cells, implying the 
contribution of A3 receptor activation to apoptosis(Fig. 3.36). 
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Fig. 3.35 Effect of A3 receptor inhibition by MRS-1220 on AIA in H9 cells. To further 
study the extracellular AIA mechanism at high adenosine levels, the involvement of A3 
receptor signaling pathway was examined with the A3 receptor specific antagonist MRS-
1220 in H9 cells. As MRS-1220 partially blocked the apoptotic effect caused by high 
concentrations of adenosine, it suggests the contribution of A3 receptor signaling in the 
high-level-adenosine-induced apoptosis in H9 cells. H9 cells cultured at the density of 
1×105 cells/ml in RPMI-1640 supplemented with 1% FBSi in the presence of 5 μM 
EHNA were treated with various concentrations of adenosine for 24 hours, in the absence 
or presence of 5 nM MRS-1220. Cells were then harvested, fixed with ethanol and stained 
with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by flow cytometer (10,000 
events per sample). Cell viability was calculated as the percentage of non-apoptotic cells. 
Data were obtained from 5 independent experiments. 
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Fig. 3.36 Effect of A3 receptor activation by IB-MECA on apoptosis in H9 cells. To 
further study the extracellular AIA mechanism at high adenosine levels, A3 receptor was 
activated with the A3 receptor specific agonist IB-MECA in H9 cells. As IB-MECA 
exhibited effective apoptotic effect similar to adenosine, it further supports the 
contribution of A3 receptor in this scenario. H9 cells cultured at the density of 1×105 
cells/ml in RPMI-1640 supplemented with 1% FBSi in the presence of 5 μM EHNA were 
treated with 1, 2 or 5 nM IB-MECA for 24 hours. Cells were then harvested, fixed with 
ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by flow 
cytometer (10,000 events per sample). Cell viability was calculated as the percentage of 
non-apoptotic cells. Data were obtained from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.6 Involvement of Nucleoside Transporters in AIA in HeLa, 
SWK6.4 and H9 Cells 
 
Previous studies conduced in HeLa, SKW6.4 and H9 cells suggest different 
patterns of apoptosis induced by high concentrations of adenosine. Consistent 
with BHK cells, my results suggest that the apoptosis induced by high 
concentrations of adenosine in HeLa cells is not via adenosine receptors, implying 
a major contribution of the nucleoside transporters in this cell line. However, 
results obtained from two Type I cell lines SKW6.4 and H9 suggest an alternative 
pattern. In spite of the observation that A1 and A2 receptors did not participate in 
AIA in these two cell lines, both antagonist and agonist studies suggest the 
contribution by A3 receptors. 
 
To complete the extracellular AIA mechanism study, the role of adenosine 
transportation via nucleoside transporters was next studied in these three cell lines 
with the specific es inhibitor NBTI and nonspecific transporter inhibitor 
dipyridamole. 
 
3.6.1 es Transporters in HeLa Cells 
The involvement of es nucleoside transporter in the HeLa AIA was examined with 
NBTI. As shown in Fig. 3.37, NBTI was not able to block the apoptosis induced 
by high concentrations of adenosine (500 and 1000 μM), suggesting the absence 
of contribution from es transporter. 
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Fig. 3.37 Effect of NBTI on AIA in HeLa cells. NBTI, an es specific transporter 
inhibitor, was used to examine the involvement of es transporter in the apoptosis induced 
by 500 μM and 1000 μM adenosine in HeLa cells. The contribution of adenosine 
transportation via es transporter to the AIA in HeLa cells is excluded as the blockage of 
this pathway by NBTI did not block the apoptosis caused by adenosine. HeLa cells 
cultured at the density of 1×104 cells/cm2 in DMEM supplemented with 1% FBSi in the 
presence of 5 μM EHNA were treated with various concentrations of adenosine for 24 
hours, in the absence or presence of 1 μM NBTI. Cells were then harvested, fixed with 
ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by flow 
cytometer (10,000 events per sample). Cell viability was calculated as the percentage of 
non-apoptotic cells. Data were obtained from 5 independent experiments. 
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3.6.2 ei Transporters in HeLa Cells 
Due to the lack of ei specific inhibitors, the nonspecific inhibitor dipyridamole 
was used to examine if adenosine transportation via ei transporter played a role in 
AIA in HeLa cells. As shown in Fig. 3.38, dipyridamole blocked apoptosis 
induced by high concentrations of adenosine (500-1000 μM) in HeLa cells 
significantly. This suggests the contribution of adenosine transportation via either 
es or ei nucleoside transporters to the apoptosis induced by high concentrations of 
adenosine in HeLa cells. Since the involvement of the es transporters was absent 
in the NBTI study, the contribution of ei transporters to apoptosis is suggested by 
this study.  
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Fig. 3.38 Effect of dipyridamole on AIA in HeLa cells. As a nonspecific nucleoside 
transporter inhibitor, dipyridamole significantly blocked the apoptosis induced by 500-
1000 μM adenosine, suggesting the involvement of nucleoside transporter (es or ei) in 
AIA in HeLa cells. HeLa cells cultured at the density of 1×104 cells/cm2 in DMEM 
supplemented with 1% FBSi in the presence of 5 μM EHNA were treated with various 
concentrations of adenosine for 24 hours, in the absence or presence of 5 μM 
dipyridamole. Cells were then harvested, fixed with ethanol and stained with 0.1 mg/ml 
PI. Apoptotic cells (late stage) were counted by flow cytometer (10,000 events per 
sample). Cell viability was calculated as the percentage of non-apoptotic cells. Data were 
obtained from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.6.3 es Transporters in SKW6.4 Cells 
The involvement of es nucleoside transporter in AIA in SKW6.4 cells was 
examined with NBTI. As shown in Fig. 3.39, NBTI was able to block apoptosis 
induced by high concentrations of adenosine (500-1000 μM), suggesting the 
contribution of adenosine transportation via es transporter in the apoptosis induced 
by high concentrations of adenosine in SKW6.4 cells. 
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Fig. 3.39 Effect of NBTI on AIA in SKW6.4 cells. The es specific transporter inhibitor 
NBTI partially blocked the apoptosis induced by 500-1000 μM adenosine, suggesting the 
contribution of es nucleoside transporter in AIA in SKW6.4 cells. SKW6.4 cells cultured 
at the density of 1×105 cells/ml in RPMI-1640 supplemented with 1% FBSi in the 
presence of 5 μM EHNA were treated with various concentrations of adenosine for 24 
hours, in the absence or presence of 1 or 20 μM NBTI. Cells were then harvested, fixed 
with ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by 
flow cytometer (10,000 events per sample). Cell viability was calculated as the 
percentage of non-apoptotic cells. Data were obtained from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
Mechanism Study of AIA 
125 
3.6.4 ei Transporters in SKW6.4 Cells 
The nonspecific inhibitor dipyridamole was used to examine if adenosine 
transportation via ei transporters played a role in AIA in SKW6.4 cells. As shown 
in Fig. 3.40, dipyridamole was shown to be a more potent blocker than NBTI in 
apoptosis induced by high concentrations of adenosine (500-1000 μM). This 
suggests that the adenosine transportation via ei nucleoside transporter might be 
responsible for apoptosis induced by high concentrations of adenosine in SKW6.4 
cells as well.  
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Fig. 3.40 Effect of dipyridamole on AIA in SKW6.4 cells. As a nonspecific nucleoside 
transporter inhibitor, dipyridamole blocked the apoptosis induced by 500-1000 μM 
adenosine more effectively than NBTI, suggesting the possible involvement of ei 
transporter in AIA in SKW6.4 cells. SKW6.4 cells cultured at the density of 1×105 
cells/ml in RPMI-1640 supplemented with 1% FBSi in the presence of 5 μM EHNA were 
treated with various concentrations of adenosine for 24 hours, in the absence or presence 
of 5 or 20 μM dipyridamole. Cells were then harvested, fixed with ethanol and stained 
with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by flow cytometer (10,000 
events per sample). Cell viability was calculated as the percentage of non-apoptotic cells. 
Data were obtained from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.6.5 es Transporters in H9 Cells 
The involvement of es nucleoside transporter in AIA in H9 cells was examined 
with NBTI. As shown in Fig. 3.41, NBTI strongly blocked the apoptosis induced 
by adenosine (500 and 1000 μM) in H9 cells, suggesting the contribution of 
adenosine transportation via es transporter to the apoptosis induced by high 
concentrations of adenosine in H9 cells. 
Mechanism Study of AIA 
128 








20 M NBTI*** ***











Fig. 3.41 Effect of NBTI on AIA in H9 cells. NBTI, an es specific transporter inhibitor, 
strongly blocked the apoptosis induced by 500-1000 μM adenosine, suggesting the 
engagement of es nucleoside transporter in AIA in H9 cells. S9 cells cultured at the 
density of 1×105 cells/ml in RPMI-1640 supplemented with 1% FBSi in the presence of 5 
μM EHNA were treated with various concentrations of adenosine for 24 hours, in the 
absence or presence of 1 or 20 μM NBTI. Cells were then harvested, fixed with ethanol 
and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) were counted by flow 
cytometer (10,000 events per sample). Cell viability was calculated as the percentage of 
non-apoptotic cells. Data were obtained from 5 independent experiments. 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.6.6 ei Transporters in H9 Cells 
The nonspecific inhibitor dipyridamole was used to examine if adenosine 
transportation via ei transporter played a role in AIA in H9 cells. As shown in Fig. 
3.42, dipyridamole blocked apoptosis more thoroughly induced by high 
concentrations of adenosine (500-1000 μM). This suggests that adenosine 
transportation via ei nucleoside transporters in inducing apoptosis by high 
concentrations of adenosine in H9 cells cannot be excluded.  
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Fig. 3.42 Effect of dipyridamole on AIA in H9 cells. As a nonspecific nucleoside 
transporter inhibitor, dipyridamole significantly blocked the apoptosis induced by 500-
1000 μM adenosine, suggesting the involvement of nucleoside transporter (either es or ei) 
in AIA in H9 cells. H9 cells cultured at the density of 1×105 cells/ml in RPMI-1640 
supplemented with 1% FBSi in the presence of 5 μM EHNA were treated with various 
concentrations of adenosine for 24 hours, in the absence or presence of 5 or 20 μM 
dipyridamole. Cells were then harvested, fixed with ethanol and stained with 0.1 mg/ml 
PI. Apoptotic cells (late stage) were counted by flow cytometer (10,000 events per 
sample). Cell viability was calculated as the percentage of non-apoptotic cells. Data were 
obtained from 5 independent experiments. 
 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.7 Involvement of Mitochondria in AIA in BHK Cells 
Results from the extracellular mechanism of adenosine-induced apoptosis 
investigations (3.3-3.6) indicate that receptor signaling pathways (A1 and A3) are 
the major contributors of the AIA at low adenosine concentrations (20-50 μM) 
(3.3 & 3.5). Adenosine transportation via nucleoside transporters is responsible 
for the apoptotic action of high concentrations of adenosine (500-1000 μM) (3.4 & 
3.6). 
 
The different patterns of apoptosis induced by different concentrations of 
adenosine in different cell lines suggest the existence of several intracellular 
signaling pathways. Based on the current knowledge of apoptosis, the 
investigation of the intracellular signaling pathways was carried out first by 
observing the mitochondrial changes during AIA. 
 
3.7.1 Mitochondrial Membrane Potential (MMP) Changes during AIA 
The loss of mitochondrial membrane potential (MMP) during the AIA in BHK 
cells was examined with a fluorescent dye MitoSensor ™, as depicted in Fig. 3.43. 
BHK cells were prepared as described in 2.2.6, MitoSensor ™ was used as the 
indicator of mitochondrial membrane potential. MitoSensor aggregated in the 
mitochondria of healthy cells, fluorescing red. In apoptotic cells, mitochondrial 
membrane potentials were altered, and MitoSensor could not aggregate in the 
mitochondria, remained as monomers and fluoresced green. i.e. the decrease of 
red density or the increase of green density correlates to the loss of MMP, and 
vice versa. 
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3.7.2 Mitochondrial Membrane Hyperpolarization 
 
More precise experiments were carried out to observe rapid fluctuations of MMP 
during AIA. As shown in Fig. 3.44, right after the addition of adenosine and prior 
to the loss of MMP, a membrane hyperpolarization (depicted by the increase of 
green and decrease of red density) was observed repeatedly. This acute rise of 
membrane potential lasted for less then 10 min, followed by a drop of MMP back 
to original level and further loss of MMP over the next 2 hours. 
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Fig. 3.43 Loss of mitochondrial membrane potential during adenosine-induced apoptosis 
in BHK cells. BHK cells were seeded on 8-well Lab-Tek™ Chambered Coverglass (Nunc) at 
the density of 1×104 cells/cm2 and grown in 0.4 ml medium supplemented with 10% FBS for 
24 hours at 37 oC with 5% CO2. Coverglass was then gently shaken, medium was replaced by 
fresh medium supplemented 1% FBSi and cells were incubated for another 12 hours before 
subject to fluorescent staining. Cells were then gently rinsed with serum-free medium for 3 
times, covered with 0.2 ml MitoSensor (Clontech) (5 μg/ml in serum-free medium and 
incubated at 37 oC in the presence of 5% CO2 for 20 min before subject to a Carl Zeiss LSM 
510 fluorescent microscope. A-F, MMP in BHK cells 0, 30, 60, 90, 120 or 240 min after 
adenosine treatment. 
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Fig. 3.44 Mitochondrial membrane hyperpolarization during adenosine-induced 
apoptosis in BHK cells. BHK cells were seeded in the same condition as described in 
last figure. A-G, 0, 2, 4, 6, 8 and 10 min after adenosine treatment. Mitochondrial 
membrane potential was increased (hyperpolarization) shortly after the addition of 
adenosine and before the eventual loss of ΔΨm. 
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3.8 Translocation of Bax and Cytochrome c 
The observation of the acute mitochondrial hyerpolarization followed by a 
prolonged mitochondrial depolarization suggests the involvement of mitochondria 
in AIA in BHK cells which may also involve the intrinsic apoptosis as well. 
Earlier experiments excluded a direct interaction between adenosine and 
mitochondria (results not shown). Therefore, the translocation of Bax from cytosol 
to mitochondria and cytochrome c from mitochondria to cytosol were next 
studied. The results are shown in Fig 3.45. Bax was shown to translocate from 
cytosol to mitochondria while apoptosis was induced over the 1.5 hrs. The release 
of cytochrome c was observed from mitochondria to cytosol over the same period 
of time. A correlation of Bax translocation to mitochondria and release of 
cytochrome c from mitochondria is strongly suggested. 




Fig. 3.45 Translocation of Bax and Cyt c during the adenosine-induced apoptosis in 
BHK cells. BHK cell lysate was prepared as described in 2.2.9. Cytosolic fraction and 
mitochondrial fraction were separated 0, 30, 60, 90 min after the addition of adenosine 
(500 µM final) into the cell lysate. Bax and cytochrome c were immunoprecipitated and 
detected by western blotting. Translocation of Bax from cytosol to mitochondria and 
cytochrome c from mitochondria to cytosol were observed. 
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3.9 Intracellular Ca++ Level during AIA 
The change of intracellular Ca++ level during the adenosine-induced apoptosis was 
studied in BHK cells with the assistance of the fluorescent Ca++ dye Fura 2-AM. 
When excited by UV light, the emission can be detected in FL1. The results are 
shown in Fig 3.46-3.54. Cytosol Ca++ level was observed to increase drastically 5 
min after the addition of adenosine (Fig. 3.48-3.49), and drop back to normal level 
20 min after (Fig. 3.50-3.54). BHK cells were prepared and stained as described in 
2.2.5.3. Unstained BHK cells (Fig. 3.46) and untreated stained BHK cells (Fig. 
3.47) were used as double negative controls. 




Fig. 3.46 Intracellular Ca++ level changes during AIA in BHK cells (negative 
control). BHK cells at 90% confluency cultured in -MEM supplemented with 
10% FBSi in the presence of 5 μM EHNA were trypsinised and resuspended in 
serum-free fresh -MEM with 5 μM EHNA at the density of ~1×106 cells/ml. 
BHK cells were then analyzed on Beckman Coulter ALTRA without Fura-2 
staining. 10,000 events were counted. 
 





Fig. 3.47 Intracellular Ca++ level changes during AIA in BHK cells (0 min). BHK 
cells at 90% confluency cultured in -MEM supplemented with 10% FBSi in the presence 
of 5 μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. BHK cells were then stained with Fura-2 for 15 
min at 37 oC as described in 2.2.5.3. Fura-2 stained samples were then analyzed on 
Beckman Coulter ALTRA without adenosine treatment. 10,000 events were counted. 




Fig. 3.48 Intracellular Ca++ level changes during AIA in BHK cells (5 min) BHK cells 
at 90% confluency cultured in -MEM supplemented with 10% FBSi in the presence of 5 
μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. BHK cells were then stained with Fura-2 for 15 
min at 37 oC as described in 2.2.5.3. Fura-2 stained samples were then treated with 
adenosine for 5 min and analyzed on Beckman Coulter ALTRA. 10,000 events were 
counted. 




Fig. 3.49 Intracellular Ca++ level changes during AIA in BHK cells (10 min). BHK 
cells at 90% confluency cultured in -MEM supplemented with 10% FBSi in the presence 
of 5 μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. BHK cells were then stained with Fura-2 for 15 
min at 37 oC as described in 2.2.5.3. Fura-2 stained samples were then treated with 
adenosine for and analyzed on Beckman Coulter ALTRA. 10,000 events were counted. 




Fig. 3.50 Intracellular Ca++ level changes during AIA in BHK cells (20 min). BHK 
cells at 90% confluency cultured in -MEM supplemented with 10% FBSi in the presence 
of 5 μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. BHK cells were then stained with Fura-2 for 15 
min at 37 oC as described in 2.2.5.3. Fura-2 stained samples were then treated with 
adenosine for 20 min and analyzed on Beckman Coulter ALTRA. 10,000 events were 
counted. 




Fig. 3.51 Effects of DPCPX & MRS-1220 on the intracellular Ca++ level changes (0 
min). BHK cells at 90% confluency cultured in -MEM supplemented with 10% FBSi in 
the presence of 5 μM EHNA were trypsinised and resuspended in serum-free fresh -
MEM with 5 μM EHNA, 7.5 μM DPCPX and 5 nM MRS-1220 at the density of ~1×106 
cells/ml. BHK cells were then stained with Fura-2 for 15 min at 37 oC as described in 
2.2.5.3 and analyzed on Beckman Coulter ALTRA. 10,000 events were counted. 




Fig. 3.52 Effects of DPCPX & MRS-1220 on the intracellular Ca++ level changes (5 
min). BHK cells at 90% confluency cultured in -MEM supplemented with 10% FBSi in 
the presence of 5 μM EHNA were trypsinised and resuspended in serum-free fresh -
MEM with 5 μM EHNA, 7.5 μM DPCPX and 5 nM MRS-1220 at the density of ~1×106 
cells/ml. BHK cells were stained with Fura-2 for 15 min at 37 oC and then treated with 20 
μM adenosine for 5 min and analyzed on Beckman Coulter ALTRA. 10,000 events were 
counted. 




Fig. 3.53 Effects of DPCPX & MRS-1220 on the intracellular Ca++ level changes (10 
min). BHK cells at 90% confluency cultured in -MEM supplemented with 10% FBSi in 
the presence of 5 μM EHNA were trypsinised and resuspended in serum-free fresh -
MEM with 5 μM EHNA, 7.5 μM DPCPX and 5 nM MRS-1220 at the density of ~1×106 
cells/ml. BHK cells were stained with Fura-2 for 15 min at 37 oC and then treated with 20 
μM adenosine for 10 min and analyzed on Beckman Coulter ALTRA. 10,000 events were 
counted. 




Fig. 3.54 Effects of DPCPX & MRS-1220 on the intracellular Ca++ level changes (20 
min). BHK cells at 90% confluency cultured in -MEM supplemented with 10% FBSi in 
the presence of 5 μM EHNA were trypsinised and resuspended in serum-free fresh -
MEM with 5 μM EHNA, 7.5 μM DPCPX and 5 nM MRS-1220 at the density of ~1×106 
cells/ml. BHK cells were stained with Fura-2 for 15 min at 37 oC and then treated with 20 
μM adenosine for 20 min and analyzed on Beckman Coulter ALTRA. 10,000 events were 
counted. 
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3.10  pH Changes during AIA 
The change of cytosol pH level during adenosine-induced apoptosis was studied 
in BHK cells with the fluorescent cytosol pH indicator carboxy SNARF-1 AM 
(Molecular Probes). Results are shown in Fig 3.55-67. BHK cells were prepared 
and stained with carboxy SNARF-1 AM as described in 2.2.5.2. Carboxy 
SNARF-1 is a long-wavelength fluorescent pH indicator with the dual emission 
spectrum undergoes a pH-dependent wavelength shift, thus allowing the ratio of 
the fluorescence intensities from the dye at two emission wavelengths to be used 
for pH determination. A ratio of PMT3 log over PMT4 log is shown in the charts 
(brown peak). A shift to the right corresponds to a shift towards a lower cytosol 
pH. BHK cells were shown to undergo an irreversible acidification 5 min after the 
addition of adenosine, indicating acidification as an early event of AIA in BHK 
cells. 




Fig. 3.55 Intracellular pH changes during AIA in BHK cells (negative control). BHK 
cells at 90% confluency cultured in -MEM supplemented with 10% FBSi in the presence 
of 5 μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. Unstained BHK cells were then analyzed on 
Becton Dickinson FACSVantage SE. 10,000 events were counted. 




Fig. 3.56 Intracellular pH changes during AIA in BHK cells (0 min). BHK cells at 
90% confluency cultured in -MEM supplemented with 10% FBSi in the presence of 5 
μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. BHK cells were then stained with carboxy 
SNARF-1 AM for 15 min at 37 oC as described in 2.2.5.2. SNARF-1 stained samples 
were then analyzed on Becton Dickinson FACSVantage SE. 10,000 events were counted. 





Fig. 3.57 Intracellular pH changes during AIA in BHK cells (5 min). BHK cells at 
90% confluency cultured in -MEM supplemented with 10% FBSi in the presence of 5 
μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. BHK cells were then stained with carboxy 
SNARF-1 AM for 15 min at 37 oC as described in 2.2.5.2. SNARF-1 stained samples 
were then treated with adenosine for 5 min and analyzed on Becton Dickinson 
FACSVantage SE. 10,000 events were counted. 




Fig. 3.58 Intracellular pH changes during AIA in BHK cells (10 min). BHK cells at 
90% confluency cultured in -MEM supplemented with 10% FBSi in the presence of 5 
μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. BHK cells were then stained with carboxy 
SNARF-1 AM for 15 min at 37 oC as described in 2.2.5.2. SNARF-1 stained samples 
were then treated with adenosine for 10 min and analyzed on Becton Dickinson 
FACSVantage SE. 10,000 events were counted. 
 




Fig. 3.59 Intracellular pH changes during AIA in BHK cells (20 min). BHK cells at 
90% confluency cultured in -MEM supplemented with 10% FBSi in the presence of 5 
μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. BHK cells were then stained with carboxy 
SNARF-1 AM for 20 min at 37 oC as described in 2.2.5.2. SNARF-1 stained samples 
were then treated with adenosine for 5 min and analyzed on Becton Dickinson 
FACSVantage SE. 10,000 events were counted. 




Fig. 3.60 Intracellular pH changes during AIA in BHK cells (30 min). BHK cells at 
90% confluency cultured in -MEM supplemented with 10% FBSi in the presence of 5 
μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. BHK cells were then stained with carboxy 
SNARF-1 AM for 15 min at 37 oC as described in 2.2.5.2. SNARF-1 stained samples 
were then treated with adenosine for 30 min and analyzed on Becton Dickinson 
FACSVantage SE. 10,000 events were counted. 




Fig. 3.61 Intracellular pH changes during AIA in BHK cells (40 min). BHK cells at 
90% confluency cultured in -MEM supplemented with 10% FBSi in the presence of 5 
μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. BHK cells were then stained with carboxy 
SNARF-1 AM for 15 min at 37 oC as described in 2.2.5.2. SNARF-1 stained samples 
were then treated with adenosine for 40 min and analyzed on Becton Dickinson 
FACSVantage SE. 10,000 events were counted. 




Fig. 3.62 Intracellular pH changes during AIA in BHK cells (50 min). BHK cells at 
90% confluency cultured in -MEM supplemented with 10% FBSi in the presence of 5 
μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. BHK cells were then stained with carboxy 
SNARF-1 AM for 15 min at 37 oC as described in 2.2.5.2. SNARF-1 stained samples 
were then treated with adenosine for 50 min and analyzed on Becton Dickinson 
FACSVantage SE. 10,000 events were counted. 




Fig. 3.63 Intracellular pH changes during AIA in BHK cells (60 min). BHK cells at 
90% confluency cultured in -MEM supplemented with 10% FBSi in the presence of 5 
μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. BHK cells were then stained with carboxy 
SNARF-1 AM for 15 min at 37 oC as described in 2.2.5.2. SNARF-1 stained samples 
were then treated with adenosine for 60 min and analyzed on Becton Dickinson 
FACSVantage SE. 10,000 events were counted. 




Fig. 3.64 Intracellular pH changes during AIA in BHK cells (90 min). BHK cells at 
90% confluency cultured in -MEM supplemented with 10% FBSi in the presence of 5 
μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. BHK cells were then stained with carboxy 
SNARF-1 AM for 15 min at 37 oC as described in 2.2.5.2. SNARF-1 stained samples 
were then treated with adenosine for 90 min and analyzed on Becton Dickinson 
FACSVantage SE. 10,000 events were counted. 




Fig. 3.65 Intracellular pH changes during AIA in BHK cells (4 hrs). BHK cells at 
90% confluency cultured in -MEM supplemented with 10% FBSi in the presence of 5 
μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. BHK cells were then stained with carboxy 
SNARF-1 AM for 15 min at 37 oC as described in 2.2.5.2. SNARF-1 stained samples 
were then treated with adenosine for 4 hours and analyzed on Becton Dickinson 
FACSVantage SE. 10,000 events were counted. 




Fig. 3.66 Intracellular pH changes during AIA in BHK cells (5 hrs). BHK cells at 
90% confluency cultured in -MEM supplemented with 10% FBSi in the presence of 5 
μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. BHK cells were then stained with carboxy 
SNARF-1 AM for 15 min at 37 oC as described in 2.2.5.2. SNARF-1 stained samples 
were then treated with adenosine for 5 hours and analyzed on Becton Dickinson 
FACSVantage SE. 10,000 events were counted. 




Fig. 3.67 Intracellular pH changes during AIA in BHK cells (6 hrs). BHK cells at 
90% confluency cultured in -MEM supplemented with 10% FBSi in the presence of 5 
μM EHNA were trypsinised and resuspended in serum-free fresh -MEM with 5 μM 
EHNA at the density of ~1×106 cells/ml. BHK cells were then stained with carboxy 
SNARF-1 AM for 15 min at 37 oC as described in 2.2.5.2. SNARF-1 stained samples 
were then treated with adenosine for 6 hours and analyzed on Becton Dickinson 
FACSVantage SE. 10,000 events were counted. 
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3.11  Involvement of Caspases during AIA in BHK Cells 
As the previous studies strongly suggest an intrinsic apoptosis pattern for AIA in 
BHK cells, the activity of the caspases in the BHK cell lysate was measured upon 
the treatment of adenosine to complete the intracellular signaling mechanism 
study. 
 
3.11.1 Activation of Caspase-3 
The activation of caspase-3 in BHK cells was measured 24 hours after the 
treatment with 1 mM adenosine and is shown in Fig. 3.68. BHK cells were 
prepared as described in 2.2.5.1. The measurement was done with the caspase-3 
assay kit from Pharmingen according to the user manual. Cell lysis buffer was 
used as blank, cell lysate alone, with caspase-3 inhibitor Ac-DEVD-CHO (N-
acetyl-Asp-Glu-Val-Asp-CHO), with or without substrate Ac-DEVD-AMC (N-
acetyl-Asp-Glu-Val-Asp-AMC) were used as negative controls. The detection of 
caspase-3 activity confirms it as the effector in the AIA in BHK cells. 
































Fig. 3.68 Caspase-3 activity during the adenosine-induced apoptosis in BHK cells. 
BHK cells were seeded on 6-well plates and apoptosis induced with adenosine for 24 
hours. Caspase-3 activity was measured by its substrate DEVD cleavage activity. The 
detection of caspase-3 activity suggests the involvement of caspase-3 as the executor 
caspase in AIA in BHK cells. 
A: Ac-DEVD-AMC+DEVD-CHO 
B: Ac-DEVD-CHO 
C: cell lysate 
D: Ac-DEVD-AMC 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.11.2 Activation of Caspase 8 
The caspase 8 activity in BHK cells was measured 24 hours after the treatment 
with 1 mM adenosine and is shown in Fig 3.69. BHK cells were prepared as 
described in 2.2.5.1. Caspase 8 activity was measured with the caspase 8 assay kit 
from Pharmingen according to the user manual. Cell lysis buffer was used as 
blank, cell lysate alone, with the caspase-8 inhibitor Ac-IETD-CHO (N-acetyl-Ile-
Glu-Thr-Asp-CHO), with or without substrate Ac-IETD-AFC (N-acetyl-Ile-Glu-
Thr-Asp-AFC) were used as negative controls. No caspase-8 activity was detected 
from the BHK cell lysate, indicating caspase-8 is not the initiator for caspase-3, 
therefore excludes the extrinsic pathway. 






























Fig. 3.69 Caspase-8 activity during the adenosine-induced apoptosis in BHK cells. 
BHK cells were seeded on 6-well plates and induced apoptosis with adenosine for 24 
hours. Caspase-8 activity was measured by its substrate IETD cleavage activity. The 
absence of caspase-8 activity excludes the involvement of caspase-8 as the initiator 




C: cell lysate 
D: IETD-AMC 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.11.3 Activation of Caspase 9 
Due to the unavailability of an assay for caspase 9 activity, the detection of 
caspase-9 cleavage was done with caspase-9 antibody (Pharmingen) which 
recognizes both procaspase 9 and caspase 9. As shown in Fig 3.70, caspase-9 
(active form) became dominant 2 hours after adenosine treatment, which suggests 
the intrinsic apoptosis pathway and caspase 9 to be the initiator caspase for 
caspase 3. 




Fig. 3.70 Activation of caspase 9 during the adenosine-induced apoptosis in BHK 
cells. BHK cells cultured at the density of 1×104 cells/cm2 in -MEM supplemented 
with 1% FBSi in the presence of 5 μM EHNA were treated with 1000 M adenosine for 1 
or 2 hours were lysed, denatured and subjected for SDS-PAGE and western blotting. 
Anti-caspase 9 (Pharmingen) was used at 1000× dilution. 
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3.12 Involvement of Caspases during AIA in SKW6.4 Cells  
Being Type I cell lines, the apoptosis in SKW6.4 and H9 cells was reported to be 
extrinsic, undertaking the death receptor-caspase 8 pathway. Therefore, the 
possible initiator and executor caspases in SKW6.4 cell AIA were also 
investigated. 
 
3.12.1 Activation of Caspase 3 
The activation of caspase 3 in SKW6.4 cells was measured 24 hours after the 
treatment with 1 mM adenosine and is shown in Fig. 3.71 and Fig. 3.72. SKW6.4 
cells were centrifuged and lysed after adenosine treatment period. Measurement 
was done with caspase 3 assay kit from Pharmingen according to the user manual. 
Cell lysis buffer was used as blank, cell lysate alone, with caspase-3 inhibitor 
DEVD-CHO, with or without substrate DEVD-AMC were used as negative 
controls. The detection of caspase 3 activity confirms it as the executor caspase in 
the adenosine-induced apoptosis in this Type I cell line. 
































Fig. 3.71 Caspase-3 activity during the adenosine-induced apoptosis in SKW6.4 cells. 
SKW6.4 cells were induced apoptosis with adenosine for 24 hours. Caspase-3 activity 
was measured by its substrate DEVD cleavage activity. The detection of caspase-3 





C: cell lysate 
D: DEVD-AMC 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.12.2 Activation of Caspase 8 
The caspase 8 activity was measured 24 hours after the treatment with 1 mM 
adenosine and is shown in Fig 3.43. BHK cells were prepared as described in 
2.2.5.1. Cell lysis buffer was used as blank, cell lysate alone, with the caspase-8 
inhibitor IETD-CHO, with or without substrate IETD-AFC were used as negative 
controls. No caspase-8 activity was detected from the BHK cell lysate, indicating 
caspase-8 is not the initiator for caspase-3, therefore excludes the extrinsic 
pathway. 































Fig. 3.72 Caspase-8 activity during the adenosine-induced apoptosis in SKW6.4 cells. 
SKW6.4 cells were induced apoptosis with adenosine for 24 hours. Caspase-8 activity 
was measured by its substrate IETD cleavage activity. The absence of caspase-8 activity 
excludes the involvement of caspase-8 as the initiator caspase and the extrinsic pathway 




C: cell lysate 
D: IETD-AMC 
ns: p > 0.05 
*: 0.01<p<0.05 
**: 0.001<p<0.01 
***: p < 0.001 
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3.12.3 Activation of Caspase 9 
The caspase 9 activity was measured 24 hours after the treatment with 1 mM 
adenosine and is shown in Fig 3.44. BHK cells were prepared as described in 
2.2.5.1. Cell lysis buffer was used as blank, cell lysate alone, with the caspase-9 
inhibitor, with or without substrate were used as negative controls. Caspase-8 
activity was detected from the BHK cell lysate, indicating caspase-9 is the 
initiator caspase for caspase-3. 
 




Fig. 3.73. Activation of caspase 9 during the adenosine-induced apoptosis in SKW6.4 
cells. SKW6.4 cells cultured at the density of 1×105 cells/ml in RPMI supplemented with 
1% FBSi in the presence of 5 μM EHNA were treated with 1000 M adenosine for 1 or 2 
hours were lysed, denatured and subjected for SDS-PAGE and western blotting. Anti-
caspase 9 (Pharmingen) was used at 1000× dilution. 







4 Chapter 4 Discussion 
 
In this chapter, the results from mechanism study of adenosine-induced apoptosis 
are analyzed and discussed. A receptor-transporter co-operation model is proposed 
as the extracellular mechanism of adenosine-induced apoptosis which explains the 
non-apoptotic, biphasic and non-biphasic apoptotic signaling patterns of 
adenosine in different cell lines. The involvement of GPCRs in apoptosis is 
discussed with the support of experimental data. With the identification of the key 
players, the intracellular events during AIA are discussed and the intracellular 
mechanism of the adenosine-induced apoptosis is proposed, the downstream of 
which resembles much of the intrinsic apoptosis with the emphasis of 
mitochondria being the central component and caspase 3 the executive caspase. 
The crosslink between extrinsic and intrinsic apoptosis pathways in the Type I cell 
lines SKW6.4 and H9 is also discussed. 
 
4.1  Adenosine-Induced Apoptosis (AIA) 
To eliminate the extracellular deaminase activity, which could rapidly convert 
adenosine into inosine, whenever extracellular adenosine was present in the 
medium, heat-inactivated fetal bovine serum (FBSi) was used. Alternatively, horse 
serum could be used. The deaminase activity in FBS could be completely heat-
inactivated at 56 oC in 2 hours. In addition, 5 μM of EHNA, a potent competitive 
inhibitor of adenosine deaminase, was used together with FBSi for a thorough 





Cell plating density for adenosine’s apoptotic effect study was optimized at 1104 
cells/cm2, which ensured enough cells for quantification. Cells were plated for 
experimental purpose when they reached 90% confluency; 20 min prior to plating, 
medium was replaced with fresh complete growth medium to achieve best cell 
activity.  
 
Identification of apoptosis caused by adenosine was first confirmed. In many 
earlier studies, the cell death caused by adenosine through the apoptosis process 
was not confirmed convincingly. Because of the complexity of apoptosis, no 
single standard is applicable for the identification of apoptosis in all cases. 
Multiple criteria therefore from early and late stage apoptosis as well as 
morphological characteristics (Fig. 3.1A, C) were employed to identify adenosine-
induced cell death to be apoptosis. 
 
Phosphatidylserine normally locates on the intracellular side of cell membrane in 
healthy cells. Because annexin V-FITC, a specific fluorescent dye for 
phosphatidylserine, is cell membrane impermeable, it cannot cross the cell 
membrane and detect the phosphatidylserine which locates on the intracellular 
side of the plasma membrane facing cytosol in healthy cells. At the early stage of 
apoptosis, phosphatidylserine is known to flip over to the extracellular side of cell 
membranes. Thus exposed, it can be detected and visualized by specific binding 
with annexin V-FITC (Martin et al. 1995). The exposure of phosphatidylserine is 
regarded as a sign of early stage apoptosis (Rimon et al. 1997, Homburg et al. 
1995) and therefore the detection of phosphatidylserine by annexin V-FITC 




exposure of phosphatidylserine was detected by annexin V-FITC in BHK cells 2 
hours after adenosine treatment. In the case of necrosis, cell membrane is 
ruptured, all cytoplasmic constituents as well as both sides of the ruptured plasma 
membrane are exposed to the environment. Phosphatidylserine therefore becomes 
assessable for annexin V-FITC. However, necrotic nuclei are morphologically 
different from those of the early stage apoptosis, which can be differentiated by 
propidium iodide (PI) staining. PI intercalates into double-stranded nucleic acids 
and is excitable at 488 nm. To exclude the possibility of necrosis, BHK cells were 
therefore double-stained, the annexin V-FITC positive and PI negative result 
confirms the early stage apoptosis (Fig. 3.1A). 
 
Late stage apoptosis in adenosine-treated BHK cells was confirmed by the 
presence of intranucleosomal DNA fragmentation into multimers of 185 bp 
nucleosomal units (DNA laddering) (Fig. 3.1B). DNA digestion at 
internucleosomal sites was recognized in 1980 as a characteristic feature of 
apoptosis, producing small double-stranded DNA fragments that migrate in a 
ladder pattern (multiples of 185 bp) after electrophoresis in agarose gels (Wyllie 
1980). Although the DNA degradation resulting in oligonucleosome-sided 
fragments does not occur in every cell death with classic apoptotic morphologies 
(Tomei et al. 1993), the result suggests adenosine-induced apoptosis in BHK cells 
share this feature characteristic of the apoptosis process.  The confirmation of the 
185 bp DNA ladder pattern during AIA was imporant as it was the prerequisite of 






Quantification of apoptosis has been one of the experimental difficulties in 
apoptosis research. Quantification methods have been developed according to 
characteristics unique to apoptosis. Several methods were experimented before 
measuring the cellular DNA concent with flow cytometry was used. Cell plating 
efficiency was firstly used as the indicator of cell viability for the evaluation of the 
apoptotic effect of adenosine. This method requires single cell solution and 
consistent operation skills to achieve statistical accuracy, and is therefore not 
suitable for cells that aggregate in cell solution or large sample size. Though 
colony forming assay is still heavily used to access the viability of haematological 
cells, it is less so in adherent cells. Moreover, colony forming ability is not a true 
indicator of apoptosis in theory. Nevertheless, however, earlier data obtained with 
this method proved to be essentially consistent with that using flow cytometry 
studies. 
 
The apoptotic effect of adenosine is cell type-dependent, as shown through Fig. 
3.2 to Fig 3.8. Adenosine induced apoptosis in a biphasic manner in BHK cells. At 
very low concentrations up to 5 μM, adenosine was not apoptotic, but low 
concentrations of adenosine (20 μM) induced significant apoptosis. Cell viability 
partially recovered with increasing concentrations of adenosine (50-200 μM) 
while high concentrations of adenosine (500-1000 μM) resulted severe in 
apoptosis. 
 
In contrast to the biphasic pattern in BHK cells, the apoptotic effect of adenosine 
in HeLa cells was observed to be dose-dependent but non-biphasic. Adenosine 




concentrations of adenosine (500-1000 μM) were shown to be very apoptotic (Fig. 
3.3). Similar dose-dependent non-biphasic pattern was also observed in two other 
cell lines SKW6.4 and H9 (Fig. 3.4). 
 
Unlike in BHK, HeLa, SKW6.4 or H9 cells, where adenosine appeared to be 
apoptotic in one way or another, adenosine did not exert any noticeable apoptotic 
effect in neuronal cell lines SY5Y and MN9D (Fig. 3.5). Each of the adenosine 
receptors was then activated selectively by agonists CCPA (A1 receptor), CGS-
21680 (A2 receptor) or IB-MECA (A3 receptor). However, such receptor 
activation did not result in any noticeable apoptosis in these two neuronal cell 
lines either (Fig. 3.6-3.8). Similar results from neuronal cell lines were obtained 
by another research group (personal communication). This “apoptotic 
insensitivity” of the neuronal cell lines to adenosine can be explained by the fact 
that neurons are more often exposed to high doses of adenosine physiologically 
where adenosine is one of the major neurotransmitters. However, neuronal 
apoptosis induced by adenosine analogue 2Cl-Ado at very high concentrations 
was observed by Abbracchio’s group (Ceruti et al. 1997). 
4.2 Extracellular Mechanism of Adenosine-induced Apoptosis 
4.2.1 GPCR-mediated Apoptosis in BHK Cells 
Extracellular adenosine, as a signaling as well as a metabolite molecule, has two 
means to exert its physiological effects. As a signaling molecule, adenosine can 
act on one or more of its four G protein-coupled receptors and activate G protein 
signaling pathways accordingly, without increasing the intracellular concentration 




by nucleoside transporters, which will be further discussed in the next section. 
With the possibilities of both receptors’ and transporters’ involvement in 
adenosine-induced apoptosis, as shown by previous researchers in various 
experimental setups (see 1.3 and table 5), it is reasonable to begin the mechanism 
study with the examination of the adenosine receptors involvement. 
 
The involvement of adenosine’s GPCRs in the adenosine-induced apoptosis in 
BHK cells was examined by using specific receptor agonists and antagonists, as 
shown through Fig. 3.3 to Fig. 3.14. Both agonist and antagonist studies were 
carried out for each of the four adenosine receptor subtypes to obtain confirming 
results. As the antagonist studies suggest, A1 and A3 receptors are involved in the 
apoptosis caused by low concentrations of adenosine (20-50 μM), as the AIA at 
this range is significantly reduced when the receptor is shut down by its specific 
antagonist. However, the contribution of A1 and A3 receptor signaling is 
insignificant in the apoptosis caused by high concentrations of adenosine (500-
1000 μM) (Fig. 3.9 and 3.13): blocking receptor pathway does not block the 
apoptotic pathway(s) employed in this situation. A1 and A3 receptor specific 
agonists CCPA and IB-MECA were used to mimic the apoptotic effect of 
adenosine by activating the A1 or A3 receptor signaling pathway. Confirming 
results obtained from both receptor antagonists suggest the contrbution of A1 and 
A3 receptor activation to AIA in BHK cells, as depicted in Fig. 3.10 and Fig. 3.14. 
 
However, the comparison between apoptosis induced by adenosine and that 
caused by A1 or A3 receptor agonist CCPA or IB-MECA should be carefully 




ligands than the natural ligand adenosine. In addition, unlike extracellular 
adenosine, 90% of which is rapidly transported into cells by nucleoside 
transporters within 3 hours, adenosine receptor agonists are more durable ligands 
to adenosine receptors and therefore exert longer-lasting apoptotic effects if the 
receptor(s) is/are involved. On the other hand, adenosine can induce apoptosis in 
BHK cells by activating both A1 and A3 receptors at the same time, whereas 
CCPA or IB-MECA can only activate the specific receptor signaling pathway of 
its own. Secondly and more importantly, the transporter studies conducted later 
suggest the contribution of adenosine transportation to apoptosis as well. As none 
of the receptor agonists is substrate for the nucleoside transporters, CCPA and IB-
MECA in fact can only partially mimic the apoptotic effect of adenosine. 
 
Given the pros and cons of the agonist study in BHK cells, the antagonist study 
proved to be a better general approach. Carefully chosen adenosine receptor 
antagonists selectively shut down one of the multiple channels through which 
adenosine may exert its apoptotic effect without interfering the rest, giving more 
consistent and conclusive data. Specific agonists proved to be a very useful tool 
studying the extracellular AIA mechanism at high adenosine concentrations in 
HeLa, SKW6.4 and H9 cells, which will be discussed later. 
 
In summary, both the antagonist and agonist studies suggest that, in the apoptosis 
induced by adenosine in BHK cells, A1 and A3 receptor signaling pathways are 
carried out at low adenosine concentrations (20-50 μM), but not at high adenosine 
concentrations (500-1000 μM). Contribution by A2 receptors was shown to be 




1000 µM), as proved by both antagonist study by DMPX (Fig. 3.11) and agonist 
study by CGS-21680 (Fig. 3.12). 
 
G protein-coupled receptors (GPCRs), also known as the seven transmembrane 
receptors, 7TM receptors, or heptahelical receptors, are a protein family of 
transmembrane receptors that transduce an extracellular signal (ligand binding) 
into an intracellular signal (G protein activation). The GPCRs are the largest 
protein family known, members of which are involved in all types of stimulus-
response pathways, from intercellular communication to regulation of behavioral 
and mood, immune system activity and inflammation, autonomic nervous system 
transmission and physiological senses such as visual sense and sense of smell. 
This has the consequence of involving GPCRs in many pathological conditions, 
which has led to GPCRs being the target of 40 to 50% of modern medicinal drugs. 
However, in spite of the involvement of GPCRs in physiological and pathological 
processes, the possibility for GPCRs’ involvement in apoptosis was rarely 
considered by scientists in review articles or textbooks. GPCRs are one of the four 
classes of cell-surface receptors classified by H. Lodish in his classic textbook The 
Molecular Cell Biology. According to Lodish, all cell-surface receptors belong to 
one of the four classes: (1) G protein-coupled receptors (GPCRs), (2) Ion-channel 
receptors, (3) Tyrosine kinase-linked receptors or (4) Receptors with intrinsic 
enzymatic activity (usually receptor serine/threoine kinases or receptor tyrosine 
kinases (RTKs)). Among the four classes of cell-surface receptors, ion-channel 
receptors are basically ion channels that are regulated by ligand binding. The latter 
two (tyrosine kinase-linked receptors and receptors with intrinsic enzymatic 




tyrosine kinase has been now well understood by the apoptosis scientists to be one 
of the most common regulatory mechanisms in apoptosis. However, the 
involvement of the G protein-coupled receptors (GPCRs) in the apoptosis is rarely 
reported, being the last class of cell-surface receptors, it remains a mysterious role 
in apoptosis. Lodish is in agreement with the possibility of GPCR-mediated 
apoptosis and thought it to be an interesting and important topic worth 
investigations (personal conversation). Our results suggesting that A1 and A3 
receptors mediate adenosine-induced apoptosis in the case of BHK cells therefore 
provides specific and convincing evidence for a role of GPCRs in apoptosis. 
 
As the GPCR signaling pathways and apoptotic signaling pathways share certain 
key cytosol molecules, the crosstalk between the two is possible in theory. If 
GPCR-mediated apoptosis ever exists, it will provoke a new field in apoptosis 
research by establishing a crosstalk between the two major signaling pathways. 
Given the fact that both GPCR and apoptosis research are the most active fields in 
biological research, an understanding of the role of GPCRs in apoptosis is of 
theoretical and pharmaceutical significance. 
 
4.2.2 Transporter-mediated Apoptosis in BHK Cells 
In the previous studies, A1 and A3 receptors have been identified to contribute to 
the adenosine-induced apoptosis in BHK cells at 20-50 μM adenosine range. 
However, the pathways that accounted for the AIA at high concentrations of 
adenosine (500-1000 μM) still remained to be further studied, with the nucleoside 
transporters being the suspected mediator. In addition, if such adenosine 




(20-50 μM), it was yet to be proven. Therefore nucleoside transporters were next 
studied to answer the questions. Two inhibitors were used for the purpose: NBTI 
is a specific es transporter inhibitor, dipyridamole is an unspecific inhibitor which 
inhibits both es and ei transporters. Due to the lack of specific ei inhibitor, the role 
of ei transporter could be understood with the combined use of the two inhibitors 
when es was not shown to be involved (i.e. when dipyridamole suggests a 
presence of either es or ei and NBTI suggests an absence of es, the presence of ei 
could be concluded). 
 
As suggested by the result shown in Fig. 3.16, es transporter is responsible for the 
AIA at high concentrations of adenosine (500-1000 μM) in BHK cells as the 
blockage by NBTI effectively blocked the AIA. Unspecific transporter inhibitor 
dipyridamole similarly blocked the apoptosis induced by 500-1000 μM adenosine, 
suggesting that at high substrate concentrations, adenosine is transported into cells 
and initiates apoptosis intracellularly (Fig. 3.17). 
 
Noteworthily, es transporter did not contribute to AIA in BHK cells when the 
adenosine concentrations were low (20-50 μM), as suggested by the observation 
that blockage of es transportation route did not block the AIA at this adenosine 
level (Fig. 3.16), nor did ei transporter showed its contribution to adenosine-
induced apoptosis at 20-50 μM adenosine concentrations(Fig. 3.16 and Fig. 3.17). 
 
Both receptor antagonism and transporter inhibition cannot completely block 
adenosine’s apoptotic machinery and thus are unable to give a complete recovery 




propentofylline was next used for a combination of both receptor antagonism and 
transporter inhibition. As seen in Fig. 3.18, propentofylline exhibited a more 
thorough blockage of the adenosine-induced apoptosis in BHK cells. Other 
receptor antagonist and transporter inhibitor combinations were also tested but due 
to the toxicity of the chemicals per se, results were not as conclusive (see Fig. S-1 
in Appendix B). 
 
When a receptor agonist induces apoptosis in BHK cells, one cannot be certain if 
it is the behavior of low or high concentrations of adenosine that is mimicked by 
the agonist, as adenosine is apoptotic at both ranges in BHK cells. In addition, the 
apoptotic effect of an agonist at a given concentration cannot be translated into 
that of adenosine concentrations. Unlike BHK cells, HeLa cells were observed to 
respond only to high concentrations of adenosine (500-1000 μM) (Fig. 3.3). 
Therefore, if an agonist induces apoptosis in HeLa cells, one can be certain that 
the agonist exerts its apoptotic effect like high concentrations of adenosine. 
Conversely, if a receptor agonist does not induce apoptosis in HeLa cells, one can 
be certain that such receptor activation does not contribute to AIA at high 
adenosine concentrations. This property makes HeLa cells experimentally useful 
for further investigation on the extracellular AIA mechanism at high 
concentrations of adenosine. 
 
The results obtained from such agonist studies are graphed in Fig. 3.20, 3.22 and 
3.24 (A1, A2 and A3 receptor respectively). As has been shown in BHK cells, these 
results prove that none of the agonists of A1, A2 or A3 receptors could cause 




concentrations of adenosine is only transporter-mediated. Antagonist studies were 
also conducted alongside the agonist studies, and similar results were obtained 
from A1, A2 and A3 receptors (Fig. 3.19, 3.21 and 3.23 respectively). 
 
Unlike in BHK cells, where agonist data alone are not conclusive (as discussed 
above) and antagonism studies are used for analysis primarily, in HeLa cells, 
agonist data are as conclusive as antagonist data due to the simplicity of its AIA 
pattern. The analyses of data from receptor agonist and antagonist studies as well 
as transporter inhibitor studies to decide the extracellular mechanism of AIA are 
summarized in Table 6 (for BHK cells) and Table 7 (for HeLa cells). 
 
Agonist and antagonist studies were also conducted in the two Type I cell lines 
SKW6.4 and H9. As it is understood that these two cell lines exhibited dose-
dependent non-biphasic apoptotic response to adenosine similar to HeLa cells, 
similar results were expected. However, although both A1 receptor and A2 
receptor involvement were shown to be absent in the AIA in SKW6.4 cells 
(shown in Fig. 3.25-3.28. Fig. 3.25, A1 antagonism, Fig. 3.26, A1 agonism, Fig. 
3.27, A2 antagonism and Fig. 3.28, A2 agonism) similar to BHK and HeLa cells, 
A3 receptor exhibited measurable contribution to the AIA in SKW6.4 cells, as 
proved by both antagonist (Fig. 3.29) and agonist (Fig. 3.30) studies. Experiments 
conducted in H9 cells suggest a similar pattern: A1 and A2 receptors are not 
involved (Fig. 3.31, A1 antagonism, Fig. 3.32, A1 agonism, Fig. 3.33, A2 
antagonism and Fig. 3.34, A2 agonism), yet both antagonist (Fig. 3.35) and agonist 
(Fig. 3.36) studies suggest a noticeable contribution of A3 receptor activation to 




Table 6 Strategies of the extracellular mechanism studies of AIA in BHK cells.  
 
Drug Figure Apoptosis Conclusion Remarks 
At low Ado conc Y2 ARs3 & ATs4 all possible   
Ado1 Fig 3.2
At high Ado conc Y ARs & ATs all possible   
A1R agonist Fig 3.10 Y A1R involved in AIA 
Supportive, 
uncertain role of 
A1R in LAIA5 
and HAIA6 
At low Ado conc R7 A1R involved in LAIA Conclusive Ado + A1R 
antagonist Fig 3.9
At high Ado conc Y A1R not involved in HAIA Conclusive 
A2R agonist Fig 3.12 N8 A2R not involved Conclusive 
At low Ado conc N A2R not involved Conclusive Ado + A2R 
antagonist Fig 3.11 
At high Ado conc N A2R not involved Conclusive 
A3R agonist Fig 3.14 Y A3R involved 
Supportive, 
uncertain role of 
A3R in LAIA and 
HAIA 
At low Ado conc R A3R involved in LAIA Conclusive Ado + A3R 
antagonist Fig 3.13 
At high Ado conc Y A3R not involved in HAIA Conclusive 
At low Ado conc Y es not involved in LAIA Conclusive Ado + es 
inhibitor Fig 3.16 
At high Ado conc R es involved in HAIA Conclusive 




At high Ado conc R ei may be involved in HAIA Non-conclusive 
Conclusion: A1R & A3R responsible for LAIA, es transporter responsible for HAIA, ei may be 
responsible for HAIA 
 
Note:  
1, Ado: adenosine; 2, Y: apoptosis; 3, AR: adenosine receptor; 4, AT: adenosine 
transporter; 5, LAIA: AIA induced by low concentrations of adenosine; 6, HAIA: AIA 




Table 7 Strategies of the extracellular mechanism studies of AIA in HeLa cells.  
 
Drug Figure Apoptosis Conclusion Remarks 
At low Ado conc N    
Ado Fig 3.3
At high Ado conc Y ARs & ATs all possible   
At low Ado conc N   Ado + A1R 
antagonist Fig 3.19
At high Ado conc Y A1R not involved Non-conclusive 
A1R agonist Fig 3.20 N A1R not involved Conclusive 
At low Ado conc N   Ado + A2R 
antagonist Fig 3.21
At high Ado conc Y A2R not involved Non-conclusive 
A2R agonist Fig 3.22 N A2R not involved Conclusive 
At low Ado conc N   Ado + A3R 
antagonist Fig 3.33
At high Ado conc Y A3R not involved Non-conclusive 
A3R agonist Fig 3.34 N A3R not involved Conclusive 
At low Ado conc N   Ado + es 
inhibitor Fig 3.37
At high Ado conc Y es not involved Conclusive 




At high Ado conc R ei involved  Conclusive 
Conclusion:  ei responsible for the AIA in HeLa cells 
 
Abbreviations as previous table. Note the difference in conclusions drawn from 




To find out the involvement of adenosine transportation during the AIA in HeLa, 
SKW6.4 and H9 cells, transporter studies were conducted in all three cell lines. In 
HeLa cells, dipyridamole (Fig. 3.38) but not NBTI (Fig. 3.37) significantly 
blocked the apoptosis induced by 500-1000 μM adenosine, suggesting the 
involvement of ei but not es transporter in HeLa cell AIA, in contrast to BHK 
cells where es is involved. However, it should be noted that NBTI exhibited 
toxicity in HeLa cells, which was not seen in other cell lines. 
 
In SKW6.4 cell, NBTI blocked AIA significantly as seen in Fig. 3.39, therefore 
the adenosine transportation via es is suggested. The engagement of ei transporter 
is possible but cannot be confirmed by the blockage effect of dipyridamole (Fig. 
3.40). Both NBTI and dipyridamole likewise blocked AIA in H9 cells (Fig. 3.41 
and Fig. 3.42 respectively), therefore same adenosine transportation pattern as 
SKW6.4 cells is suggested for H9 cells. 
 
Base on these findings, it is concluded that the first phase (20-50 μM adenosine) 
in the biphasic AIA in BHK cells is mediated by A1 and A3 receptors, the second 
phase (500-1000 μM adenosine) is mediated by es and possibly ei transporters. 
 
Despite the evidence for the involvement of the equilibrium transporters in the 
adenosine-induced apoptosis, it by no means suggests the absence of the active 
transport systems. On the contrary, given the origin of the BHK cells, it is likely 
that the cells poccess the active transport systems as well. However, owing to the 
lack of pharmacological means, scientists often found it difficult to access the 




4.2.3 Postulated Extracellular Mechanism for the Biphasic, Non-
biphasic and Non-Apoptotic Effects of Adenosine 
The biphasic apoptotic effects of adenosine in BHK cells suggest the existence of 
multiple pathways which are responsible for low, middle and high concentrations 
of adenosine. This hypothesis is further supported by the observation of non-
biphasic apoptotic effects of adenosine in HeLa cells. Based on the experimental 
results, it is hypothesized that: (1) the pathway that low concentrations of 
adenosine induces apoptosis is its GPCRs (A1 and A3); (2) the pathway that high 
concentrations of adenosine induces apoptosis is nucleoside transporters (es and 
sometimes ei); (3) these pathways are cell type dependent. Specifically, both 
pathways are functional in BHK cells therefore a biphasic apoptosis pattern was 
observed; only the latter pathway is functional in HeLa cells, therefore shows a 
dose-dependent non-biphasic pattern, but neither pathways are functional in SY5Y 
and MN9D cells (or the signal is offset by A2 receptors Cunha 1994, O’Kane & 
Stone 1998), and therefore such cell lines do not exhibit an apoptotic response to 
adenosine up to 1000 µM. It is possible that, because of their neuronal origin, the 
cells are often exposed to high concentrations of adenosine which has an 
important physiological role in the nervous system. This extracellular model best 
explains the experimental observations in the research, as well as most of the 
observations reported previously (Table 5). 
 
4.3 Intracellular Mechanism of Adenosine-induced Apoptosis 
The study of the extracellular AIA mechanism provided an insight to the 




starts the intracellular apoptosis machinery, i.e. by activation of Gαi that coupled to 
both A1 and A3 receptors or by an elevated cytosolic adenosine. On the other 
hand, knowledge of the processes involved in apoptosis has accumulated over the 
past 20 years and can now provide a general paradigm of the major subcellular 
events leading to cell death by apoptosis. More likely than not, the signaling 
pathway of the adenosine-induced apoptosis would join the mainstream apoptotic 
signaling at some point because it would be highly impossible for AIA to 
undertake a unique mechanism that has never been reported before. Therefore, the 
strategy of the intracellular mechanism study was to firstly identify the 
downstream pathway of AIA. With the Gαi activation and elevated intracellular 
adenosine in mind as the first cellular events of the AIA, efforts were than made to 
establish connections between the mainstream late cellular events of apoptosis and 
the early cellular events of AIA to get the complete picture of adenosine-induced 
apoptosis signaling mechanism. 
 
4.3.1 Mitochondrial Hyperpolarization and Depolarization during 
AIA 
Mitochondria play a critical role in apoptosis induction in response to myriad 
stimuli. These organelles release proteins into the cytosol which trigger caspase 
activation or perform other functions relevant to apoptosis, including cytochrome 
c (cyt-c), AIF (apoptosis inducing factor) and SMAC (Diablo). 
 
The mitochondria of healthy cells maintain an electrochemical gradient (i.e. 
mitochondrial membrane potential, ΔΨm) across their inner membrane which is 




these organelles in conjunction with electron transport through the respiratory 
chain (Hatefi 1985). The electrochemical gradient consists of ΔpH and ΔVm 
components, but fundamentally is caused by a net efflux of H+ ions from matrix to 
the outer surface of the inner membrane, with the membrane acting like a 
capacitor that builds up charge and is poised to discharge when conditions are 
permissive. Influx of protons back into the matrix is thought to be mediated 
chiefly by the F0F1-ATPase/ H+ pump. This multi-subunit protein complex 
includes a H+ channel coupled to an ATPase (Konforti 1999). 
 
To examine the change of ΔΨm during BHK cell AIA, a fluorescent mitochondrial 
membrane potential indictor ApoAlert™ MitoSensor from Pharmingen was used 
in the experiments. ApoAlert™ MitoSensor was suspected to be chemically very 
similar to the cationic JC-1 from Molecular Probes. MitoSensor reagent is a 
cationic dye sensitive to the permeability of mitochondrial membrane. In 
apoptotic cells, it cannot get into the mitochondria and thus remains in the 
cytoplasm as monomers. In non-apoptotic cells, it can cross the mitochondrial 
membrane and aggregate in the mitochondria. When the dye accumulates as 
aggregates in the mitochondria that have normal MMP, the cells show a red 
fluorescence. In contrast, when the dye stays in the cytoplasm as monomers, the 
cells show a green fluorescence. The loss of ΔΨm over 3 hr upon the induction of 
apoptosis by 1 mM adenosine was observed (Fig. 3.43 A-F), suggesting the 
involvement of mitochondria in AIA in BHK cells and a Type II apoptotic 
scenario (see below), which has been more correctly named mitochondria-





In 1998, Scaffidi et al firstly reported two independent pathways through which 
apoptosis is induced, in one of which Fas receptor binds to FADD (Fas-associated 
death domain) and subsequently activates the initiator caspase 8 (Type I), while in 
the other pathway (Type II) cytochrome c is released from mitochondria, forming 
an apoptotic complex (apoptosome) with Apaf-1 (apoptotic protein activation 
factor 1) and dATP, pro-caspase 9 is then cleaved and activated, being the initiator 
caspase. As the two pathways were found in different cell lines, these cell lines 
were classified into Type I and Type II cell lines (Scaffidi et al. 1998). Both 
pathways share caspase 3 as the executor caspase. In Type II cell lines, which 
account for most reported studies but two: SKW6.4 and H9, the depolarization of 
mitochondria and loss of the membrane potential (ΔΨm) is universally associated 
with apoptosis, although the mechanisms responsible and the kinetics of ΔΨm 
disruption remain debated (Kroemer & Reed 2000). 
 
When the mitochondrial membrane potential was monitored more precisely at 
shorter time intervals, an interesting observation was made. An unusual initial 
acute rise in mitochondrial membrane potential (hyperpolarization) was repeatedly 
observed shortly after the treatment of adenosine and before the prolonged 
depolarization (Fig. 3.44). Unlike depolarization, hyperpolarization of the 
mitochondrial inner membrane is not an early apoptotic event characteristic in 
every case of mitochondria-dependent apoptosis. However, this observation is in 
agreement with that of some other researchers. Several groups have reported 
evidence of an initial increase of ΔΨm, occurring before or contemporaneously 
with cyt-c release, and preceding caspase activation and subsequent membrane 




Minn et al. 1999, Krohn et al. 1999). Difficulties however exist with interpreting 
results derived from use of cationic dyes for monitoring ΔΨm (Petronilli et al. 
1998, Rottenberg & Wu 1998). For example, the amount of the dyes which 
accumulate in mitochondria is dependent not only on ΔΨm but also the volume of 
the organelles, thus complicating the interpretation when organelles swell. Some 
of the commonly used dyes also can leak out of mitochondria when permeability 
transition (PT) occurs, due to simple diffusion rather than partitioning in 
accordance with membrane potential. Other problems include auto-quenching 
when intra-mitochondrial concentrations of dye are too high and destruction by 
oxidation. Also, dye entry into cells is regulated at the plasma membrane, in 
addition to mitochondrial membranes. 
 
With these difficulties bearing in mind, the experiment was designed to perform 
real time observation where living cells were observed over 3 hrs upon the 
treatment of adenosine. BHK cells were cultured on 8-well Lab-Tek™ Chambered 
Coverglass (Nunc) for 12 hours to reach healthy status. Coverglasses were 
observed through a temperature-CO2 control apparatus mounted on Carl Zeiss 
LSM 510 confocal microscope, which maintains the cultural temperature at 37 oC 
with a constant supply of 5% CO2 to simulate an incubator-like environment 
throughout the observation. This experimental setup avoided several arguments 
about the hyperpolarization observation. For example, the comparison made is 
ΔΨm of same cells at different time points, rather than ΔΨm of different cells from 
different fixed slides. The inconsistency of staining as well as dye delivery across 





However, certain arguments still remain valid. For example, if mitochondria 
swelled, more dye would be taken in, resulting a rise in fluorescence, which would 
look same as the acute hyperpolarization of mitochondrial inner membrane. For 
these reasons, an alternative approach was used which monitors the local 
mitochondria pH directly using pH-dependent GFPs (Llopis et al. 1998, 
Matsuyama et al. 2000). The observation was that stimuli such as Bax over-
expression which induces mitochondria-dependent apoptosis induce rapid matrix 
alkalinization, with a substantial change in pH estimated at ~0.5 pH. This 
observation suggests the increase in ΔpH (alkalinization) account for the 
hyperpolarization noted when using cationic dyes. Therefore, acute 
hyperpolarization of mitochondrial inner membrane observed using cationic dyes, 
in spite of the effects of mitochondrial volume, dye leakage, auto-quenching and 
membrane delivery, can be regard as an early event in adenosine-induced 
apoptosis in BHK cells. The matrix alkalinization/depolarization is believed to be 
a result of reverse function of F0F1-ATPase which will be discussed later together 
with cytosolic acidification. 
 
4.3.2 Cytochrome c Release during AIA 
As a result of the ΔΨm loss, cytochrome c is usually released into cytosol which 
forms apoptosome with Apaf-1 and dATP/ATP, cleaves and activates procaspase 
9 into caspase 9. Caspase 9 in turn cleaves procaspase 3, resulting the active 
executor caspase 3. Therefore, the release of cytochrome c was next studied in the 





Nucleoside transporters were shown to contribute to adenosine-induced apoptosis, 
especially those of es transporter type (Fig. 3.16-3.17) as observed in BHK cells at 
high micromolar concentrations of adenosine. Given the kinetics of es 
transporters, this implies a rapid cytosolic adenosine elevation. However, little 
was understood on the intracellular events an elevated cytosolic adenosine level 
would cause beside the shift of the metabolism equilibrium. There were two 
possibilities that adenosine could cause the dysfunction of mitochondria and 
subsequently the release of cytochrome c: (1) the possibility of direct interaction 
between adenosine and mitochondria (specifically, the ANT on the mitochondrial 
inner membrane). If adenosine induces the mitochondrial permeability transition 
pore (MPTP) by acting on ANT (adenine nucleotide translocator), as a result, it 
will cause the mitochondrial depolarization and release cytochrome c from 
mitochondria. (2) the possibility of indirect interaction. As a cellular response to 
elevated intracellular adenosine, the pro-apoptotic Bcl-2 family protein 
translocates to mitochondrial outer membrane and form a pore for the release of 
cytochrome c. Both possibilities needed to be examined. The possible direct 
adenosine-mitochondria interaction was first test out with purified mitochondria to 
exclude cytosolic interferences. However, adenosine did not appear to cause the 
release of cytochrome c from mitochondria in such an experimental setup (See 
Fig. S-2 in Appendix B). This possibility was discarded. The second possibility 
was next investigated using a cell-free system. Healthy BHK cells at 90% 
confluency were used to prepare the native cell lysate. Adenosine was then added 
to the final concentration of 500 µM. Mitochondria were then separated from 
cytosol after the treatment period. Cytosol was immunoprecipitated for Bax and 




PAGE. The western blotting result is shown in Fig. 3.45. The cotranslocation of 
Bax from cytosol to mitochondria and cytochrome c from mitochondria to cytosol 
strongly suggests that this scenario belongs to one of the two currently-accepted 
models for the release of cytochrome c as well as other mitochondrial pro-
apoptotic proteins. 
 
Most of the major cellular events during apoptosis have been well studied and 
understood over the past 20 years, one of the issues that remain unclear and is still 
under active research now is how cytochrome c as well as other mitochondrial 
proapoptotic proteins finds its way out of mitochondria into cytosol upon an 
apoptotic stimulus. It is so mainly because of two reasons: (1) the exact structure 
of MPTP is still under debate, which is the key to a thorough understanding of 
mitochondrial dysfunction during apoptosis; (2) the mechanism of how 
cytochrome c detaches from mitochondrial inner membrane is still uncertain. 
Currently, two models have been proposed: (1) Bax (in some cases Bak and/or t-
Bid as well) inserts into the mitochondrial outer membrane (MOM), oligomerizes 
and forms a pore for the release of cyt c; (2) an opening of the mitochondrial 
permeability transition pore (MPTP) occurs, which consists of voltage-dependent 
anion channel (VDAC) on the MOM, adenine nucleotide translocator (ANT) on 
the MIM (mitochondrial inner membrane), cyclophilin D (CyD) as well as several 
other proteins. PTP formation results in the swelling of the mitochondrial matrix, 
followed by the rupture of the MOM (mitochondrial outer membrane) and 





However, both models have flaws and cannot account for the general release of 
cyt c. The cytochrome c release during apoptosis is believed to be “rapid and 
complete” (Goldstein et al. 2000). In addition, in mitochondria, most of 
cytochrome c is membrane bound. Of this, ~85% resides within the cristae, only 
~15% locates on the non-cristal inner membrane (MIM). An electron microscopic 
study revealed that the width of the cristae is ~27 nm, the diameter of the cristal 
junctions is ~28 nm and the average distance across the outer membrane and inner 
boundary membrane is 20 nm, which narrows to 14 nm at contact sites (Frey & 
Mannella 2000). Given the narrow structure of mitochondrial cristae, detached 
cristal cytochrome c, which accounts for the majority of mitochondrial 
cytochrome c and is essential for the “rapid and complete” release, cannot get out 
of mitochondria rapidly and completely enough in model 1. That is to say, model 
1 requires a cytochrome c detaching mechanism as well as a mechanism for 
cytochrome c to get a “rapid and complete” access to the pore formed on the 
MOM to be complete. 
 
In model 2, as a result of MPTP opening, the mitochondrial matrix swells, 
therefore most cristae are unfolded, providing a mechanism for the “rapid and 
complete” release of cytochrome c. However, the structure of the mitochondrial 
permeability transition pore is still debatable. Brdiczka et al. (2006) recently 
proposed a more complicated structure of the mitochondrial contact sites which 
switch between an antiporter state and a uniporter state. At the later state, the 
complex becomes non-specific pores that can be assigned for permeability 
transition. The basic structure is a complex with VDAC (voltage-dependent anion 




inner membrane. More specifically, there are three states for the complex. State I 
is a heterotetramer formed by a VDAC dimmer and an ANT dimmer (less stable); 
state II is a VDAC tetramer and an ANT tetramer associated by a creatine kinase 
(CK) octamer which locates in the mitochondrial inner membrane space (IMS); 
state III is a VDAC tetramer and an ANT tetramer associated by a hexokinase 
(HK) octamer from cytosol. State II acts as an antiporter, state III acts as a 
uniporter (MPTP). The three states are interchangeable when conditions change. 
In addition, cardiolipin is always bound to ANT in all three states; cytochrome c is 
bound to cardiolipin. This refined model provides a detailed structure of MPTP 
and a good insight into the regulation of Ca2+ and ADP in some apoptotic events 
such as mitochondrial swelling, membrane disruption and cytochrome c release. 
However, there are some flaws in the model. For example, cyclophilin D is 
proposed to be the site where Ca2+ acts, but it lacks theoretical and experimental 
supports (Halestrap AP, personal communications). In addition, a recent research 
article by Bernardi group disapproves the requirement of VDAC1 for MPTP using 
VDAC -/- mice (Krauskopf et al. 2006), while VDAC is an essential building 
block of the structure proposed in this model. 
 
In disagreement to the mainstream notion that MPTP consists of VDAC on the 
outer membrane, ANT on the inner membrane with cyclophilin D associated with 
ANT from the matrix, Halestrape AP argues that the basic structure of MPTP only 
consists of ANT and cardiolipin (Halestrap & Brennerb 2003) (personal 
communications). In addition, there is growing evidence suggesting that matrix 
swelling leads to both necrosis and apoptosis. A recent model hypothesizes a 




inner membrane space (IMS) as an earlier event prior to cyt c release. Though this 
remodeling concept has not attracted enough attention yet, it best explains the 
mechanism for the release of cytochrome c in many apoptotic cases including 
adenosine-induced apoptosis in BHK cells. 
 
In mitochondria, the binding of cytochrome c to mitochondrial inner membrane is 
through a mitochondrial specific glycerophospholipid cardiolipin, which unlike 
other glycerophospholipids, has two phosphatidyl groups i.e. four fatty acid 
sidechains, mostly being C16 and C18, with two of which inserted into the bilayer 
mitochondrial inner membrane like normal phospholipids, the other two being 
outside of the membrane. A widely accepted model of cyt c:cardiolipin binding 
proposes that cardiolipin holds cyt c to membrane with two fatty acid sidechains 
inserted into the cyt c pocket while the other two in the mitochondrial inner 
membrane. The force that holds cytochrome c to the fatty acid chains can be either 
electrostatic or hydrophobic interaction. A recent view argues that, based on this 
cyt c:cardiolipin model, most cyt c binds loosely with cardiolipin through 
electrostatic interactions while a small amount of cyt c in cristae binds tightly to 
cardiolipin through stronger hydrophobic interactions, and those cardiolipin fatty 
acid sidechains are more likely to be long ones (C22 or C24) (Kagan et al. 2004). 
 
As the experimental data support the Bax dimmerization on the MOM, a 
mechanism for the detachment of cytochrome c from cardiolipin was needed. To 
understand the cytochrome c binding and release mechanism better, experiments 
were carried out using purified mitochondria. It is found that (1) mitochondrial 




not lead to a rapid and complete release of mitochondrial cyt c within 10 min, 
which suggests that cytochrome c is detached from mitochondrial inner membrane 
through a different mechanism; (2) an pore on the mitochondrial outer membrane 
was necessary but not sufficient for the release of cytochrome c, which once again 
suggests a mechanism for cytochrome c detachment; (3) oxidative stress is able to 
detach most mitochondrial cytochrome c. As adenosine is known to cause the 
accumulation of NO through elevated intracellular ATP level (Hon et al.1999), it 
provides an important connection between adenosine signaling and apoptotic 
signaling. In the case of adenosine-induced apoptosis in BHK cells, an 
accumulation of NO as an oxidative stress resulted by an elevated cellular 
adenosine level through ATP can detach cytochrome c from mitochondrial inner 
membrane, at the same time, a pore formed by Bax dimmerization on the 
mitochondrial outer membrane provides a passage for cytochrome c to cytosol, 
eventually activates caspase 9 and caspase 3. Although the accumulation of NO as 
a result of elevated intracellular adenosine was observed and confirmed in the lab 
previously, unfortunately, this experiment was not reproduced in this research. 
These findings support the two-step process of cytochrome c release that 
Orrenius’s group had proposed (Ott et al. 2002) (personal communication). Other 
findings from the experiment include: (4) fatty acid chain when bound to reduced 
cyt c, induces a conformational change in cyt c, the resulting complex resembles 
oxidized cyt c; The oxidized state of cytochrome c is known to be the state where 
cytochrome c is at in the apoptosome in cytosol. The reduced cytochrome c does 
not play a role in apoptosis (Balaban et al. 2005). (5) ~5% of total cytochrome c 
binds to cardiolipin through hydrophobic interactions (more difficult to detach), 




account for the “rapid and complete” release of cytochrome c during apoptosis; 
and (6) the hydrophobic interaction is unlikely between cytochrome c and C22 or 
C24 fatty acids as opposed to Kagan (Kagan et al. 2004). 
 
4.3.3 Intracellular Ca2+ Elevation during AIA 
An altered, usually elevated intracellular Ca2+ concentration is a common key 
player in many apoptotic cases. Fura 2-AM was used to observe if there were any 
changes of cytosol Ca2+ level during AIA in BHK cells. Fura 2-AM is a cell 
permeable fluorescent Ca2+ indicator which is able to cross the cell membrane due 
to its AM ester structure. Esterases in the cell then hydrolyze the AM ester to yield 
non-permeable Fura 2 which therefore cannot exit the cell. Fura 2 is non-
fluorescent until associated with Ca2+. Once complexed with Ca2+, Fura 2 emits at 
526 nm when excited at 506 nm (Kao et al. 1989). BHK cells at 90% confluency 
were used to prepare a cell solution (1×106 cells/ml) for the study. BHK cell 
solution was stained with Fura 2-AM according to 2.2.5.3. Samples were then 
subject to flow cytometry analysis. 
 
As shown in Fig 3.48-3.49, [Ca2+]c was increased ~10-fold within 10 min upon the 
treatment of 20 µM adenosine. The elevation of intracellular Ca2+ level ([Ca2+]c) 
can be a result of either the import through the plasma membrane or the 
endoplasmic reticulum (ER) Ca2+ store ([Ca2+]e) opening as observed in most 
physiological and pathological conditions (Orrenius et al. 2003). This can also 
explain the case of adenosine-induced apoptosis in BHK cells. While ER Ca2+ 




and increased IP3 level is a common intracellular response of Gαi, the intracellular 
Ca2+ elevation can be a cellular response of A1 and A3 receptor activation. 
Antagonists were used to examine if the elevated [Ca2+]c was a result of A1R/A3R 
activation. As shown in Fig. 3.51-3.54, a combination of DPCPX and MRS-1220 
was able to block the [Ca2+]c elevation caused by 20 µM adenosine in BHK cells, 
suggesting the mediation via these two Gαi-coupled receptors. 
 
As a second messenger, cellular Ca2+ ([Ca2+]c) regulates a wide spectrum of 
physiological and pathological processes. In the context of apoptosis, an elevated 
[Ca2+]c is found to impair the function of mitochondria and cause apoptosis 
through increased matrix Ca2+ concentration in many mitochondria-dependent 
apoptosis. As a result, the mitochondrial membrane potential is usually altered, the 
mitochondrial permeability transition pore forms and cytochrome c releases 
(Orrenius et al. 2003).  
 
As [Ca2+]c elevation was observed at 20 µM adenosine in BHK cells and was 
proved to be mediated by A1R and A3R (Fig. 3.46-3.54), it provides a possible 
intracellular mechanism for the AIA in BHK cells at low concentrations of 
adenosine (20-50 µM), as well as an intracellular apoptotic signaling pathway for 
G protein-coupled receptor-mediated apoptosis. Specifically, activation of the A1 
and A3 receptors by adenosine at low micromolar range (20-50 µM) inhibits 
adenylyl cyclase (AC) activity through activation of Gαi proteins and results in 
increased activity of phospholipase C (PLC) via Gβγ subunits (Ralevic & 
Burnstock 1998, Jacobson & Gao 2006). Increased activity of PLC in turn results 




1998, Jacobson & Gao 2006). Elevated IP3 level acts on the IP3 receptor on ER 
and opens the ER calcium store, resulting a rapid increase of cytosolic Ca2+ 
(Berridge et al. 2003). Elevated [Ca2+]c subsequently alters MMP, causes the 
formation of MPTP and the release of cytochrome c, caspase 9 and caspase 3 are 
then activated (see discussion in the next section). 
 
4.3.4 Intracellular Acidification during AIA 
Intracellular pH change was also investigated using a fluorescent pH indicator 
carboxy SNARF-1. Carboxy SNARF-1 is a long-wavelength fluorescent pH 
indicator developed by Molecular Probes. The emission spectrum of carboxy 
SNARF-1 undergoes a pH-dependent wavelength shift, thus allowing the ratio of 
the fluorescence intensities from the day at two emission wavelengths to be used 
for more accurate determinations of pH. In the experiments, carboxy SNARF-1 
was used by exciting the dye at 520 nm, while monitoring the fluorescence 
emission at two wavelengths, 580 nm and 640 nm. As depicted in Fig. 3.57-3.67, 
a cytosol acidification was observed within 20 min. The drop of pH was estimated 
at ~0.4 pH unit. Unstained samples (Fig. 3.55) and untreated samples (Fig. 3.56) 
were used as double negative controls. A dual staining with both [Ca2+] indicator 
Fura 2-AM and pH indicator SNARF-1 shows that the elevation of [Ca2+]c is an 
earlier event to cytosol acidification (data not shown). In all experiments, multiple 
negative controls were used with unstained samples setting the fluorescent 






The first observations of an intracellular acidification in mammalian cells 
undergoing apoptosis were made about one and a half decades ago (Barry & 
Eastman 1992). Since then, several reports have supported the view that this 
phenomenon might be a more generalized apoptotic feature than previously 
thought. However, if the cellular acidification is a cause or a result of apoptosis 
still remains to be further understood. 
 
As ΔpH makes major contributions to ΔΨm across the mitochondrial inner 
membrane (see 4.3.1), the mitochondrial depolarization observed earlier is mainly 
contributed by mitochondrial matrix alkalinization, which is a parallel event of 
cellular acidification. It has been demonstrated that upon apoptotic stimuli, 
mitochondrial alkalinization and cytosolic acidification are induced, then allowing 
cytochrome c release and caspase activation, and that the use of F0F1-ATPase/H+ 
pump inhibitors such as oligomycin prevents both mitochondrial and cytosolic pH 
alternations as well as caspase activation (Matsuyama et al. 2000). The authors 
therefore proposed that these changes are due to the reverse operation of F0F1-
ATPase. Our study is in favor of this proposal. In addition, NO has been shown to 
induce cytosolic acidification as well (Vincent et al. 1999), which could also 
contribute to the cytosolic acidification in the case of BHK cell AIA. 
 
The exact role of cytosolic acidification in apoptosis is still unclear. As pH 
clamping does not completely prevent cell apoptosis in most cases, it is suggested 
that cytosolic acidification has more to do with the kinetics rather than with the 
triggering phase of apoptosis (Lagadic-Gossmann et al. 2004). While the kinetics 




apoptosis, caspases, endonucleases and Bcl-2 family proteins have been identified 
to be sensitive to the apoptotic cellular acidification. Specifically, caspase 9 is 
reported to have a pH optimum of 6.3-6.8 and the kinetics of apoptosome 
assembly in favor of acidic pH 6.4 (Matsuyama & Reed 2000, Matsuyama et al. 
2000). Caspase 3 has been reported to be in favor of acidic pH as well (Roy et al. 
2001, Segal & Beem 2001). 
4.3.5 Activation of Caspases during AIA 
The activity of caspase 3 was measured to confirm its role as the executor caspase 
in adenosine-induced apoptosis in BHK cells. The activity of caspase 8 was also 
measured. Due to the unavailability of caspase 9 substrate, procaspase 9 and 
caspase 9 were westernblotted using BHK cell lysate with or without the presence 
of 500 µM adenosine. As can be seen in Fig 3.70, procaspase 9 is cleaved into its 
active form caspase 9 1 hour after the addition of adenosine. Together with the 
absence of caspase 8 activation (Fig. 3.69) and presence of caspase 3 activation 
(Fig. 3.68), it suggests an intrinsic apoptosis mechanism with caspase 9 being the 
initiator caspase and caspase 3 the executor caspase in BHK cell AIA (caspase 8 is 
not involved). 
 
Interesting findings were observed in SKW6.4 cell line, which is a type I cell line 
and bears an extrinsic apoptotic signaling pathway with caspase 8 being the 
initiator caspase (Scaffidi et al. 1998). When SKW6.4 cells were treated with 500 
µM adenosine, caspase 3 was identified to be the executor caspase (Fig. 3.71). 
However, the activation of caspase 9 (Fig. 3.73) was observed yet caspase 8 





4.4 An Integrated Signaling Model for AIA 
With the identification of the cellular events such as MMP depolarization, 
cytochrome c release, [Ca2+]c elevation, as well as caspase activation, a model for 
the intracellular AIA mechanism in BHK cells can now be proposed, which 
briefly suggests (1) adenosine (extracellular, 20-50 µM) > A1R/A3R > Gαi/Gβγ > 
IP3 > [Ca2+]c > mitochondria > cytochrome c > caspase 9 > caspase 3 pathway and 
(2) adenosine (extracellular, 500-1000 µM) > es/ei > adenosine (intracellular) > 
ATP > NO > mitochondria > cytochrome c > caspase 9 > caspase 3 (Fig. 4.3) 
 
As adenosine is the pivot of the extracellular and the intracellular mechanisms of 
AIA, to achieve an integrated view of the adenosine-induced apoptosis signaling, 





Fig. 4.1 Pathways of adenosine production, metabolism and transport, with 
indications of the sites of action of various enzyme inhibitors. Abbreviations are as 
follows: ADA, adenosine deaminase; AK, adenosine kinase; AOPCP, α,β-methylene 
ADP; EHNA, erythro-9-(2-hydroxy-3-nonyl)adenosine; es, equilibrative-sensitive 
nucleoside transporters; ei, equilibrative-insensitive nucleoside transporters; PDE, cAMP 
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Fig 4.2 Adenosine receptor signaling pathways. Activation of the A1 and A3 adenosine 
receptors (ARs) inhibits adenylyl cyclase activity through activation of pertussis toxin-
sensitive Gi proteins and results in increased activity of phospholipase C (PLC) via Gβγ 
subunits. Activation of the A2A and A2B receptors increases adenylyl cyclase activity 
through activation of Gs proteins. Activation of the A2A receptors to induce formation of 
inositol phosphates can occur under certain circumstances, possibly via the pertussis 
toxin-insensitive Gα15 and Gα16 proteins. A2B receptor-induced activation of PLC is 
through Gq proteins. All four subtypes of ARs can couple to mitogen-activated protein 
kinase (MAPK), giving them a role in cell growth, survival, death and differentiation 
(adapted from (Jacobson & Gao 2006)). Apart from cytolysis and vesicular release, ATP 
release is thought to be mediated by activation of ABC proteins (Bodin & Burnstock 
2001). CREB, cAMP response element binding protein; DAG, diacylglycerol; IP3, 
inositol 1,4,5-trisphosphate; PI3K, phosphatidylinositol 3-kinase; PIP2, 
phosphatidylinositol-4,5-bisphosphate; PK, protein kinase; PLD, phospholipase D; NF-









































Fig 4.3 An integrated model for adenosine-induced apoptosis. Extracellular 
adenosine initiates apoptosis through two pathways: (a) via its G protein-coupled 
receptors; (b) via its transporters. In the case of BHK cells, extracellular adenosine 
binds to A1 and/or A3 receptors to activate intracellular signaling pathways. As the 
result, the activity of phospholipase C (PLC) is upregulated and the level of IP3 
(inositol 1,4,5-trisphosphate) is elevated. IP3 opens the ER Ca2+ store through its 
receptor on ER surface. The increased intracellular Ca2+ releases cytochrome c 
from the inner membrane space of mitochondria. The second mechanism of 
cytochrome c release begins with the elevated intracellular adenosine as the result 
of transportation of high micromolars of adenosine via es and/or ei transporters. 
Elevated intracellular adenosine concentration shifts the equilibrium of adenosine 
metabolism towards ATP. The production of NO increases as a result of high 
intracellular ATP level. NO causes a remodeling of the inner mitochondrial 
membrane. Cytochrome c is therefore released from mitochondria. Cytosol 
cytochrome c forms apoptosome which cleaves pro-caspase 9 to its active form 
caspase 9. Caspase 9 in turn activates the executor caspase 3 from pro-caspase 3. 
Although AIA via A2A and A2B was excluded in the experimented cell lines, such 
pathways were suggested by other researchers (Peyot et al. 2000, Walker et al. 





4.4.1.1 The Origin and Fate of Adenosine 
In spite of the accepted role of adenosine as a key regulator of many physiological 
processes, there has been considerable controversy about the origin of 
extracellular adenosine and the mechanisms of its disappearance. Adenosine 
metabolism is highly complex and rapid in mammalian tissues. Extracellular 
adenosine may appear by direct release from cells or by degradation of released 
adenine nucleotides, mainly ATP.  
 
As a whole the appearance and disappearance of extracellular adenosine is a 
dynamic process which cannot be isolated from intracellular purine metabolism. 
Adenosine once enters the cell by mediated transport, can follow two distinct 
pathways as depicted in Fig. 4.1. It can be phosphorylated by adenosine kinase or 
it can be deaminated by intracellular adenosine deaminase. 
 
In addition, extracellular inosine produced by ecto-adenosine deaminase can be 
transported by Na+-independent and Na+-dependent nucleoside carriers, which 
also translocate adenosine. Inosine can follow the degradative pathway to uric 
acid or be converted into IMP via hypoxanthine. It has even been demonstrated 
that inosine functions in the non-glycolytic pig erythrocytes as an ‘in vivo’ energy 
substrate. 
 
On the other hand, once within the cell, adenosine may be used for nucleotide 
synthesis via adenosine kinase. Early radioactive labeling studies indicated that 




is the metabolic product of adenosine transported by the equilibrative transporters 
(Kolassa et al. 1977, Agarwal & Parks 1975). 
 
Adenosine may be formed intracellularly from degradation of AMP, and then exit 
via bi-directional nucleoside transporters, or extracellularly by the metabolism of 
released nucleotides (Fig. 4.1). At least four different 5’-nucleotidase activities 
have been described in mammalian tissues with different biochemical and 
molecular properties (Zimmermann 1992). However, more than 90% of the total 
production of adenosine occurs intracellularly under well-oxygenated conditions. 
Quantitatively, the most important source is 5’-AMP which is hydrolyzed by 
cytosolic 5’-nucleotidase. Hydrolysis of S-adenosylhomocysteine and 
extracellular dephosphorylation of 5’-AMP further contribute to total production. 
Rapid enzymatic conversion of adenosine is provided by adenosine kinase and 
adenosine deaminase, keeping the cytosolic adenosine concentration in the 
nanomolar range. Due to the high intracellular rates of adenosine 
rephosphorylation and deamination the cytosolic concentration is normally below 
the extracellular adenosine concentration, making the cytosol to a sink rather than 
a source of adenosine.  
 
Most of the extracellular adenosine (~90%) is produced intracellularly by 
hydrolization from 5’-AMP and transported across the plasma membrane to the 
extracellular space. It re-enters the cell via the same transportation system. 
Therefore, one can reasonably conclude that the extracellular adenosine of 
intracellular origin will not exert its physiological functions as elevated 




intracellular adenosine to exert its function by exiting and re-entering the cell. 
Besides, the concentration of re-entered adenosine will not be as high as that of 
pre-transported cellular adenosine. Therefore, it is proposed that the extracellular 
adenosine of intracellular origin exerts its physiological functions mainly through 
its cell surface receptors, and that the transportation of extra- and intracellular 
adenosine and the intracellular adenosine metabolism are in dynamic equilibrium 
and do not alter the physiology of the cell. 
 
On the other hand, when large amount of adenosine is formed extracellularly, by 
hydrolization from ATP and 5’-AMP under pathological conditions, the 
extracellular adenosine can enter the cell via transporters and cause a substantial 
elevation of intracellular adenosine concentration. The elevated intracellular 
adenosine may alter the physiology of the cell by shifting the equilibrium of its 
metabolic pathways. In the case of AIA in BHK cells, it is hypothesized that 
elevated ATP level and accumulated NO concentration are the result of a rapidly 
increased cytosolic adenosine. 
 
Cytosolic adenosine kinase effectively phosphorylates cytosolic adenosine to 5′-
AMP. As the Km-value of adenosine kinase is approximately 1 µM (Schutz et al. 
1981) and the free cytosolic adenosine concentration was estimated in a range of 
0.01–0.1 µM under physiological conditions (Deussen et al. 1988, Deussen et al. 
1999, Kroll et al. 1992), the enzyme operates usually below its Km value. In 
hypoxia or ischemia a cytosolic adenosine concentration would arise and thereby 





While adenosine kinase activity is confined to the cytosolic region, differences 
may exist with respect to localization of adenosine deaminase activity. In guinea 
pig heart adenosine deaminase activity has been demonstrated exclusively in the 
cytosolic fraction (Schutz et al. 1981), whereas in rat heart and pig lung the 
enzyme activity is in part extracellular (Hellewell & Pearson 1983, Meghji et al. 
1988). For rabbit heart an association of membrane adenosine deaminase with an 
adenosine deaminase binding protein has been suggested (Schrader & West 1990, 
Schrader et al. 1979). Adenosine deaminase activity is also found on the surface 
of blood cells (Aran et al. 1991) and in blood plasma (Morisaki et al. 1985, 
Niedzwicki & Abernethy 1991). The two isoforms of plasma adenosine 
deaminase termed ADA1 and ADA2 exhibit distinct susceptibility to different 
enzyme inhibitors (Niedzwicki & Abernethy 1991).  
4.4.1.2 Signaling Pathways of Adenosine 
The work of adenosine signaling research over the past 3 decades is best 
summarized in the two-volume Handbook of Experimental Pharmacology 
(Abbracchio & Williams 2001a, b). Given the fact that the Gα proteins adenosine 
receptors couple can be Gαs, Gαi or Gαq and that adenosine receptors are universally 
expressed in almost every tissue type, adenosine receptors mediate a broad range 
of signaling responses to adenosine. All these signaling pathways fit into the 
general GPCR signaling pattern as illustrated in Fig. 4.2. Specifically, the A1 
receptor couples to different G proteins within the Gi/o family. The most widely 
recognized signaling pathway of A1 receptors is inhibition of adenylyl cyclase 
causing a decrease in the second messenger cAMP. This in turn modulates the 




proteins targets. Another signaling mechanism of A1 receptors is activation of 
Phospholipase C (PLC) leading to membrane phosphoinositide metabolism and 
increased production of inositol 1,4,5-triphosphate (IP3) and Ca2+ mobilization. 
IP3 stimulates the release of Ca2+ from intracellular stores via interactions with 
specific receptors located on the sarcoplasmic reticulum (SR) or endoplasmic 
reticulum (ER). Elevation of cytosolic Ca2+ by IP3 can stimulate a variety of 
signaling pathways, including protein kinase C (PKC), Phospholipase A2 (PLA2), 
Ca2+-dependent K+ channels as well as nitric oxide synthase (NOS). 
 
The most commonly recognized signal transduction mechanism for A2A receptors 
is activation of adenylyl cyclase through the coupling with the G protein Gs. In 
addition, in some neuronal tissues, A2A receptors are suggested to mediate through 
PKA and PKC. A2B receptor coupling to different signaling pathways has been 
identified, inducing activation of adenylyl cyclase through Gs, Gq/11-mediated 
coupling to PLC and IP3 increase through PI3K. 
 
The A3 receptor is mainly linked to Gi and to a lesser extent, to Gq/11 proteins. 
Intracellular signal transduction mechanisms include PLC stimulation, IP3 and 





4.4.1.3 An Integrated Model for AIA in BHK Cells 
With the identification of the extracellular pathways through which extracellular 
adenosine initiates the intracellular apoptosis at different concentrations as well as 
the intracellular events during the adenosine-induced apoptosis, an integrated 
model for the adenosine-induced apoptosis is proposed to explain the biphasic 
apoptotic effect of adenosine observed in BHK cells, as well as the dose-
dependent non-biphasic apoptotic effect of adenosine observed in HeLa, SKW6.4 
and H9 cells and the non-apoptotic effect of adenosine in neuronal SY5Y and 
MN9D cells. 
 
Firstly, there are two pathways which are responsible for low micromolar (20-50 
μM) and high micromolar (500-1000 μM) concentrations of adenosine. Low 
micromolar adenosine activates the cell surface G protein-coupled adenosine 
receptor A1/A3 to activate the intracellular PLC activity. At a result, the 
intracellular Ca2+ concentration is elevated. Elevated Ca2+ results the dysfunction 
of mitochondria including the mitochondrial depolarization and cytochrome c 
release.  
 
The second pathway mediates the apoptotic effect of high micromolar 
concentrations of adenosine (500-1000 μM). Adenosine at this concentration 
range enters the cell via es transporter, causing a rapid intracellular adenosine rise. 
This elevated intracellular adenosine level shifts the equilibrium of adenosine 
metabolism, as a result, ATP level is elevated and NO is accumulated. NO acts on 
the mitochondria as the oxidative stress, detaching cytochrome c from 




outer membrane, dimmerizes and forms a pore on the MOM, allowing the exit of 
cytochrome c from mitochondria to cytosol. 
 
Both pathways join at the point of cytosolic cytochrome c, which forms the 
apoptosome complex with Apaf-1 and ATP/dATP, cleaving and activating 
caspase 9 and subsequently caspase 3, which as the executor caspase, results in 
apoptosis. Noteworthily, as the result of elevated intracellular adenosine, the 
increased cytosol ATP level might contribute to the dynamics of the apoptosome 
complex formation as well. 
 
Secondly, as these two pathways are responsible for low and high micromolar 
concentrations of adenosine respectively, they might not be exclusive. With the 
dominance of the major pathway, the apoptosis contribution by the other might 
not be significant. 
 
Thirdly, these two pathways are cell type-dependent. As one or both of the 
pathways might not contribute to apoptosis in certain cell lines, this explains the 
different apoptotic pattern of AIA observed by different researchers. In addition, 
due to the difference of adenosine receptors and transporters across tissue types, 
the working concentration of adenosine of these two pathways may vary in cells 
of different tissue origin. This explains the observation that the apoptotic 





4.5 Implications of the Findings of the Study 
4.5.1 A Better Understanding of Adenosine Physiology 
This research is focused on understanding the apoptosis inducing effect of 
adenosine. Various apoptotic effects of adenosine were observed in different cell 
lines. Efforts were made to reconcile/unify the observations which may look 
exclusive to each other. An extracellular model is proposed as a result based on 
experimental data as well as current knowledge about adenosine physiology. In 
agreement with the current signal transduction mechanisms of adenosine, this 
model suggests the involvement of A1 and A3 receptors in the adenosine-induced 
apoptosis. In addition, this model emphasizes the role of adenosine transportation 
in the signaling when adenosine is of an extracellular origin. 
 
4.5.2 GPCR-mediated Apoptosis 
This research provided first-hand experimental evidence for the GPCR-mediated 
apoptosis in BHK cells and HeLa cells as discussed in 4.2.1. The existence of 
GPCR-mediated apoptosis will connect the two well-studied signal transduction 
fields and lead to new discoveries that might be overlooked previously. 
 
4.5.3 Mitochondria-mediated Apoptosis in Type I Cells 
Type I cells were long believed to undertake a death receptor-mediated apoptosis 
mechanism with caspase 8 being the initiator caspase and non-involvement of 
mitochondria. Our experimental data suggest an exception, which is better 
explained by the extrinsic and intrinsic proposal that these apoptotic pathways are 





4.5.4 Mechanism of Cytochrome c Release 
Efforts were made in the research to better understand the mechanism of 
cytochrome c release. Due to the complexity of the mitochondrial structure, the 
mechanism of cytochrome c during apoptosis still remains elusive in spite that 
most of the cellular events during apoptosis are well understood. Our research is 
in favor of an early remodeling as the premise of a “rapid and complete” release 
of cytochrome c.  
 
4.5.5 Pharmaceutical Implications 
While micromolar level of adenosine is achievable physiologically, the medium 
concentrations of adenosine used in the study project to the pathological 
conditions. The high concentrations of adenosine experimented in the study (0.5 
& 1 mM) may only have pharmacological significance. Current adenosine 
derivatives that have pharmaceutical applications are primarily used as non-
metabolic adenosine analogues to interfere with DNA synthesis in chemotherapy. 
A better understanding of adenosine-induced apoptosis may lead to discoveries of 
novel adenosine analogues that might control tumor growth and/or kill tumor cells 
by apoptosis. This therapy strategy is of advantage compared to chemotherapy as 
it is less destructive and causes less side effects. 
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5 Chapter 5 Conclusion and Future Directions 
5.1  Conclusion 
 
The apoptotic effect of adenosine is shown to be cell type dependent, as proved in 
BHK, HeLa, SKW6.4, H9, SY5Y and MN9D cell lines. In BHK cells, adenosine 
exhibits a biphasic apoptotic effect dose-dependently; while in HeLa, SKW6.4 
and H9 cells, adenosine exhibits a non-biphasic apoptotic effect in a dose-
dependent manner. Neuronal cell lines SY5Y and MN9D are shown to be resistant 
to adenosine’s apoptotic effect. 
 
Multiple apoptosis pathways exist whereby adenosine induces apoptosis which are 
responsible for the apoptosis induced by adenosine at different concentration 
levels. Unlike conventional apoptosis pathways, transportation of apoptotic factor 
(adenosine) is responsible for the apoptosis mechanism in adenosine-induced cell 
death in BHK cells. 
 
A1 and A3 adenosine receptors conduct adenosine-induced apoptosis in one 
apoptosis pathway where low concentrations of adenosine induces apoptosis; 
nucleoside transporters mediate another pathway which is responsible for 
apoptosis induced by high concentrations of adenosine in BHK cells. Whereas in 
the case of non-biphasic apoptosis, adenosine receptors do not have measurable 
contribution to apoptosis, only nucleoside transporters mediate apoptosis caused 
by high concentrations of adenosine. In cases like SY5Y and MN9D, none of the 
two pathways contribute to apoptosis. This receptor-transporter co-mediation 
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model best explains the biphasic, non-biphasic apoptotic effect as well as non-
apoptotic effect of adenosine in different cell types. 
 
There are two possible pathways account for the intracellular mechanism of 
adenosine-induced apoptosis in BHK cells. In the first pathway, adenosine enters 
cells via nucleoside transporters. Elevated intracellular adenosine results in an 
increase ATP level; subsequently NO is accumulated as a result. Bax translocates 
onto the mitochondrial outer membrane and forms a pore; NO detaches 
cytochrome c from mitochondrial inner membrane and causes the release of 
cytochrome c into cytosol through the Bax pore.  
 
In the second pathway, adenosine acts on A1 and A3 receptors. As a result, 
phospholipase C (PLC) activity increases, which raises the inositol 1,4,5-
trisphosphate (IP3) concentration. IP3 acts on its receptors which locate on ER 
and results a rapid Ca2+ release from ER into cytosol. Elevated cytosol Ca2+ level 
causes the opening of the mitochondrial permeability transition pore (MPTP) and 
results in mitochondrial matrix swelling, followed by outer membrane rupture and 
cytochrome c release. 
 
Cytosol cytochrome c forms the apoptotic complex (apoptosome) with Apaf-1 and 
ATP/dATP, cleaves and actives the initiator caspase 9, which in turn cleaves and 
actives the executor caspase 3 and subsequently apoptosis. 
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The presence of caspase 9 and caspase-3 activity and the absence of caspase-8 
activity suggest that BHK is a Type II cell line and the apoptosis-induced by 
adenosine in BHK cells fits into the intrinsic scenario. 
 
5.2 Future Directions 
5.2.1 Studies of Adenosine-Induced Apoptosis 
The whole picture of adenosine-induced apoptosis still requires clarification to 
provide a finalized mechanism of AIA. Further studies in this direction could 
focus on the following: 
 
 The study of involvement of adenosine receptors and nucleotide 
transporters using gene knock-out method. Data obtained by this method 
can be used for comparison with those from inhibitor studies. Also, by 
using P1 receptor -/- models, the involvement of GPCRs in apoptosis can 
be finally confirmed. 
 Further experiments can be carried out to confirm the mechanism by 
which adenosine causes the rapid intracellular Ca2+ rise and the cytosol 
acidification. Phospholipase C activity and intracellular inositol 1,4,5-
trisphosphate (IP3) are to be measured to support the hypothesis. 
 The change of intracellular ATP level and the production of NO upon the 
treatment of adenosine are to be measured to confirm the role of oxidative 
stress in the adenosine-induced apoptosis in BHK cells. 
 The cytochrome c release mechanism is to be investigated. However, that 
would be an independent project. The possibility of cristae remodeling 
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needs to be studied and the two cytochrome c release models to be further 
examined. Electron microscope can be employed for the observation of 
cristae structural changes during apoptosis. 
 The exact mechanism for cytochrome c to detach from cardiolipin is worth 
further study as well. To achieve this, cytochrome c:cardiolipin interaction 
study can be carried out on liposome. 
 The mechanism that results the acute depolarization prior to mitochondrial 
hyperpolarization needs further investigation. Although the depolarization 
might not play a key role in the AIA pathways, it might lead to other 
interesting findings. 
 
5.2.2 Adenosine and Adenosine Analogues for Tumor-Control and/or 
Tumor Suppression 
Investigations on the pharmaceutical values of adenosine and adenosine 
derivatives can be carried out using genetically modified mouse cancer models 
from which more reliable data can be obtained. In addition, with ideal animal 
models available, a wide range of adenosine derivatives could be test for their 
pharmaceutical potentials in tumor-control and in tumor suppression. A 
preliminary study conducted with mice showed that adenosine may have some 
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10 mM Tris-HCl (pH 8.0)  
5 mM EDTA  
100 mM NaCl  
0.5% SDS 
10 μg/ml proteinase K 
 
TBE buffer (Tris-borate EDTA buffer), 5x (1 liter): 
 
54g Tris base 
27.5 g boric acid 
20 ml 0.5 M EDTA (pH 8.0) 
 
20 x propidium iodide stock solution (1mg/ml) 
 
10 mg propidium iodide 
10 ml H2O 
Filter through 0.22 μm filter 
Store at 4 oC in dark 
 
Propidium iodide (PI) staining solution (50 μg/ml) 
 
0.5 ml 20x propidium iodide stock solution 
1000 units DNase-free RNase A 
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10 ml sample buffer 




1 g glucose 
1 ml Triton X-100 
1 liter PBS without Ca++ or Mg++ 
Filter through 0.22 μm filter 




Preparation of SDS-PAGE 
Resolving gel: 
Component volumes (ml) per 2 mini gels (10 
ml) Solution components 
10% 12% 15% 
H2O 4.0 3.3 2.3 
30% acrylamide mix 3.3 4.0 5.0 
1.5 M Tris-HCl (pH 8.8) 2.5 2.5 2.5 
10% SDS 0.1 0.1 0.1 
10% ammonium persulfate 
(APS) 
0.1 0.1 0.1 
TEMED 0.008 0.008 0.008 
 
Stacking gel: 
Component volumes (ml) per 2 mini gels (10 
ml) Solution components 
 
H2O 2.7 
30% acrylamide mix 0.67 
0.5 M Tris-HCl (pH 6.8) 0.50 
10% SDS 0.04 







Sucrose buffer I: 
 
0.25 M sucrose 
5 mM HEPES 
0.5 mM EGTA 
Adjust pH to 7.5 
 
Sucrose buffer II: 
 
0.25 M sucrose 
5 mM HEPES 
Adjust pH to 7.5 
 
Boiling lysis buffer: 
 
1 % SDS 
1.0 mM Na2V2O5 




1% Triton X-100 
150 mM NaCl 
10 mM Tris pH 7.4 
1 mM EDTA 
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1 mM EGTA pH 8.0 
0.2 mM Na2V2O5 
0.5 % IGEPAL CA-630 
Protease inhibitor cocktail (Boehringer Mannheim) 
 
1.5 M Tris (pH 8.8) 
 
36.3 g Trizma-base 
8 ml 10 % SDS 
180 ml Milli-Q water 
Adjust pH to 8.8 with HCl 
Add Milli-Q water to bring volume to 200 ml  
 
0.5 M Tris (pH 6.8) 
 
0.06 g Trizma-base 
8 ml 10% SDS 
90 ml Milli-Q water 
Adjust pH to 6.8 with HCl 
Add Milli-Q water to bring volume to 100 ml 
 
10× Running buffer: 
 
30.3 g Trizma-base 
144 g glycine 
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10 g SDS 
Milli-Q water to 1 liter 
 
5× SDS-PAGE loading buffer: 
 
940 μl 10 % SDS 
470 μl 1 M Tris-HCl (pH 7.5) 
95 μl 100 mM EDTA 
2.45 ml glycerol 
545 μl distilled water 
205 μl 2-mercaptoethanol 
a dash of bromophenol blue 
 
Protein transfer buffer (10 ×): 
 
30.3g Trizma-base 
144.1 g glycine 
Dissolve in 900 ml Milli-Q water, adjust pH to 6.8 with HCl.  
Add Milli-Q water to bring to final volume of 1000 ml 
 
Protein transfer buffer (1 ×): 
 
200 ml MeOH 
500 ml Milli-Q water 
100 ml 10 × protein transfer buffer 
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Add Milli-Q water to bring to final volume of 1000 ml 
 
5 × Tris buffered saline-Tween (TBS-T): 
 
12.1 g Trizma-base 
40.0 g NaCl 
900 ml Milli-Q water 
Adjust pH to 7.6 with HCl 
Bring to final volume of 1000 ml with Milli-Q water 














7.5 M DPCPX + 5 nM MRS-1220
7.5 M DPCPX + 5 nM MRS-1220 + 5 M DIP












Fig. S-1 BHK cells treated with combinations of receptor antagonists and 
transporter inhibitor. BHK cells cultured at the density of 1×104 cells/cm2 in α-MEM 
supplemented with 1% FBSi in the presence of 5 μM EHNA were treated with 0, 20, 50, 
500 or 1000 μM adenosine for 24 hours. A mixer of 7.5 μM DPCPX and 5 nM MRS-
1220 was added to group 2 to achieve a combined antagonism on A1 & A3 receptors. 7.5 
μM DPCPX, 5 nM MRS-1220 and 5 μM dipyridamole were added to the third group for 
the blockage of signaling through A1R, A3R and equilibrium transporters. Cells were then 
harvested, fixed with ethanol and stained with 0.1 mg/ml PI. Apoptotic cells (late stage) 
were counted by flow cytometer (10,000 events per sample). Cell viability was calculated 









Fig. S-2. 1 mM Adenosine does not cause cyt c release from mitochondria directly.  
Lane 1, 10 ng cyt c; lane 2, Ado solution after 30 min co-incubation with enriched 
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Adenosine, as a ubiquitous metabolite, mediates many
physiological functions via activation of plasma membrane
receptors. Mechanisms of most of its physiological roles
have been studied extensively, but research on adenosine-
induced apoptosis (AIA) has only started recently. In this
study we demonstrate that adenosine dose-dependently
triggered apoptosis of cultured baby hamster kidney
(BHK) cells. Adenosine-induced apoptotic cell death was
characterized by DNA laddering, changes in nuclear
chromatin morphology and phosphatidylserine staining.
Apoptosis was also quantified by flow cytometry. Results





as well as equilibrative nucleoside transporters in
apoptosis induced by adenosine. These results indicate a
receptor-transporter co-signaling mechanism in AIA in





implies a possible apoptotic pathway mediated by G
protein-coupled receptors.
Keywords: Adenosine, Adenosine receptor, Apoptosis, BHK
cells, Nucleoside transporter
Introduction
Adenosine (Ado) is a primordial signaling molecule that
modulates physiological responses in all mammalian tissues,
many of which have been well studied and documented
(Abbracchio and Williams 2001a, Abbracchio and Williams
2001b). However, less attention has been paid to the study of
adenosine-induced apoptosis (AIA) (Chow et al., 1997).
While several researchers reported that adenosine or
adenosine analogs have apoptotic effect on cells (Szondy
1994; Tanaka et al., 1994; Wakade et al., 1995; Szondy 1995;
Abbracchio et al., 1995; Shneyvays et al., 1997; Ceruti et al.,
1997; Kohno et al., 1998; Barbieri et al., 1998; Rounds et al.,
1998; Peyot et al., 2000; Schrier et al., 2001; Di Iorio et al.,
2002; Koshiba et al., 2002; Schrier et al., 2002), anti-
apoptotic effects of adenosine have also been reported
(Walker et al.,1997; Yao et al., 1997). Both adenosine
receptor-mediated pathways (Szondy 1994; Abbracchio et al.,
1995; Shneyvays et al., 1997; Ceruti et al., 1997; Walker et
al.,1997; Yao et al., 1997; Kohno et al., 1998; Barbieri et al.,
1998; Peyot et al., 2000; Di Iorio et al., 2002) and transporter
mediated pathways (Tanaka et al., 1994; Wakade et al., 1995;
Szondy 1995; Rounds et al., 1998; Barbieri et al., 1998;
Schrier et al., 2001; Di Iorio et al., 2002; Koshiba et al., 2002;
Schrier et al., 2002) were suggested. The results appear to
indicate that the mechanism(s) of adenosine-induced
apoptosis may be more complicated than expected, involving
multiple pathways through which adenosine induces apoptosis
under various conditions and in different type of cells.









been cloned and characterized by pharmacological studies
(Palmer et al., 1995). All of the four subtype adenosine













receptors mainly couple with G
αi
 and interact with
phospholipase C (Ralevic et al., 1998) by which most of
adenosine’s physiological functions are mediated (Abbracchio
and Williams 2001a, Abbracchio and Williams 2001b). In
addition to being mediated by receptors, extracellular
adenosine is also a substrate for the membrane nucleoside
transporters, through which adenosine can enter cells and be
sequentially phosphorylated intracellularly to AMP, ADP and
Abbreviations: Ado, adenosine; DIP, dipyridamole; DMPX, 3,7-
dimethyl-1-propargylxanthine; DPCPX, 1,3-dipropyl-8-cyclopentylx-
anthine; EHNA, erytro-9-(2-hydroxy-3-nonyl) adenine; MRS-1220,
9-chloro-2-(2-furyl)-5-phenylacetylamino-[1,2,4]-triazolo[1,5-
c]quinazoline; NBMPR/NBTI: nitrobenzylmercaptopurine ribonucle-
oside or S-(4-nitrobenzyl)-6-thioinosine.
*To whom correspondence should be addressed.
Tel: 65-6874-3245; Fax: 65-6779-1453
Email: bchtanch@nus.edu.sg
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ATP. This intracellular pathway is also responsible for some
of adenosine’s physiological functions (Cass et al., 1998).
Membrane nucleoside transporters are categorized into two
groups on the basis of transport mechanisms (Griffith et al.,
1996). The equilibrative, or Na+-independent nucleoside
transporters are “facilitators” and are driven solely by the
concentration of nucleoside permeates. Na+-independent
nucleoside transporters are further subdivided on the basis of
sensitivity to NBMPR: es (equilibrative & sensitive) type and
ei (equilibrative & insensitive) (Griffith et al., 1996). Concentrative
nucleoside transporters are classified into 6 subtypes
according to permeate selectivity and sensitivity to NBMPR:
cif (N1), cit (N2), cib (N3), cit (N4), cs (N5) and csg (N6)
(Cass et al., 1998).
In this study, we found that adenosine played different roles
in cell death at different adenosine concentrations. In BHK
cells, very low concentrations (2-5 µM) of adenosine enhanced
cell proliferation slightly while higher concentrations (10-
1000 µM) caused apoptosis, with medium concentrations (50-
200 µM) showing decreased apoptotic effects. Using selective





 Ado receptors mediated apoptosis induced by low
concentrations (20-50 µM) of adenosine; whereas both ei type




 Ado receptors mediated
adenosine-induced apoptosis at high adenosine concentrations
(500-1000 µM). This study is the first to demonstrate that
adenosine’s physiological function can be co-mediated by
both adenosine receptors and nucleoside transporters. In
addition, this study provides evidence for the possible
involvement of GPCRs in apoptosis, for which there is yet no
firm conclusion.
Materials and Methods
Culture of BHK cells BHK cells were maintained in α-MEM
(Sigma M0894) supplemented with 10% FBS, 20 mM NaHCO
3
,
5 mM HEPES and 100 U/ml penicillin at 37oC in a humid
atmosphere of 5% CO
2
/air. In this study, 24 h prior to any
experiment, BHK cells were seeded on coverslips or in 75 cm2
culture flasks at the density of 1 × 104 cells/cm2. When adenosine
was present in medium, 1% heat inhibited FBS
i
 (56oC, 2 h) was
used instead of 10% FBS, 5 µM EHNA was added to medium.
Double-staining of BHK cells with annexin V-FITC and
propidium iodide (PI) Externalization of phosphatidylserine and
condensed/fragmented chromatin were detected by an annexin V-
FITC-Propidium Iodide double staining using an adaptation of the
protocol outlined in the annexin V-FITC apoptosis detection kit
(Pharmingen, BD Biosciences). Briefly, BHK cells seeded on
coverslips in 6-well plates were incubated with 1 mM adenosine for
2 h or 24 h. At the end of incubation period, medium was replaced
by fresh α-MEM, annexin V-FITC and PI were added for an
additional 30-minute incubation. Coverslips were then placed
upside down on a glass slide and immediately observed by
fluorescence microscopy (Carl Zeiss LSM 510).
Analysis of internucleosomal DNA fragmentation: DNA
laddering BHK cells were seeded in 6 culture flasks. 24 h after
medium in each flask was replaced with α-MEM containing 0, 10,
20, 500, 1000 µM adenosine or 10 µM camptothecin, cells were
incubated for another 24 h. DNA fragmentation was determined
using an adaptation of a described technique (Liu et al., 1996).
Briefly, after shaking the flasks, weakly adherent and non-adherent
cells were collected by centrifugation of the cell culture medium
(200 g, 5 min). Adherent cells were trypsinised, harvested and kept
seperately. Cells were incubated at 37oC for 3 h in a lysis buffer
consisting of, in mM, Tris-HCl (pH 8.0) 10, EDTA 5, and NaCl
100, as well as 0.5% SDS and 10 µg/ml proteinase K (Boehringer)
under agitation. This incubation was followed by dropwise addition
of 5 M NaCl to a final concentration of 1 M and incubation at 4oC
for 1 h. After centrifugation at 15,000 g for 30 min at 4oC,
supernatants were recovered. DNA was extracted with an equal
volume of 25 : 24 : 1 phenol/chloroform/isoamyl alcohol (vol : vol :
vol) and precipitated in the presence of an equal volume of
isopropanol at −20oC overnight. After centrifugation at 15,000 g for
10 min at 4oC, the pellets were washed in 75% ethanol,
resuspended in water and digested with 1 mg/ml DNase-free RNase
for 30 min at 37oC. DNA electrophoresis was carried out in 2%
agarose gel containing 0.5 µg/ml ethidium bromide. DNA
fragments were visualized under UV light.
Assessment of apoptosis by flow cytometry using DNA fragment
measurements BHK cells seeded in 6-well plates were treated
with receptor antagonists or transporter inhibitors in the absence or
presence of various concentrations of adenosine for 24 h. Cells in
supernant were collected by centrifugation (200 g, 5 min) and
combined with adherent cells which were trypsinised and
harvested. Cells were then washed with 5 ml PBS (pH 7.2), fixed
by dropwise addition of ice cold 70% ethanol for no less than 2 h
and passed through 0.44 mm filter to remove aggregates. Prior to
flow cytometry, cells were centrifuged at 200 g for 5 min to remove
ethanol and stained with 1ml PI/Triton X-100 staining solution with
RNase A for 15 min at 37oC. Apoptotic cells were quantified using
flow cytometry (Becton Dickinson FACSVantage SE). Data were
obtained from triplicates. 10,000 events were counted for each
sample.
Results and Discussion
Induction of BHK cell apoptosis by adenosine Two hours
after the induction of apoptosis with adenosine, BHK cells were
double-stained with annexin V-FITC and PI. Phosphatidylserine
was detected by annexin V-FITC (Fig. 1A) but no condensed
or fragmented chromatin was detected by PI, indicating an
early stage of apoptosis. Phosphatidylserine normally locates
on the intracellular side of cell membrane in healthy cells.
During the early stages of apoptosis, phosphatidylserine is
known to flip over to the extracellular side of cell membranes.
Thus exposed, it can be detected and visualized by annexin V-
FITC (Martin et al., 1995). The exposure of phosphatidylserine
is regarded as a sign of early stage apoptosis (Homburg et al.,
1995; Rimon et al., 1997). Induction of apoptosis by adenosine
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was confirmed by the presence of intranucleosomal DNA
fragmentation of adenosine-treated BHK cells into multimers
of 180 bp nucleosomal units (Fig. 1B). In adherent adenosine-
treated BHK cells and control cells, no DNA fragmentation
was detected (lane 5, 6). A 24-hour exposure of BHK cells to
10, 20, 500 or 1000 mM adenosine resulted in DNA
fragmentation typical of apoptosis (lane 1, 2, 3 and 4
respectively). Together with the morphological changes
observed in BHK cells after a 24-hour exposure to 1 mM
adenosine (Fig. 1C), nucleus fragmentation with condensed
chromatin detected by PI (Fig. 1C) suggests a late stage of
apoptosis.
Dose-dependent BHK cell apoptosis induced by adenosine
AIA in BHK cells, measured by detection of DNA
fragmentation using flow cytometry, was shown to be strongly
dependent on the extracellular adenosine concentration (Fig.
2). It should be noted that in the control cells without added
adenosine, apoptosis remained at a low level (~5%).
Treatment with low concentrations of adenosine (10-20 µM)
decreased cell viability significantly to 60-70%. Cell viability
recovered with increasing concentrations of adenosine (50-
200 µM) while higher concentrations (500-1000 µM) resulted
in reduced viability (Fig. 2). These results show a biphasic
apoptotic effect of adenosine in BHK cells.
Involvement of adenosine receptors in adenosine-induced
apoptosis in BHK cells AIA in BHK cells might occur in
one of the following ways: (a) binding to one or more of its
receptors, (b) intracellularly after adenosine uptake by
nucleoside transporters or (c) a combination of both. To
determine the possible adenosine receptor subtypes (if any)
involved in AIA in BHK cells, all the four subtypes of
adenosine receptors were investigated using selective receptor
antagonists. The subtype specific adenosine receptor
antagonists we used in this study were: DPCPX, an A
1
receptor antagonist; DMPX, a non-specific A
2
 receptor
antagonist and MRS 1220, an A
3
 receptor antagonist. As
shown in Fig. 3A, DPCPX (7.5 and 30 µM) successfully
blocked two thirds of the apoptosis induced by 20, 500 and
Fig. 1. Induction of BHK cell apoptosis by adenosine. (A) Photomicrograph showing the exposure of phosphatidylserine in adenosine-
treated BHK cells. BHK cells were incubated in α-MEM with 1 mM adenosine for 2 hours, double-stained with annexin V-FITC and
PI, examined by laser scanning microscope LSM 510 (Call Zeiss). Membrane phosphatidylserine was visualized by FITC, however no
condensed or fragmented chromatin was detected, indicating an early stage of apoptosis. (B) Electrophoretic analysis of internucleosomal
DNA fragmentation in adenosine-induced BHK cells. DNA was isolated from non-treated, adenosine-treated or camptothecin-treated
BHK cells. M, 100-bp DNA ladder; lane 1-4, detached adenosine-treated BHK cells (lane1, 10 µM Ado; lane 2, 20 µM Ado; lane 3,
500 µM Ado; lane 4, 1000 µM Ado); lane 5, adherent adenosine-treated BHK cells (1000 µM); lane 6, BHK cells without treatment,
lane 7, camptothecin-treated (10 µM) BHK cells. (C) Photomicrograph showing the nuclear morphology of adenosine-treated BHK cells.
BHK cells were incubated 1 mM adenosine for 24 h, double-stained with annexin V-FITC and PI. Both morphology and condensed or
fragmented chromatin suggest a late stage of apoptosis.
Fig. 2. Biphasic apoptotic effect of adenosine in BHK cells.
BHK cells were treated with adenosine for 24 h. Apoptotic cells
(late stage) were counted by flow cytometer. Cell viability was
calculated as the percentage of non-apoptotic cells. Data were
obtained from triplicates, 10,000 events were counted for each
sample.
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1000 µM of adenosine. In contrast, the blocking of A
2
receptors by DMPX had no significant effect on AIA (data
not shown). Fig. 3B shows that the A
3 
receptor specific
antagonist, MRS-1220 (5 and 20 nM) could block one half to
two thirds of the apoptosis induced by both low and high
concentrations of adenosine. These results suggest that AIA in










 adenosine receptors appeared to be
involved in the regulator of cell proliferation and survival in









) in BHK cells was confirmed by
immunochemistry (data not shown).
Involvement of nucleoside transporters in adenosine-
induced apoptosis in BHK cells In addition to the receptor-
mediated mechanism, nucleoside transporter-mediated pathways
were also investigated in this study. Two transporter inhibitors
were employed to identify the involvement of es and/or ei
type equilibrative nucleoside transporters. Dipyridamole is an
inhibitor which can block both es and ei type adenosine
transport, whereas NBTI is only effective against es type. Fig.
4A shows that dipyridamole could effectively protect BHK
cells from apoptosis induced by high concentrations (500,
1000 µM) of adenosine but not by low concentrations (20, 50
µM). This suggests that in addition to the receptor-mediated
pathway, nucleoside transporter-mediated pathway might also
Fig. 3. (A) Effect of DPCPX on apoptosis induced by adenosine
in BHK cells. BHK cells were treated with 20, 50, 500 and
1000 µM adenosine for 24 h, in the absence or presence of 1,
7.5 or 30 µM DPCPX. Apoptotic cells (late stage) were counted
by flow cytometer. Cell viability was calculated as the
percentage of non-apoptotic cells. Data were obtained from
triplicates, 10,000 events were counted for each sample. (B)
Effect of MRS-1220 on apoptosis induced by adenosine in BHK
cells. BHK cells were treated with 20, 50, 500 and 1000 µM
adenosine for 24 h, in the absence or presence of 1, 5 or 20 nM
MRS-1220. Apoptotic cells (late stage) were counted by flow
cytometer. Cell viability was calculated as the percentage of non-
apoptotic cells. Data were obtained from triplicates, 10,000
events were counted for each sample.
Fig. 4. (A) Effect of DIP on apoptosis induced by adenosine in
BHK cells. BHK cells were treated with 20, 50, 500 and 1000
µM adenosine for 24 h, in the absence or presence of 1, 5 or 20
µM DIP. Apoptotic cells (late stage) were counted by flow
cytometer. Cell viability was calculated as the percentage of non-
apoptotic cells. Data were obtained from triplicates, 10,000
events were counted for each sample. (B) Effect of NBTI on
apoptosis induced by adenosine in BHK cells. BHK cells were
treated with 20, 50, 500 and 1000 µM adenosine for 24 h, in the
absence or presence of 1, or 20 µM NTBI. Apoptotic cells (late
stage) were counted by flow cytometer. Cell viability was
calculated as the percentage of non-apoptotic cells. Data were
obtained from triplicates, 10,000 events were counted for each
sample.
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take part in AIA in BHK cells at high adenosine concentrations
(>500 µM). NBTI could not block this nucleoside transporter-
mediated pathway as significantly as dipyridamole (Fig. 4B),
implying the involvement of ei type nucleoside transporter.
All these results suggest that the mechanism of AIA at low





mediated; while the mechanism of AIA at high concentrations





receptors. This hypothesis was
further confirmed by the use of propentophylline which is
both an adenosine transport inhibitor and a non-selective
adenosine receptor antagonist (Parkinson et al., 1991;
Parkinson et al., 1993) (data not shown). In our study only the
involvement of equilibrative nucleoside transporters in AIA in
BHK cells was shown, that of concentrative nucleoside
transporters cit, cif and cib is still uncertain (subtype cs and
csg can be excluded as they are sensitive to NBTI).
Adenosine signaling mediated by receptors and uptake by
nucleoside transporters has been extensively studied. The
mechanisms of adenosine’s physiological functions via
receptors and nucleoside transporters are well documented.
However, given the universal expression of adenosine
receptors and nucleoside transporters in almost all mammalian
cells, more complicated mechanisms can not be excluded. Our
study provides a good reason to take into consideration the
possibility of adenosine receptor-transporter co-signaling in
the physiological micro-environment.
Membrane receptors are one of the most important
functional cell membrane protein families. Currently cell
surface receptors are classified into four classes: G protein-
coupled receptors (GPCRs), ion-channel receptors, tyrosine
kinase-linked receptors and receptor tyrosine kinases (RTKs)
(Lodish et al., 2000). The latter two types of receptors have
been shown to play an important role in apoptosis. However,
even though the involvement of GPCRs in apoptosis has been
implied by many scientists, it is still to be confirmed and a
model of GPCR-mediated apoptosis is yet to be established.
Our study as well suggests a high possibility for the existence
of GPCR-mediated apoptotic pathway(s).
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